



US012384782B2

(12) **United States Patent**  
**Sintim et al.**(10) **Patent No.:** US 12,384,782 B2  
(45) **Date of Patent:** Aug. 12, 2025(54) **INHIBITORS OF KINASE NETWORKS AND USES THEREOF**(71) Applicant: **Purdue Research Foundation**, West Lafayette, IN (US)(72) Inventors: **Herman O. Sintim**, West Lafayette, IN (US); **Neetu Dayal**, West Lafayette, IN (US); **Clement Opoku-Temeng**, West Lafayette, IN (US)(73) Assignee: **Purdue Research Foundation**, West Lafayette, IN (US)

(\*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: 18/392,204

(22) Filed: Dec. 21, 2023

(65) **Prior Publication Data**

US 2024/0208971 A1 Jun. 27, 2024

**Related U.S. Application Data**

(62) Division of application No. 17/243,629, filed on Apr. 29, 2021, now Pat. No. 11,891,391, which is a division of application No. 16/499,133, filed as application No. PCT/US2018/024991 on Mar. 29, 2018, now Pat. No. 11,040,973.

(60) Provisional application No. 62/478,069, filed on Mar. 29, 2017, provisional application No. 62/616,643, filed on Jan. 12, 2018.

(51) **Int. Cl.**

**C07D 471/16** (2006.01)  
**C07D 209/08** (2006.01)  
**C07D 231/56** (2006.01)  
**C07D 401/14** (2006.01)  
**C07D 413/14** (2006.01)  
**C07D 417/12** (2006.01)  
**C07D 471/04** (2006.01)  
**C07D 471/14** (2006.01)  
**C07D 491/147** (2006.01)  
**C07D 491/16** (2006.01)  
**C07D 495/14** (2006.01)  
**C07D 495/16** (2006.01)  
**C07D 498/04** (2006.01)  
**C07D 513/04** (2006.01)  
**C07D 519/00** (2006.01)

(52) **U.S. Cl.**

CPC ..... **C07D 471/14** (2013.01); **C07D 209/08** (2013.01); **C07D 231/56** (2013.01); **C07D 401/14** (2013.01); **C07D 413/14** (2013.01); **C07D 417/12** (2013.01); **C07D 471/04** (2013.01); **C07D 491/147** (2013.01); **C07D 495/14** (2013.01); **C07D 498/04** (2013.01); **C07D 513/04** (2013.01); **C07D 519/00** (2013.01); **C07B 2200/05** (2013.01)

(58) **Field of Classification Search**

CPC ..... C07D 471/16; C07D 491/16; C07D 497/16; C07D 495/16

USPC ..... 546/64  
See application file for complete search history.

(56) <b>References Cited</b>			
U.S. PATENT DOCUMENTS			
3,947,434	A	3/1976	Spencer et al.
11,040,973	B2	6/2021	Sintim et al.
2004/0024208	A1	2/2004	Das et al.
2005/0043233	A1	2/2005	Stefanic et al.
2005/0080260	A1	4/2005	Mills et al.
2016/0083379	A1	3/2016	Boloor et al.

## FOREIGN PATENT DOCUMENTS

EP	0187705	A2	7/1986
EP	0638571	A1	2/1995
JP	2002542193	A	12/2002
JP	2006524634	A	11/2006
JP	2008545785	A	12/2008
JP	2013542243	A	11/2013
WO	2006138347	A2	12/2006
WO	2007005887	A2	1/2007
WO	2011043359	A1	4/2011
WO	2012065963	A2	5/2012
WO	2016112284	A1	7/2016

## OTHER PUBLICATIONS

Wang, W. et al.: Iodine-catalyzed synthesis of thiopyran[3,4-c] quinoline derivatives via imino-Diels-Alder reaction. J. of Chem. Res., vol. 36, pp. 318-321, 2012.\*

Wang, W. et al.: Highly efficient synthesis of 7-aryl-pyrano[3,4-c] pyrazolo[4,3-f]quinoline derivatives catalyzed by iodine. ARKIVOC, vol. 6, pp. 214-221, 2012.\*

Aly, 2016, Quinoline-based small molecules as effective protein kinases inhibitors, Journal of American Science, 12(5):10-32.

Fabbro, 2015, 25 years of small molecular weight kinase inhibitors: potentials and limitations, Mol. Pharmacol, 87:766-775.

Fabbro, 2015, Ten things you should know about protein kinases: IUPHAR Review 14, Br J Pharmacol, 172:2675-2700.

James, 2007, Rho Kinase (ROCK) Inhibitors, J Cardiovasc Pharmacol, 50(1):17-24.

Kontzias, 2012, Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease, Curr. Opin. Pharmacol, 12(4):464-470.

Lindblad, 2016, Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML, Oncogene, 35(39):5119-5131.

Mali, 2011, Rho kinase regulates the survival and transformation of cells bearing oncogenic forms of KIT, FLT3, and BCR-ABL, Cancer Cell, 20(3):357-369.

O'Hare, 2007, Bcr-Abl kinase domain mutations, drug, resistance, and the road to a cure for chronic myeloid leukemia, 110(7):2242-2249.

\* cited by examiner

Primary Examiner — Charanjit Aulakh

(74) Attorney, Agent, or Firm — Brown Rudnick LLP;  
Adam M. Schoen(57) **ABSTRACT**

The present invention generally relates to compounds as a dual kinase-demethylase inhibitor useful for the treatment of diseases mediated by a kinase and/or a histone demethylase, such as inflammation, cancer, viral and bacterial infections, neurological and immunological disorders. Pharmaceutical compositions and methods for treating those diseases are within the scope of this invention.

1

# INHIBITORS OF KINASE NETWORKS AND USES THEREOF

## CROSS REFERENCE TO RELATED APPLICATIONS

The present U.S. patent application is a divisional application of U.S. patent application Ser. No. 17/243,629, filed Apr. 29, 2021, which is a divisional application of U.S. application Ser. No. 16/499,133, filed Sep. 27, 2019, which relates to, and claims the priority benefit of, and is a 35 U.S.C. 371 national stage application of International Patent Application Serial No. PCT/US2018/024991 to Sintem et al., filed Mar. 29, 2018, which relates to and claims the priority benefit of U.S. Provisional Application Ser. No. 62/478,069, filed Mar. 29, 2017, and U.S. Provisional Application Ser. No. 62/616,643, filed Jan. 12, 2018. The entire contents of each of the aforementioned priority application which are hereby expressly incorporated herein by reference in their entireties.

targets, such as LRRK2, have also been shown to be important for CNS-related diseases, such as Alzheimer's or Parkinsons.<sup>9</sup> A privileged chemical scaffold, which can be tuned to selectively inhibit a disease-related kinase or inhibit


5 a group of kinases that lie in a particular pathway or network could facilitate the treatment of diverse disease states.

2

## SUMMARY OF THE INVENTION

The present invention generally relates to compounds that inhibit kinase and/or histone demethylase networks as useful compounds for the treatment of diseases mediated by a kinase, such as inflammation, cancer, viral and bacterial infections, neurological and immunological disorders. Pharmaceutical compositions and methods for treating those diseases are within the scope of this invention.

In some illustrative embodiments, the present invention relates to a compound having a formula



## TECHNICAL FIELD

The present invention generally relates to compounds as a kinase inhibitor and methods for the treatment of diseases mediated by a kinase, such as inflammation, cancer, viral and bacterial infections, neurological and immunological disorders.

## BACKGROUND

This section introduces aspects that may help facilitate a better understanding of the disclosure. Accordingly, these statements are to be read in this light and are not to be understood as admissions about what is or is not prior art.

The cell contains over 500 kinases, which regulate diverse processes such as cell cycle, growth, migration, immune response.<sup>1</sup> Several deregulated kinases, i.e. kinases that have attained a gain-of-function mutation or are over-expressed, drive cancer proliferation.<sup>1</sup> Small molecule inhibitors of cancer-driver kinases (for example BCR-ABL1 fusion protein, FLT3-ITD, mutated or over-expressed ALK, EGFR, PDGFR, Kit, VEGFR, B-Raf, BTK, PI3Kδ, ErbB2) have seen clinical successes.<sup>2</sup> Recently efforts have been made to target other kinases, such as cell cycle kinases (CDKs), or kinases that target histones, cytoskeleton or other processes that are important for the cell, to arrest cancer growth. Most of the kinase inhibitors that proceed to the clinic work initially but over time resistant clones emerge that render the drugs ineffective.<sup>3</sup> Various mechanisms account for cancer cell resistance to kinase inhibitors. For example copy number multiplication, additional kinase mutations (such as secondary mutations that arise in the tyrosine kinase domain of FLT3-ITD kinase) or the activation of alternative kinase pathways and/or downstream targets can bypass the inhibition of a particular kinase target.<sup>4</sup> Kinase inhibitors that inhibit a cancer-driver kinase and also downstream targets (both kinase and non-kinase targets, such as histone demethylase) and/or kinases that collaborate with the driver kinase could have enhanced potency and reduced probability of resistance being generated against that kinase inhibitor.<sup>5</sup> A challenge however with such a polypharmacophore is to avoid promiscuous binding, which can lead to toxicity.

Kinase inhibitors have also been shown to be effective for the treatment of immune disorders (such as JAK kinases<sup>6</sup>), hypertension and erectile dysfunction (ROCK1/2 kinases<sup>7</sup>) and glaucoma (ROCK and LIMK kinases<sup>8</sup>). Other kinase


or a pharmaceutically acceptable salt thereof, wherein R<sup>1</sup> is amino, hydroxyl, and derivatives thereof, an alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, heterocyclyl, cycloalkyl, cycloalkenyl, cycloheteroalkyl, cycloheteroalkenyl, acyl, aryl, heteroaryl, arylalkyl, arylalkenyl, or arylalkynyl, each of which is optionally substituted;

R<sup>2</sup> and R<sup>3</sup> are each independently selected from the group consisting of hydrogen, deuterium, halo, azido, cyano, nitro, hydroxy, amino, thio, carboxy, ester, amide, and derivatives thereof, and acyl, sulfoxyl, sulfonyl, phosphate, phosphoryl, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, heterocyclyl, cycloalkyl, cycloalkenyl, cycloheteroalkyl, cycloheteroalkenyl, aryl, heteroaryl, arylalkyl, arylalkenyl, and arylalkynyl, each of which is optionally substituted;

or R<sup>2</sup> and R<sup>3</sup> are taken together with the attached carbons to form an optionally substituted cyclic or heterocyclic moiety; and

R<sup>4</sup> represents four substituents, each independently selected from the group consisting of hydrogen, deuterium, halo, azido, cyano, nitro, hydroxy, amino, thio, carboxy, ester, amide, and derivatives thereof, and acyl, sulfoxyl, sulfonyl, phosphate, phosphoryl, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, heterocyclyl, cycloalkyl, cycloalkenyl, cycloheteroalkyl, cycloheteroalkenyl, aryl, heteroaryl, arylalkyl, arylalkenyl, and arylalkynyl, each of which is optionally substituted; or any two adjacent substituents of the four substituents are taken together with the attached carbons form an optionally substituted cyclic or heterocyclic moiety.

In some illustrative embodiments, the present invention relates to a compound having a formula:

5  
(II)

or a pharmaceutically acceptable salt thereof, wherein n=1~5; the bonding between A and B, between B and 20 D may be a double bond or a single bond, but cannot be double bond at the same time; A, B, and D represents, independently, C, O, N, and S wherein at least one of A, B, and D is a heteroatom;


R<sup>1</sup> is amino, hydroxyl, and derivatives thereof, an alkyl, 25 alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, heterocyclyl, cycloalkyl, cycloalkenyl, cycloheteroalkyl, cycloheteroalkenyl, acyl, aryl, heteroaryl, arylalkyl, arylalkenyl, or arylalkynyl, each of 30 which is optionally substituted;

R<sup>2</sup> and R<sup>3</sup> are each independently selected from the group consisting of hydrogen, deuterium, halo, azido, cyano, nitro, hydroxy, amino, thio, carboxy, ester, amide, and derivatives thereof, and acyl, sulfoxyl, sulfonyl, phosphate, phosphoryl, alkyl, 35 alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, heterocyclyl, cycloalkyl, cycloalkenyl, cycloheteroalkyl, cycloheteroalkenyl, acyl, aryl, heteroaryl, arylalkyl, arylalkenyl, and arylalkynyl, each of which is optionally substituted; or R<sup>2</sup> and R<sup>3</sup> are taken together with the attached carbons to form an 40 optionally substituted cyclic or heterocyclic moiety;


R<sup>4</sup> represents two substituents, each independently selected from the group consisting of hydrogen, deuterium, 45 halo, azido, cyano, nitro, hydroxy, amino, thio, carboxy, ester, amide, and derivatives thereof, and acyl, sulfoxyl, sulfonyl, phosphate, phosphoryl, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, heterocyclyl, cycloalkyl, cycloalkenyl, cyclohet- 50 eroalkyl, cycloheteroalkenyl, aryl, heteroaryl, arylalkyl, arylalkenyl, and arylalkynyl, each of which is optionally substituted; or the two substituents are taken together with the attached carbons to form an optionally 55 substituted cyclic or heterocyclic moiety; and

depending on the element of A, B and D, R<sup>5</sup> represents two or three substituents, each independently selected from the group consisting of hydrogen, deuterium, 60 halo, azido, cyano, nitro, hydroxy, amino, thio, carboxy, ester, amide, and derivatives thereof, and acyl, sulfoxyl, sulfonyl, phosphate, phosphoryl, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, heterocyclyl, cycloalkyl, cycloalkenyl, cyclohet- 65 eroalkyl, cycloheteroalkenyl, aryl, heteroaryl, arylalkyl, arylalkenyl, and arylalkynyl, each of which is optionally substituted.

In some illustrative embodiments, the present invention relates to a compound having a formula (II), wherein R<sup>1</sup> is:



In some illustrative embodiments, the present invention relates to a compound having a formula (III),



(III)

or a pharmaceutically acceptable salt thereof, wherein n=1~5: the bonding between A and B, between B and D may be a double bond or a single bond, but cannot be double bond at the same time; A, B, and D represents, independently, C, O, N, and S wherein at least one of A, B, and D is a heteroatom; R<sup>1</sup> is amino, hydroxyl, and derivatives thereof, an alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, heterocyclyl, cycloalkyl, cycloalkenyl, cycloheteroalkyl, cycloheteroalkenyl, aryl, heteroaryl, arylalkyl, arylalkenyl, and arylalkynyl, each of which is optionally substituted,

cycloheteroalkyl, cycloheteroalkenyl, acyl, aryl, heteroaryl, arylalkyl, arylalkenyl, or arylalkynyl, each of which is optionally substituted;

$R^4$  represents two substituents, each independently selected from the group consisting of hydrogen, deuterium, halo, azido, cyano, nitro, hydroxy, amino, thio, carboxy, ester, amide, and derivatives thereof, and acyl, sulfoxyl, sulfonyl, phosphate, phosphoryl, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, heterocyclyl, cycloalkyl, cycloalkenyl, cyclohet-

5

10

15

20

25

30

35

arylkyl, arylalkenyl, and arylalkynyl, each of which is optionally substituted; or the two substituents are taken together with the attached carbons form an optionally substituted cyclic or heterocyclic moiety.

depending on the element of A, B and D,  $R^5$  represents two or three substituents, each independently selected from the group consisting of hydrogen, deuterium, halo, azido, cyano, nitro, hydroxy, amino, thio, carboxy, ester, amide, and derivatives thereof, and acyl, sulfoxyl, sulfonyl, phosphate, phosphoryl, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, heterocyclyl, cycloalkyl, cycloalkenyl, cyclohet-

20

25

30

35

eroalkyl, cycloheteroalkenyl, aryl, heteroaryl, arylalkyl, arylalkenyl, and arylalkynyl, each of which is optionally substituted; and depending on the value of n,  $R^6$  represents two to six substituents, each independently selected from the group consisting of hydrogen, deuterium, halo, azido, cyano, nitro, hydroxy, amino, thio, carboxy, ester, amide, and derivatives thereof, and acyl, sulfoxyl, sulfonyl, phosphate, phosphoryl, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, heterocyclyl, cycloalkyl, cycloalkenyl, cyclohet-



25

30


35

eroalkyl, cycloheteroalkenyl, aryl, heteroaryl, arylalkyl, arylalkenyl, and arylalkynyl, each of which is optionally substituted.

In some illustrative embodiments, the present invention relates to a compound having a formula (III), wherein  $R^1$  is



In some illustrative embodiments, the present invention relates to a compound having a formula (IV),



or a pharmaceutically acceptable salt thereof, wherein  $n=1\sim 5$ ;

$R^1$  is amino, hydroxyl, and derivatives thereof, an alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, heterocyclyl, cycloalkyl, cycloalkenyl, cyclohet-

40

45

50

55

60

65

eroalkyl, cycloheteroalkenyl, acyl, aryl, heteroaryl, arylalkyl, arylalkenyl, or arylalkynyl, each of which is optionally substituted;

$R^2$  and  $R^3$  are each independently selected from the group consisting of hydrogen, deuterium, halo, azido, cyano, nitro, hydroxy, amino, thio, carboxy, ester, amide, and derivatives thereof, and acyl, sulfoxyl, sulfonyl, phosphate, phosphoryl, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, heterocyclyl, cycloalkyl, cycloalkenyl, cyclohet-

eroalkyl, cycloheteroalkenyl, aryl, heteroaryl, arylalkyl, arylalkenyl, and arylalkynyl, each of which is optionally substituted; or  $R^2$  and  $R^3$  are taken together with the attached carbons to form an optionally substituted cyclic or heterocyclic moiety;

$R^4$  represents two substituents, each independently selected from the group consisting of hydrogen, deuterium, halo, azido, cyano, nitro, hydroxy, amino, thio, carboxy, ester, amide, and derivatives thereof, and acyl, sulfoxyl, sulfonyl, phosphate, phosphoryl, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, heterocyclyl, cycloalkyl, cycloalkenyl, cyclohet-

eroalkyl, cycloheteroalkenyl, aryl, heteroaryl, arylalkyl, arylalkenyl, and arylalkynyl, each of which is optionally substituted; or the two substituents are taken together with the attached carbons to form an optionally substituted cyclic or heterocyclic moiety;

depending on the element of A and B specified below.  $R^5$  represents one or two substituents, each independently selected from the group consisting of hydrogen, deuterium, halo, azido, cyano, nitro, hydroxy, amino, thio, carboxy, ester, amide, and derivatives thereof, and acyl,


sulfoxy, sulfonyl, phosphate, phosphoryl, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, heterocycl, cycloalkyl, cycloalkenyl, cyclohet-  
eroalkyl, cycloheteroalkenyl, aryl, heteroaryl, arylalkyl, arylalkenyl, and arylalkynyl, each of which is  
optionally substituted;

A and B represents, independently, CR<sup>8</sup>, N, or NR<sup>9</sup>,  
wherein R<sup>8</sup> and R<sup>9</sup> represent independently hydrogen,  
alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, het-  
eroalkynyl, heterocycl, cycloalkyl, cycloalkenyl,  
cycloheteroalkyl, cycloheteroalkenyl, acyl, aryl, het-  
eroaryl, arylalkyl, arylalkenyl, or arylalkynyl, each of  
which is optionally substituted;

depending on the value of n, R<sup>6</sup> represents two to six  
substituents, each independently selected from the  
group consisting of hydrogen, deuterium, halo, azido,  
cyano, nitro, hydroxy, amino, thio, carboxy, ester,  
amide, and derivatives thereof, and acyl, sulfoxy, sulfonyl,  
phosphate, phosphoryl, alkyl, alkenyl, alky-  
nyl, heteroalkyl, heteroalkenyl, heteroalkynyl, hetero-  
cycl, cycloalkyl, cycloalkenyl, cycloheteroalkyl,  
cycloheteroalkenyl, aryl, heteroaryl, arylalkyl, arylalkenyl,  
and arylalkynyl, each of which is optionally  
substituted; and


R<sup>7</sup> is an alkyl, alkenyl, alkynyl, heteroalkyl, heteroalk-  
enyl, heteroalkynyl, heterocycl, cycloalkyl, cycloalk-  
enyl, cycloheteroalkyl, cycloheteroalkenyl, acyl, aryl,  
heteroaryl, arylalkyl, arylalkenyl, or arylalkynyl, each  
of which is optionally substituted.

In some illustrative embodiments, the present invention  
relates to a compound having a formula (IV), wherein R<sup>1</sup> is



8  
-continued


10 In some illustrative embodiments, the present invention relates to a compound having a formula (IV), wherein R<sup>1</sup> is



A is carbon (C); B is nitrogen (N); R<sup>5</sup>, R<sup>6</sup>, and R<sup>7</sup> all represent hydrogen, and R<sup>4</sup> represents two substituents, each independently selected from the group consisting of hydrogen, deuterium, halo, azido, cyano, nitro, hydroxy, amino, thio, carboxy, ester, amide, and derivatives thereof, and acyl, sulfoxy, sulfonyl, phosphate, phosphoryl, alkyl, alkenyl, alky-  
nyl, heteroalkyl, heteroalkenyl, heteroalkynyl, hetero-  
cycl, cycloalkyl, cycloalkenyl, cycloheteroalkyl, cyclohet-  
eroalkenyl, aryl, heteroaryl, arylalkyl, arylalkenyl, and aryl-  
alkynyl, each of which is optionally substituted;


or the two substituents are taken together with the  
attached carbons form an optionally substituted cyclic  
or heterocyclic moiety.

In some illustrative embodiments, the present invention  
relates to a compound having a formula (IV), wherein R<sup>3</sup> is




**9**












-continued

**10**

-continued




In some illustrative embodiments, the present invention relates to a compound having a formula (IV), wherein R<sup>1</sup> is




In some illustrative embodiments, the present invention relates to a compound having a formula (I), wherein the compound is

HSD1342




HSD1335




US 12,384,782 B2

**11**  
-continued




HSD1336

5




HSD1355

15  
20




HSD1356

30  
35




HSD1345

40  
45








50  
55



60  
65







**12**

-continued










**13**

-continued

**14**

-continued



**15****16**

more compounds disclosed herein, or a pharmaceutically acceptable salt thereof, together with one or more diluents, excipients or carriers.

In some illustrative embodiments, the present invention relates to a kinase inhibitor, wherein the kinase is selected from the group consisting of FLT3, MNK1/2, JAK1/2/3, Limk1/2, various CDKs, Haspin, ROCK1/2, TOPK, LRRK2, GSK3a/3b, RSK1-4, ERK, P7056K, AKT, PI3K, p38, PKC, PKA, FGFR1-4, VEGFR1-3, ALK, AXL, 5 LIMK1/2, Aurora A/B, ABL1, AKT, CSF1R, CSNK1D, DCAMKL1, CSNKIG2, EPHA2, ERBB2, IKK-alpha, IKK-beta, JNK1/2/3, MARK3, MEK1/2, MET, MLK1, PAK1/2/4, PDGFRa/b, PIM1/2/3, PLK1/2/3/4, PRKCE, PRKX, RET, TAOK2, TRKA/B/C, ULK2, and receptor-interacting protein kinase 4 (RIPK4).

In some illustrative embodiments, the present invention relates to a method for treating diseases mediated by a kinase and/or histone demethylases, including inflammation, cancer, viral and bacterial infections, gastrointestinal disorders, 10 eye diseases, neurological, cardiovascular and immunological disorders, comprising the step of administering a therapeutically effective amount of one or more compounds disclosed herein, and one or more carriers, diluents, or excipients, to a patient in need of relief from said cancer.

In some illustrative embodiments, the present invention relates to a method for treating diseases mediated by a kinase and histone demethylases, including inflammation, cancer, viral and bacterial infections, gastrointestinal disorders, eye 20 diseases, neurological, cardiovascular and immunological disorders, comprising the step of administering a therapeutically effective amount of a compound disclosed herein in combination with one or more other compounds of the same or different mode of action, and one or more carriers, diluents, or excipients, to a patient in need of relief from said 25 cancer.

These and other features, aspects and advantages of the present invention will become better understood with reference to the following detailed description and claims.

40

## DETAILED DESCRIPTION

While the concepts of the present disclosure are illustrated and described in detail in the description herein, results in their description are to be considered as exemplary and 45 not restrictive in character; it being understood that only the illustrative embodiments are shown and described and that all changes and modifications that come within the spirit of the disclosure are desired to be protected.

The present invention generally relates to compounds as 50 kinase inhibitor useful for the treatment of diseases mediated by a kinase, such as inflammation, cancer, viral and bacterial infections, neurological and immunological disorders. Pharmaceutical compositions and methods for treating those diseases are within the scope of this invention.

55 As used herein, the following terms and phrases shall have the meanings set forth below. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood to one of ordinary skill in the art.

60 In the present disclosure the term "about" can allow for a degree of variability in a value or range, for example, within 10%, within 5%, or within 1% of a stated value or of a stated limit of a range. In the present disclosure the term "substantially" can allow for a degree of variability in a value or range, for example, within 90%, within 95%, 99%, 99.5%, 99.9%, 99.99%, or at least about 99.999% or more of a stated value or of a stated limit of a range.

In this document, the terms "a," "an," or "the" are used to include one or more than one unless the context clearly dictates otherwise. The term "or" is used to refer to a nonexclusive "or" unless otherwise indicated. In addition, it is to be understood that the phraseology or terminology employed herein, and not otherwise defined, is for the purpose of description only and not of limitation. Any use of section headings is intended to aid reading of the document and is not to be interpreted as limiting. Further, information that is relevant to a section heading may occur within or outside of that particular section. Furthermore, all publications, patents, and patent documents referred to in this document are incorporated by reference herein in their entirety, as though individually incorporated by reference. In the event of inconsistent usages between this document and those documents so incorporated by reference, the usage in the incorporated reference should be considered supplementary to that of this document; for irreconcilable inconsistencies, the usage in this document controls.

The term "substituted" as used herein refers to a functional group in which one or more hydrogen atoms contained therein are replaced by one or more non-hydrogen atoms. The term "functional group" or "substituent" as used herein refers to a group that can be or is substituted onto a molecule. Examples of substituents or functional groups include, but are not limited to, a halogen (e.g., F, Cl, Br, and I); an oxygen atom in groups such as hydroxyl groups, alkoxy groups, aryloxy groups, aralkyloxy groups, oxo (carbonyl) groups, carboxyl groups including carboxylic acids, carboxylates, and carboxylate esters; a sulfur atom in groups such as thiol groups, alkyl and aryl sulfide groups, sulfoxide groups, sulfone groups, sulfonyl groups, and sulfonamide groups; a nitrogen atom in groups such as amines, azides, hydroxylamines, cyano, nitro groups, N-oxides, hydrazides, and enamines; and other heteroatoms in various other groups.

The term "alkyl" as used herein refers to substituted or unsubstituted straight chain and branched alkyl groups and cycloalkyl groups having from 1 to about 20 carbon atoms ( $C_1-C_{20}$ ), 1 to 12 carbons ( $C_1-C_{12}$ ), 1 to 8 carbon atoms ( $C_1-C_8$ ), or, in some embodiments, from 1 to 6 carbon atoms ( $C_1-C_6$ ). Examples of straight chain alkyl groups include those with from 1 to 8 carbon atoms such as methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl, n-heptyl, and n-octyl groups. Examples of branched alkyl groups include, but are not limited to, isopropyl, iso-butyl, sec-butyl, t-butyl, neopentyl, isopentyl, and 2,2-dimethylpropyl groups. As used herein, the term "alkyl" encompasses n-alkyl, isoalkyl, and anteisoalkyl groups as well as other branched chain forms of alkyl. Representative substituted alkyl groups can be substituted one or more times with any of the groups listed herein, for example, amino, hydroxy, cyano, carboxy, nitro, thio, alkoxy, and halogen groups.

The term "alkenyl" as used herein refers to substituted or unsubstituted straight chain and branched divalent alkenyl and cycloalkenyl groups having from 2 to 20 carbon atoms ( $C_2-C_{20}$ ), 2 to 12 carbons ( $C_2-C_{12}$ ), 2 to 8 carbon atoms ( $C_2-C_8$ ) or, in some embodiments, from 2 to 4 carbon atoms ( $C_2-C_4$ ) and at least one carbon-carbon double bond. Examples of straight chain alkenyl groups include those with from 2 to 8 carbon atoms such as  $-\text{CH}=\text{CH}-$ ,  $-\text{CH}=\text{CHCH}_2-$ , and the like. Examples of branched alkenyl groups include, but are not limited to,  $-\text{CH}=\text{C}(\text{CH}_3)-$  and the like.

An alkynyl group is the fragment, containing an open point of attachment on a carbon atom that would form if a hydrogen atom bonded to a triply bonded carbon is removed

from the molecule of an alkyne. The term "hydroxyalkyl" as used herein refers to alkyl groups as defined herein substituted with at least one hydroxyl ( $-\text{OH}$ ) group.

The term "cycloalkyl" as used herein refers to substituted or unsubstituted cyclic alkyl groups such as, but not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl groups. In some embodiments, the cycloalkyl group can have 3 to about 8-12 ring members, whereas in other embodiments the number of ring carbon atoms range from 3 to 4, 5, 6, or 7. In some embodiments, cycloalkyl groups can have 3 to 6 carbon atoms ( $C_3-C_6$ ). Cycloalkyl groups further include polycyclic cycloalkyl groups such as, but not limited to, norbornyl, adamantyl, bornyl, camphenyl, isocamphenyl, and carenyl groups, and fused rings such as, but not limited to, decalinyl, and the like.

The term "acyl" as used herein refers to a group containing a carbonyl moiety wherein the group is bonded via the carbonyl carbon atom. The carbonyl carbon atom is also bonded to another carbon atom, which can be part of a substituted or unsubstituted alkyl, aryl, aralkyl cycloalkyl, cycloalkylalkyl, heterocycl, heterocyclalkyl, heteroaryl, heteroarylalkyl group or the like. In the special case wherein the carbonyl carbon atom is bonded to a hydrogen, the group is a "formyl" group, an acyl group as the term is defined herein. An acyl group can include 0 to about 12-40, 6-10, 1-5 or 2-5 additional carbon atoms bonded to the carbonyl group. An acryloyl group is an example of an acyl group. An acyl group can also include heteroatoms within the meaning here. A nicotinoyl group (pyridyl-3-carbonyl) is an example of an acyl group within the meaning herein. Other examples include acetyl, benzoyl, phenylacetyl, pyridylacetyl, cinnamoyl, and acryloyl groups and the like. When the group containing the carbon atom that is bonded to the carbonyl carbon atom contains a halogen, the group is termed a "haloacyl" group. An example is a trifluoroacetyl group.

The term "aryl" as used herein refers to substituted or unsubstituted cyclic aromatic hydrocarbons that do not contain heteroatoms in the ring. Thus aryl groups include, but are not limited to, phenyl, azulenyl, heptalenyl, biphenyl, indacenyl, fluorenyl, phenanthrenyl, triphenylenyl, pyrenyl, naphthacenyl, chrysene, biphenylenyl, anthracenyl, and naphthyl groups. In some embodiments, aryl groups contain about 6 to about 14 carbons ( $C_6-C_{14}$ ) or from 6 to 10 carbon atoms ( $C_6-C_{10}$ ) in the ring portions of the groups. Aryl groups can be unsubstituted or substituted, as defined herein. Representative substituted aryl groups can be mono-substituted or substituted more than once, such as, but not limited to, 2-, 3-, 4-, 5-, or 6-substituted phenyl or 2-8 substituted naphthyl groups, which can be substituted with carbon or non-carbon groups such as those listed herein.

The term "aralkyl" and "aryalkyl" as used herein refers to alkyl groups as defined herein in which a hydrogen or carbon bond of an alkyl group is replaced with a bond to an aryl group as defined herein. Representative aralkyl groups include benzyl and phenylethyl groups and fused (cycloalkylaryl)alkyl groups such as 4-ethyl-indanyl. Aralkenyl groups are alkenyl groups as defined herein in which a hydrogen or carbon bond of an alkyl group is replaced with a bond to an aryl group as defined herein.

The term "heterocycl" as used herein refers to substituted or unsubstituted aromatic and non-aromatic ring compounds containing 3 or more ring members, of which, one or more is a heteroatom such as, but not limited to, B, N, O, and S. Thus, a heterocycl can be a cycloheteroalkyl, or a heteroaryl, or if polycyclic, any combination thereof. In some embodiments, heterocycl groups include 3 to about

20 ring members, whereas other such groups have 3 to about 15 ring members. In some embodiments, heterocyclyl groups include heterocyclyl groups that include 3 to 8 carbon atoms ( $C_3$ - $C_8$ ), 3 to 6 carbon atoms ( $C_3$ - $C_6$ ) or 6 to 8 carbon atoms ( $C_6$ - $C_8$ ).

A heteroaryl ring is an embodiment of a heterocyclyl group. The phrase "heterocyclyl group" includes fused ring species including those that include fused aromatic and non-aromatic groups. Representative heterocyclyl groups include, but are not limited to pyrrolidinyl, azetidinyl, piperidinyl, piperazinyl, morpholinyl, chromanyl, indolinonyl, isoindolinonyl, furanyl, pyrrolidinyl, pyridinyl, pyrazinyl, pyrimidinyl, triazinyl, thiophenyl, tetrahydrofuranyl, pyrrolyl, oxazolyl, oxadiazolyl, imidazolyl, triazoyl, tetrazolyl, benzoxazoliny, benzthiazoliny, and benzimidazoliny groups.

The term "heterocyclalkyl" as used herein refers to alkyl groups as defined herein in which a hydrogen or carbon bond of an alkyl group as defined herein is replaced with a bond to a heterocyclyl group as defined herein. Representative heterocyclalkyl groups include, but are not limited to, furan-2-yl methyl, furan-3-yl methyl, pyridine-3-yl methyl, tetrahydrofuran-2-yl methyl, and indol-2-yl propyl.

The term "heteroarylalkyl" as used herein refers to alkyl groups as defined herein in which a hydrogen or carbon bond of an alkyl group is replaced with a bond to a heteroaryl group as defined herein.

The term "alkoxy" as used herein refers to an oxygen atom connected to an alkyl group, including a cycloalkyl group, as are defined herein. Examples of linear alkoxy groups include but are not limited to methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, and the like. Examples of branched alkoxy include but are not limited to isopropoxy, sec-butoxy, tert-butoxy, isopentyloxy, isohexyloxy, and the like. Examples of cyclic alkoxy include but are not limited to cyclopropoxy, cyclobutoxy, cyclopentyloxy, cyclohexyloxy, and the like. An alkoxy group can further include double or triple bonds, and can also include heteroatoms. For example, an allyloxy group is an alkoxy group within the meaning herein. A methoxyethoxy group is also an alkoxy group within the meaning herein, as is a methylenedioxy group in a context where two adjacent atoms of a structure are substituted therewith.

The term "amine" as used herein refers to primary, secondary, and tertiary amines having, e.g., the formula  $N(\text{group})_3$  wherein each group can independently be H or non-H, such as alkyl, aryl, and the like. Amines include but are not limited to  $R-\text{NH}_2$ , for example, alkylamines, arylamines, alkylarylamines;  $R_2\text{NH}$  wherein each R is independently selected, such as dialkylamines, diarylamines, aralkylamines, heterocycllamines and the like; and  $R^3\text{N}$  wherein each R is independently selected, such as trialkylamines, dialkylarylamines, alkyldiarylamines, triarylamines, and the like. The term "amine" also includes ammonium ions as used herein.

The term "amino group" as used herein refers to a substituent of the form  $-\text{NH}_2$ ,  $-\text{NHR}$ ,  $-\text{NR}_2$ ,  $-\text{NR}_3^+$ , wherein each R is independently selected, and protonated forms of each, except for  $-\text{NR}_3^+$ , which cannot be protonated. Accordingly, any compound substituted with an amino group can be viewed as an amine. An "amino group" within the meaning herein can be a primary, secondary, tertiary, or quaternary amino group. An "alkylamino" group includes a monoalkylamino, dialkylamino, and trialkylamino group.

The terms "halo," "halogen," or "halide" group, as used herein, by themselves or as part of another substituent, mean, unless otherwise stated, a fluorine, chlorine, bromine, or iodine atom.

5 The term "haloalkyl" group, as used herein, includes mono-halo alkyl groups, poly-halo alkyl groups wherein all halo atoms can be the same or different, and per-halo alkyl groups, wherein all hydrogen atoms are replaced by halogen atoms, such as fluoro. Examples of haloalkyl include trifluoromethyl, 1,1-dichloroethyl, 1,2-dichloroethyl, 1,3-dibromo-3,3-difluoropropyl, perfluorobutyl,  $-\text{CF}(\text{CH}_3)_2$  and the like.

10 The term "optionally substituted," or "optional substituents," as used herein, means that the groups in question are either unsubstituted or substituted with one or more of the substituents specified. When the groups in question are substituted with more than one substituent, the substituents may be the same or different. When using the terms "independently," "independently are," and "independently selected from" mean that the groups in question may be the same or different. Certain of the herein defined terms may occur more than once in the structure, and upon such occurrence each term shall be defined independently of the other.

15 The compounds described herein may contain one or more chiral centers, or may otherwise be capable of existing as multiple stereoisomers. It is to be understood that in one embodiment, the invention described herein is not limited to any particular stereochemical requirement, and that the compounds, and compositions, methods, uses, and medicaments that include them may be optically pure, or may be any of a variety of stereoisomeric mixtures, including racemic and other mixtures of enantiomers, other mixtures of 20 diastereomers, and the like. It is also to be understood that such mixtures of stereoisomers may include a single stereochemical configuration at one or more chiral centers, while including mixtures of stereochemical configuration at one or more other chiral centers.

25 30 35 40 Similarly, the compounds described herein may include geometric centers, such as cis, trans, E, and Z double bonds. It is to be understood that in another embodiment, the invention described herein is not limited to any particular geometric isomer requirement, and that the compounds, and compositions, methods, uses, and medicaments that include them may be pure, or may be any of a variety of geometric isomer mixtures. It is also to be understood that such mixtures of geometric isomers may include a single configuration at one or more double bonds, while including mixtures of geometry at one or more other double bonds.

45 50 55 60 65 As used herein, the term "salts" and "pharmaceutically acceptable salts" refer to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic groups such as amines; and alkali or organic salts of acidic groups such as carboxylic acids. Pharmaceutically acceptable salts include the conventional non-toxic salts or the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. For example, such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, and nitric; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic,

2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, and isethionic, and the like.

Pharmaceutically acceptable salts can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods. In some instances, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred. Lists of suitable salts are found in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pa., 1985, the disclosure of which is hereby incorporated by reference.

The term "solvate" means a compound, or a salt thereof, that further includes a stoichiometric or non-stoichiometric amount of solvent bound by non-covalent intermolecular forces. Where the solvent is water, the solvate is a hydrate.

The term "prodrug" means a derivative of a compound that can hydrolyze, oxidize, or otherwise react under biological conditions (*in vitro* or *in vivo*) to provide an active compound, particularly a compound of the invention. Examples of prodrugs include, but are not limited to, derivatives and metabolites of a compound of the invention that include biohydrolyzable moieties such as biohydrolyzable amides, biohydrolyzable esters, biohydrolyzable carbamates, biohydrolyzable carbonates, biohydrolyzable ureides, and biohydrolyzable phosphate analogues. Specific prodrugs of compounds with carboxyl functional groups are the lower alkyl esters of the carboxylic acid. The carboxylate esters are conveniently formed by esterifying any of the carboxylic acid moieties present on the molecule. Prodrugs can typically be prepared using well-known methods, such as those described by Burger's Medicinal Chemistry and Drug Discovery 6th ed. (Donald J. Abraham ed., 2001, Wiley) and Design and Application of Prodrugs (H. Bundgaard ed., 1985, Harwood Academic Publishers GmbH).

Further, in each of the foregoing and following embodiments, it is to be understood that the formulae include and represent not only all pharmaceutically acceptable salts of the compounds, but also include any and all hydrates and/or solvates of the compound formulae or salts thereof. It is to be appreciated that certain functional groups, such as the hydroxy, amino, and like groups form complexes and/or coordination compounds with water and/or various solvents, in the various physical forms of the compounds. Accordingly, the above formulae are to be understood to include and represent those various hydrates and/or solvates. In each of the foregoing and following embodiments, it is also to be understood that the formulae include and represent each possible isomer, such as stereoisomers and geometric isomers, both individually and in any and all possible mixtures. In each of the foregoing and following embodiments, it is also to be understood that the formulae include and represent any and all crystalline forms, partially crystalline forms, and non-crystalline and/or amorphous forms of the compounds.

The term "pharmaceutically acceptable carrier" is art-recognized and refers to a pharmaceutically-acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting any subject composition or component thereof. Each carrier must be "acceptable" in the sense of being compatible with the subject composition and its components and not injurious to the patient. Some examples of materials which may serve as pharmaceutically acceptable carriers include: (1) sugars, such as lactose, glucose and sucrose; (2) starches, such as corn starch and

potato starch; (3) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar, (14) buffering agents, such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) ethyl alcohol; (20) phosphate buffer solutions; and (21) other non-toxic compatible substances employed in pharmaceutical formulations.

As used herein, the term "administering" includes all means of introducing the compounds and compositions described herein to the patient, including, but are not limited to, oral (po), intravenous (iv), intramuscular (im), subcutaneous (sc), transdermal, inhalation, buccal, ocular, sublingual, vaginal, rectal, and the like. The compounds and compositions described herein may be administered in unit dosage forms and/or formulations containing conventional nontoxic pharmaceutically acceptable carriers, adjuvants, and vehicles.

Illustrative formats for oral administration include tablets, capsules, elixirs, syrups, and the like. Illustrative routes for parenteral administration include intravenous, intraarterial, intraperitoneal, epidural, intraurethral, intrasternal, intramuscular and subcutaneous, as well as any other art recognized route of parenteral administration.

Illustrative means of parenteral administration include needle (including microneedle) injectors, needle-free injectors and infusion techniques, as well as any other means of parenteral administration recognized in the art. Parenteral formulations are typically aqueous solutions which may contain excipients such as salts, carbohydrates and buffering agents (preferably at a pH in the range from about 3 to about 9), but, for some applications, they may be more suitably formulated as a sterile non-aqueous solution or as a dried form to be used in conjunction with a suitable vehicle such as sterile, pyrogen-free water. The preparation of parenteral formulations under sterile conditions, for example, by lyophilization, may readily be accomplished using standard pharmaceutical techniques well known to those skilled in the art. Parenteral administration of a compound is illustratively performed in the form of saline solutions or with the compound incorporated into liposomes. In cases where the compound in itself is not sufficiently soluble to be dissolved, a solubilizer such as ethanol can be applied.

The dosage of each compound of the claimed combinations depends on several factors, including: the administration method, the condition to be treated, the severity of the condition, whether the condition is to be treated or prevented, and the age, weight, and health of the person to be treated. Additionally, pharmacogenomic (the effect of genotype on the pharmacokinetic, pharmacodynamic or efficacy profile of a therapeutic) information about a particular patient may affect the dosage used.

It is to be understood that in the methods described herein, the individual components of a co-administration, or combination can be administered by any suitable means, contemporaneously, simultaneously, sequentially, separately or in a single pharmaceutical formulation. Where the co-administered compounds or compositions are administered in separate dosage forms, the number of dosages administered per day for each compound may be the same or

23

different. The compounds or compositions may be administered via the same or different routes of administration. The compounds or compositions may be administered according to simultaneous or alternating regimens, at the same or different times during the course of the therapy, concurrently in divided or single forms.

The term "therapeutically effective amount" as used herein, refers to that amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue system, animal or human that is being sought by a researcher, veterinarian, medical doctor or other clinician, which includes alleviation of the symptoms of the disease or disorder being treated. In one aspect, the therapeutically effective amount is that which may treat or alleviate the disease or symptoms of the disease at a reasonable benefit/risk ratio applicable to any medical treatment. However, it is to be understood that the total daily usage of the compounds and compositions described herein may be decided by the attending physician within the scope of sound medical judgment. The specific therapeutically-effective dose level for any particular patient will depend upon a variety of factors, including the disorder being treated and the severity of the disorder; activity of the specific compound employed; the specific composition employed; the age, body weight, general health, gender and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidentally with the specific compound employed; and like factors well known to the researcher, veterinarian, medical doctor or other clinician of ordinary skill.


Depending upon the route of administration, a wide range of permissible dosages are contemplated herein, including doses falling in the range from about 1 µg/kg to about 1 g/kg. The dosages may be single or divided, and may administered according to a wide variety of protocols, including q.d. (once a day), b.i.d. (twice a day), t.i.d. (three times a day), or even every other day, once a week, once a month, once a quarter, and the like. In each of these cases it is understood that the therapeutically effective amounts described herein correspond to the instance of administration, or alternatively to the total daily, weekly, monthly, or quarterly dose, as determined by the dosing protocol.

In addition to the illustrative dosages and dosing protocols described herein, it is to be understood that an effective amount of any one or a mixture of the compounds described herein can be determined by the attending diagnostician or physician by the use of known techniques and/or by observing results obtained under analogous circumstances. In determining the effective amount or dose, a number of factors are considered by the attending diagnostician or physician, including, but not limited to the species of mammal, including human, its size, age, and general health, the specific disease or disorder involved, the degree of or involvement or the severity of the disease or disorder, the response of the individual patient, the particular compound administered, the mode of administration, the bioavailability characteristics of the preparation administered, the dose regimen selected, the use of concomitant medication, and other relevant circumstances.

The term "patient" includes human and non-human animals such as companion animals (dogs and cats and the like) and livestock animals. Livestock animals are animals raised for food production. The patient to be treated is preferably a mammal, in particular a human being.

24

In some illustrative embodiments, the present invention relates to a compound having a formula




or a pharmaceutically acceptable salt thereof, wherein R¹ is amino, hydroxyl, and derivatives thereof, an alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, heterocyclyl, cycloalkyl, cycloalkenyl, cycloheteroalkyl, cycloheteroalkenyl, acyl, aryl, heteroaryl, arylalkyl, arylalkenyl, or arylalkynyl, each of which is optionally substituted;

R² and R³ are each independently selected from the group consisting of hydrogen, deuterium, halo, azido, cyano, nitro, hydroxy, amino, thio, carboxy, ester, amide, and derivatives thereof, and acyl, sulfoxyl, sulfonyl, phosphate, phosphoryl, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, heterocyclyl, cycloalkyl, cycloalkenyl, cycloheteroalkyl, cycloheteroalkenyl, aryl, heteroaryl, arylalkyl, arylalkenyl, and arylalkynyl, each of which is optionally substituted;

or R² and R³ are taken together with the attached carbons to form an optionally substituted cyclic or heterocyclic moiety; and

R⁴ represents four substituents, each independently selected from the group consisting of hydrogen, deuterium, halo, azido, cyano, nitro, hydroxy, amino, thio, carboxy, ester, amide, and derivatives thereof, and acyl, sulfoxyl, sulfonyl, phosphate, phosphoryl, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, heterocyclyl, cycloalkyl, cycloalkenyl, cycloheteroalkyl, cycloheteroalkenyl, aryl, heteroaryl, arylalkyl, arylalkenyl, and arylalkynyl, each of which is optionally substituted; or any two adjacent substituents of the four substituents are taken together with the attached carbons form an optionally substituted cyclic or heterocyclic moiety.

In some illustrative embodiments, the present invention relates to a compound having a formula:



or a pharmaceutically acceptable salt thereof, wherein n=1~5; the bonding between A and B, between B and D may be a double bond or a single bond, but cannot be double bond at the same time; A, B, and D represents, independently, C, O, N, and S wherein at least one of A, B, and D is a heteroatom;

## 25

R<sup>1</sup> is amino, hydroxyl, and derivatives thereof, an alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, heterocyclyl, cycloalkyl, cycloalkenyl, cycloheteroalkyl, cycloheteroalkenyl, acyl, aryl, heteroaryl, arylalkyl, arylalkenyl, or arylalkynyl, each of which is optionally substituted;


R<sup>2</sup> and R<sup>3</sup> are each independently selected from the group consisting of hydrogen, deuterium, halo, azido, cyano, nitro, hydroxy, amino, thio, carboxy, ester, amide, and derivatives thereof, and acyl, sulfoxyl, sulfonyl, phosphate, phosphoryl, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heterocyclyl, cycloalkyl, cycloalkenyl, cycloheteroalkyl, cycloheteroalkenyl, aryl, heteroaryl, arylalkyl, arylalkenyl, and arylalkynyl, each of which is optionally substituted; or R<sup>2</sup> and R<sup>3</sup> are taken together with the attached carbons to form an optionally substituted cyclic or heterocyclic moiety;

R<sup>4</sup> represents two substituents, each independently selected from the group consisting of hydrogen, deuterium, halo, azido, cyano, nitro, hydroxy, amino, thio, carboxy, ester, amide, and derivatives thereof, and acyl, sulfoxyl, sulfonyl, phosphate, phosphoryl, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heterocyclyl, cycloalkyl, cycloalkenyl, cycloheteroalkyl, cycloheteroalkenyl, aryl, heteroaryl, arylalkyl, arylalkenyl, and arylalkynyl, each of which is optionally substituted; or the two substituents are taken together with the attached carbons to form an optionally substituted cyclic or heterocyclic moiety; and

depending on the element of A, B and D, R<sup>5</sup> represents two or three substituents, each independently selected from the group consisting of hydrogen, deuterium, halo, azido, cyano, nitro, hydroxy, amino, thio, carboxy, ester, amide, and derivatives thereof, and acyl, sulfoxyl, sulfonyl, phosphate, phosphoryl, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heterocyclyl, cycloalkyl, cycloalkenyl, cycloheteroalkyl, cycloheteroalkenyl, aryl, heteroaryl, arylalkyl, arylalkenyl, and arylalkynyl, each of which is optionally substituted.


In some illustrative embodiments, the present invention relates to a compound having a formula (II), wherein

R<sup>1</sup> is:




## 26

-continued



In some illustrative embodiments, the present invention relates to a compound having a formula (III),



or a pharmaceutically acceptable salt thereof, wherein n=1~5; the bonding between A and B, between B and D may be a double bond or a single bond, but cannot be double bond at the same time; A, B, and D represents, independently. C, O, N, and S wherein at least one of A, B, and D is a heteroatom;

R<sup>1</sup> is amino, hydroxyl, and derivatives thereof, an alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, heterocyclyl, cycloalkyl, cycloalkenyl, cycloheteroalkyl, cycloheteroalkenyl, acyl, aryl, heteroaryl, arylalkyl, arylalkenyl, or arylalkynyl, each of which is optionally substituted;

R<sup>4</sup> represents two substituents, each independently selected from the group consisting of hydrogen, deuterium, halo, azido, cyano, nitro, hydroxy, amino, thio, carboxy, ester, amide, and derivatives thereof, and acyl, sulfoxyl, sulfonyl, phosphate, phosphoryl, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heterocyclyl, cycloalkyl, cycloalkenyl, cycloheteroalkyl, cycloheteroalkenyl, aryl, heteroaryl, arylalkyl, arylalkenyl, and arylalkynyl, each of which is optionally substituted; or the two substituents are taken together with the attached carbons to form an optionally substituted cyclic or heterocyclic moiety.


depending on the element of A, B and D, R<sup>5</sup> represents two or three substituents, each independently selected from the group consisting of hydrogen, deuterium, halo, azido, cyano, nitro, hydroxy, amino, thio, carboxy, ester, amide, and derivatives thereof, and acyl, sulfoxyl, sulfonyl, phosphate, phosphoryl, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heterocyclyl, cycloalkyl, cycloalkenyl, cycloheteroalkyl, cycloheteroalkenyl, acyl, aryl, heteroaryl, arylalkyl, arylalkenyl, and arylalkynyl,

27

eroalkyl, cycloheteroalkenyl, aryl, heteraryl, arylalkyl, arylalkenyl, and arylalkynyl, each of which is optionally substituted; and

depending on the value of n, R<sup>6</sup> represents two to six substituents, each independently selected from the group consisting of hydrogen, deuterium, halo, azido, cyano, nitro, hydroxy, amino, thio, carboxy, ester, amide, and derivatives thereof, and acyl, sulfoxyl, sulfonyl, phosphate, phosphoryl, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, heterocycl, cycloalkyl, cycloalkenyl, cycloheteroalkyl, cycloheteroalkenyl, aryl, heteraryl, arylalkyl, arylalkenyl, and arylalkynyl, each of which is optionally substituted.


In some illustrative embodiments, the present invention relates to a compound having a formula (III), wherein R<sup>1</sup> is



In some illustrative embodiments, the present invention relates to a compound having a formula (IV).

28

(IV)



or a pharmaceutically acceptable salt thereof, wherein n=1~5;

R<sup>1</sup> is amino, hydroxyl, and derivatives thereof, an alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, heterocycl, cycloalkyl, cycloalkenyl, cycloheteroalkyl, cycloheteroalkenyl, acyl, aryl, heteraryl, arylalkyl, arylalkenyl, or arylalkynyl, each of which is optionally substituted;

R<sup>2</sup> and R<sup>3</sup> are each independently selected from the group consisting of hydrogen, deuterium, halo, azido, cyano, nitro, hydroxy, amino, thio, carboxy, ester, amide, and derivatives thereof, and acyl, sulfoxyl, sulfonyl, phosphate, phosphoryl, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, heterocycl, cycloalkyl, cycloalkenyl, cycloheteroalkyl, cycloheteroalkenyl, aryl, heteraryl, arylalkyl, arylalkenyl, and arylalkynyl, each of which is optionally substituted; or R<sup>2</sup> and R<sup>3</sup> are taken together with the attached carbons to form an optionally substituted cyclic or heterocyclic moiety;

R<sup>4</sup> represents two substituents, each independently selected from the group consisting of hydrogen, deuterium, halo, azido, cyano, nitro, hydroxy, amino, thio, carboxy, ester, amide, and derivatives thereof, and acyl, sulfoxyl, sulfonyl, phosphate, phosphoryl, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, heterocycl, cycloalkyl, cycloalkenyl, cyclohetereoalkyl, cycloheteroalkenyl, aryl, heteraryl, arylalkyl, arylalkenyl, and arylalkynyl, each of which is optionally substituted; or the two substituents are taken together with the attached carbons to form an optionally substituted cyclic or heterocyclic moiety:

depending on the element of A and B specified below, R<sup>5</sup> represents one or two substituents, each independently selected from the group consisting of hydrogen, deuterium, halo, azido, cyano, nitro, hydroxy, amino, thio, carboxy, ester, amide, and derivatives thereof, and acyl, sulfoxyl, sulfonyl, phosphate, phosphoryl, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, heterocycl, cycloalkyl, cycloalkenyl, cyclohetereoalkyl, cycloheteroalkenyl, aryl, heteraryl, arylalkyl, arylalkenyl, and arylalkynyl, each of which is optionally substituted;

A and B represents, independently, CR<sup>8</sup>, N, or NR<sup>9</sup>, wherein R<sup>8</sup> and R<sup>9</sup> represent independently hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, heterocycl, cycloalkyl, cycloalkenyl, cycloheteroalkyl, cycloheteroalkenyl, acyl, aryl, heteraryl, arylalkyl, arylalkenyl, or arylalkynyl, each of which is optionally substituted;


depending on the value of n, R<sup>6</sup> represents two to six substituents, each independently selected from the group consisting of hydrogen, deuterium, halo, azido, cyano, nitro, hydroxy, amino, thio, carboxy, ester, amide, and derivatives thereof, and acyl, sulfoxyl,

29


sulfonyl, phosphate, phosphoryl, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, heterocycl, cycloalkyl, cycloalkenyl, cycloheteroalkyl, cycloheteroalkenyl, aryl, heteroaryl, arylalkyl, arylalkenyl, and arylalkynyl, each of which is optionally substituted; and

$R^7$  is an alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, heterocycl, cycloalkyl, cycloalkenyl, cycloheteroalkyl, cycloheteroalkenyl, acyl, aryl, heteroaryl, arylalkyl, arylalkenyl, or arylalkynyl, each of which is optionally substituted.

In some illustrative embodiments, the present invention relates to a compound having a formula (IV), wherein  $R^1$  is



In some illustrative embodiments, the present invention relates to a compound having a formula (IV), wherein  $R^1$  is




A is carbon (C); B is nitrogen (N);  $R^5$ ,  $R^6$ , and  $R^7$  all represent hydrogen, and  $R^4$  represents two substituents, each


30

independently selected from the group consisting of hydrogen, deuterium, halo, azido, cyano, nitro, hydroxy, amino, thio, carboxy, ester, amide, and derivatives thereof, and acyl, sulfoxyl, sulfonyl, phosphate, phosphoryl, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, heterocycl, cycloalkyl, cycloalkenyl, cycloheteroalkyl, cycloheteroalkenyl, aryl, heteroaryl, arylalkyl, arylalkenyl, and arylalkynyl, each of which is optionally substituted; or the two substituents are taken together with the attached carbons to form an optionally substituted cyclic or heterocyclic moiety.

In some illustrative embodiments, the present invention relates to a compound having a formula (IV), wherein  $R^3$ ,




In some illustrative embodiments, the present invention relates to a compound having a formula (IV), wherein  $R^1$  is




**31**

-continued

**32**


-continued



US 12,384,782 B2


**33**

-continued




**34**

-continued




**35**

-continued


**36**

-continued




**37**

-continued


**38**

-continued

HSD-02-937



HSD-02-938



15

20

25

30

35

40


45

50


55

60


65




HSD-02-939




HSD-02-940



HSD-02-941





HSD-02-942



HSD-02-935







HSD-02-936



In some illustrative embodiments, the present invention relates to a compound having a formula (I), wherein the compound is


US 12,384,782 B2

**39**  
-continued




**40**  
-continued


HSD-02-943




HSD-02-944




HSD-02-98




HSD-02-09



HSD-02-91



HSD-02-92



HSD-02-93

HSD-02-94

HSD-02-95


HSD-02-96

HSD-02-97


HSD-02-99

US 12,384,782 B2


**41**  
-continued




HSD-02-910




HSD-02-911



HSD-02-912




HSD-02-913




HSD-02-914


**42**  
-continued




HSD915




HSD916




HSD917



HSD918



HSD919




HSD920

US 12,384,782 B2


**43**

-continued



**44**







-continued



US 12,384,782 B2

**45**


-continued




**46**

-continued


HSD-02-947



HSD-02-948




HSD-02-949




HSD-02-950

HSD-02-955

HSD-02-951



HSD-02-952



HSD-02-953


HSD-02-954

HSD-02-956

HSD-02-957


US 12,384,782 B2

**47**  
-continued



HSD-02-958

**48**  
-continued



HSD-02-959

HSD-02-960

HSD-02-961

HSD-02-962

HSD-02-963

60  
65

HSD-02-964

HSD-02-965

HSD-02-966







HSD-02-967

HSD-02-968

US 12,384,782 B2

**49**


-continued




**50**

-continued


HSD-02-969




HSD-02-970




HSD-02-971



HSD-02-972



HSD-02-973



HSD-02-974

HSD-02-976

HSD-02-977


HSD-02-978

HSD-02-980


HSD-02-981

US 12,384,782 B2


**51**  
-continued




HSD-02-982




HSD-02-983




HSD-02-984



HSD-02-985




HSD-02-986




HSD-02-987


**52**  
-continued



5




HSD-02-988




10

HSD-02-989




15

HSD-02-990




20

HSD-02-991




25

HSD-02-992



30


HSD-02-993



35


US 12,384,782 B2

**53**  
-continued




HSD-02-994

5




HSD-02-995

10




HSD-02-996

15




HSD-02-997

20




HSD-02-998

25




**54**  
-continued


HSD-02-1001




HSD1032



HSD1033



HSD1034




HSD1035

US 12,384,782 B2

**55**

-continued




HSD1037

**56**

-continued

HSD 02-1224



5

10

15

HSD1043

20

25

HSD1044

35

40

HSD1045

45



50

55

HSD 02-1223



60

65




HSD 02-1225


HSD 02-1228



HSD1229



HSD1255




HSH205

US 12,384,782 B2

**57**


-continued




HSD-02-1002

**58**


-continued




HSD-02-1007




HSD-02-1003




HSD-02-1008




HSD-02-1004




HSD-02-1009




HSD-02-1005



HSD-02-1010



HSD-02-1006




HSD-02-1011

US 12,384,782 B2

**59**

-continued




**60**

-continued


HSD-02-1012

HSD-02-1017




HSD-02-1013

HSD-02-1018




HSD-02-1014

HSD-02-1019




HSD-02-1015

HSD-02-1020




HSD-02-1016

HSD-02-1021




60

HSD-02-1022




US 12,384,782 B2

**61**  
-continued




HSD-02-1023


**62**  
-continued




HSD-02-1031




HSD-02-1024




HSD-02-1036




HSD-02-1025




HSD-02-1071




HSD-02-1026



HSD-02-1077



HSD-02-1027




HSD-02-1079

US 12,384,782 B2

**63**

-continued

HSD-02-1046




5

**64**


-continued

HSD-02-1051




10

HSD-02-1047




15




20

HSD-02-1048




25




30

HSD-02-1049




35




40


HSD-02-1050



45



50



55

60

65

HSD-02-1054


HSD-02-1055

US 12,384,782 B2

**65**

-continued


HSD-02-1056



5

10

15



HSD-02-1057


20

25

30

HSD-02-1058

35




40

45

50

HSD-02-1059

55




60

65

**66**

-continued

HSD-02-1060




5

10

15

HSD-02-1061




HSD-02-1057

20

25


HSD-02-1062



30

35

HSD-02-1063




40

45

50

HSD-02-1081




US 12,384,782 B2

**67**


-continued

HSD-02-1082




5

HSD-02-1083




10

HSD-02-1084




15

HSD-02-1085




20

HSD-02-1086




25

HSD-02-1087




30

HSD-02-1088



35

HSD-02-1089



40

HSD-02-1090



45

HSD-02-1091



50

HSD-02-1092



55

HSD-02-1093



60

HSD-02-1094




65

HSD-02-1095


**68**

-continued


HSD-02-1088




5




10




15




20




25




30



35



40



45



50



55



60



65




70

US 12,384,782 B2

**69**

-continued


HSD-02-1094



**70**



-continued

HSD-02-1099



HSD-02-1095



HSD-02-1100



30

HSD-02-1096



HSD-02-1101



HSD-02-1102

HSD-02-1097



45



HSD-02-1103

HSD-02-1098

55




60


65

US 12,384,782 B2

**71**  
-continued




**72**  
-continued




US 12,384,782 B2

**73**  
-continued




HSD1114A

5




HSD-02-1115

10




HSD-02-1116

20




HSD1169

25



HSD1170


30




**74**  
-continued

HSD-02-1276

5




10




HSD-02-1279

20




HSD-02-1280

30



HSD-02-1281

35



HSD-02-1282

40

45

50


55

60

65


US 12,384,782 B2

**75**  
-continued




HSD1285

5




HSD1286

10




HSD1287

15



HSD-02-1117


20



HSD-02-1118


25

**76**  
-continued




HSD-02-1119

5




HSD-02-1120

10




HSD-02-1121

15



HSD-02-1122

20



25

30

35

40

45

50

55


60

65

US 12,384,782 B2


**77**  
-continued

HSD-02-1123




**78**  
-continued


HSD-02-1127



HSD-02-1124




HSD-02-1128




35

HSD-02-1125




HSD-02-1129




55

HSD-02-1126



HSD-02-1143




US 12,384,782 B2


**79**

-continued


HSD-02-1144




HSD-02-1145



HSD-02-1146




HSD-02-1147




**80**

-continued



HSD-02-1148




HSD-02-1149




HSD-02-1150



HSD-02-1152



HSD-02-1153



50

55


60

65

US 12,384,782 B2


**81**

-continued



**82**

-continued




US 12,384,782 B2

**83**

-continued

HSD-02-1164




5

**84**


-continued

HSD-02-1173




10

HSD-02-1165




15

HSD-02-1166




20




HSD-02-1174

HSD-02-1167




30




HSD-02-1175

HSD-02-1168




40




HSD-02-1176

HSD-02-1169




50




HSD-02-1177

HSD-02-1171



60




HSD-02-1178


65

US 12,384,782 B2

85  
-continued









86  
-continued



US 12,384,782 B2


**87**  
-continued



**88**  
-continued

HSD-02-1196

5



HSD-02-1197

10

15

20

30

35

45

55

60

65

HSD 02-1203

HSD 02-1204

HSD 02-1205

HSD 02-1207

HSD 02-1208

HSD-1198

25

HSD-1199

30

HSD-1200




40

50

HSD-1202

60


65



US 12,384,782 B2

**89**


-continued




HSD 02-1209

**90**


-continued




HSD 02-1215




HSD 02-1210




HSD 02-1217




HSD 02-1211 30




HSD 02-1218




HSD 02-1213



HSD 02-1219




HSD 02-1214



HSD 02-1220


US 12,384,782 B2

**91**  
-continued




HSD 02-1221

5




HSD 02-1222

15




HSD1288

25



HSD1293


20



HSD1294



HSD1289

30




HSD1295

35




HSD290

40




HSD1291

45




HSD1296

50



HSD1297

55




60

65

US 12,384,782 B2

**93**


-continued



**94**


-continued

HSD1302




HSD1064

HSD303 15





HSD1065



30

HSD1068

HSD1066




35

HSD1068

HSD1067

HSD1069




45

HSD1069

HSD1419


HSD1070



55

HSD1070

60








65

US 12,384,782 B2

**95**


-continued




**96**

-continued


HSD1420




HSD1421




HSD1422




HSD1071



HSD1072



60



65

HSD1073

HSD1074

HSD1075

HSD1076


HSD1077

HSD1078

US 12,384,782 B2

**97**


-continued




HSD1079

**98**


-continued




HSD1080




HSD-02-1232




HSD-02-1233




HSD-02-1234




HSD-02-1235




HSD-02-1236



HSD-02-1237





HSD-02-1238




HSD-02-1239

## US 12,384,782 B2



**99****100**-continued  
HSD-02-1240

HSD-02-1243





HSD-02-1242

HSD-02-1243




HSD-02-1244

HSD-02-1245





HSD-02-1246

HSD-02-1247




HSD-02-1248

HSD-02-1252




## US 12,384,782 B2

**101**

-continued


HSD-02-1253

**102**


HSD-02-1254

HSD1416


HSD1417




HSD1418




HSD-02-1256




HSD-02-1257





HSD-02-1258



HSD-02-1259




HSD-02-1260




US 12,384,782 B2

**103**




**104**

-continued  
HSD-02-1261




HSD-02-1262

HSD-02-1263




HSD-02-1264


HSD-02-1265



HSD-02-1266





HSD-02-1267




HSD-02-1268


HSD-02-1269



HSD-02-1270




## US 12,384,782 B2

**105****106**

-continued


HSD-02-1271

HSD-02-1272




HSD-02-1273

HSD-02-1274




HSD-02-1275

HSD1304




HSD1308

HSD1310














HSD311

HSD312




HSD-02-1273




**107****108**-continued  
HSD1313


HSD1315




HSD1317




HSH124



HSH156



HSH162



HSD1314

HSD1316

HSD1318


HSH127

HSH159

HSH163

US 12,384,782 B2


109



110


-continued

HSH164




HSH165


HSD1319




HSD1320




HSD1321




HSD1322




HSD1323



HSD1324




## US 12,384,782 B2


**111****112**

-continued

HSD1325





HSD1326




HSD1327

HSD1328





HSD1329

HSD1330





HSD1331

HSD1332




HSD1333

HSD1334



US 12,384,782 B2


113




114

-continued


HSD1335




HSD1336




HSD1337




HSD1338




HSD1339




HSD1340




HSD1341



HSD1342




HSD1343



HSD1345


## US 12,384,782 B2

**115****116**

-continued



HSD1347

HSD1348





HSD1349

HSD1350





HSD1351

HSD1352





HSD1353B

HSD1355




HSD1356

HSD1357




## US 12,384,782 B2

**117****118**


-continued

HSD1358




HSD1359


HSD1360




HSD1361




HSD1362




HSD1363




HSD1364




HSD1365



HSD1366




HSD1368



US 12,384,782 B2


119




120

-continued


HSD1369




HSD1370




HSD1371




HSD1372




HSD1373




HSD1374




HSD1375



HSD1376




HSD1377



HSD1378

US 12,384,782 B2

121




122

-continued


HSD1379

HSD1380




HSD1381

HSD1382




HSD1383

HSD1384





HSH-2-52

HSD1385




HSD1386

HSD1387



US 12,384,782 B2


123




124

-continued


HSD1388




HSD1389




HSD1390




HSD1391




HSD1392




HSD1394




HSD1395



HSD1396




HSD1397



HSD1398

US 12,384,782 B2

125




126

-continued



HSD1399

HSD1400





HSD1401

HSD1402





HSD1403

HSGN46





HSGN16

HSD1404




HSD1405

HSD1406




US 12,384,782 B2

127




128


-continued  
HSD1407 HSD1409




HSD1410




HSD1411




HSD1412




HSD1413




HSD1414




HSD1415



HSD1423




HSD1424




US 12,384,782 B2

129




130


-continued  
HSD1425




HSD1426




HSD1427




HSD1428




HSD1429




HSD1430




HSD1431



HSD1432




HSD1433



HSD1434


US 12,384,782 B2

131




132


-continued  
HSD1435




HSD1436




HSD1437




HSD1438




HSD1439




HSD1440




HSD1441



HSD1442




HSD1443



HSD1444


US 12,384,782 B2

133




134


-continued  
HSD1445




HSD1446




HSD1447




HSD1448




HSD1449



HSD1450




HSD1451




HSD1452

## US 12,384,782 B2


**135**

-continued

HSD1453

**136**



HSD1454



HSD1584



HSD1454

HSD1455





HSD1456


HSD1457




HSD1458

**137**-continued  
HSD1459**138**


HSD1460




HSD1461




HSD1462




HSD1463




HSD1464




HSD1465



HSD1466




HSD1467



HSD1468

US 12,384,782 B2


139




140

-continued


HSD1469




HSD1470




HSD1471




HSD1472




HSD1473




HSD1474




HSD1475



HSD1476





HSD1477



HSD1478


## US 12,384,782 B2

**141****142**

-continued


HSD1479

HSD1480





HSD1481

HSD1482





HSD1483

HSD1484





HSD1485

HSD1486




HSD1487

HSD1488




US 12,384,782 B2

143




144



-continued


HSD1489

HSD1490




HSD1491

HSD1492




HSD1493

HSD1494




HSD1495

HSD1496




HSD1497

HSD1498




## US 12,384,782 B2

**145****146**


-continued

HSD1499




HSD1500


HSD1501




HSD1502




HSD1503




HSD1504




HSD1505




HSD1506



HSD1507




HSD1508




US 12,384,782 B2

147




148


-continued  
HSD1509




HSD1510




HSD1511




HSD1512




HSD1512





HSD1513



HSD1514




HSD1515



HSD1516

US 12,384,782 B2


**149**




**150**

-continued


HSD1517




HSD1518




HSD1519




HSD1520



HSD1521




HSD1522




HSD1523



HSD1524



HSD1525

HSD1526




**151****152**

-continued


HSD1527

HSD1528




HSD1529

HSD1530




HSD1531

HSD1532




HSD1533

HSD1534




HSD1535

HSD1536




HSD1537

HSD1538



US 12,384,782 B2


153



-continued


HSD1539

154




HSD1540

HSD1541




HSD1542

HSD1543




HSD1544

HSD1545




HSD1546

HSD1547




HSD1548

HSD1549




HSD1550



US 12,384,782 B2


**155**




-continued

HSD1551


**156**




HSD1552




HSD1553




HSD1554




HSD1555




HSD1556




HSD1557




HSD1558




HSD1559




HSD1560




HSD1561



HSD1562


**157****158**

-continued  
HSD1563      HSD1564




US 12,384,782 B2

159



160




-continued

HSD1571

HSD1572


HSD1573

HSD1574




HSD1575

HSD1576





HSD1577


HSD1578




HSD1579

HSD1580




**161****162**-continued  
HSD1581

HSD1582



HSD1583



In some illustrative embodiments, the present invention relates to a pharmaceutical composition comprising one or more compounds disclosed herein, or a pharmaceutically acceptable salt thereof, together with one or more diluents, excipients or carriers.

In some illustrative embodiments, the present invention relates to a kinase inhibitor, wherein the kinase is selected from the group consisting of FLT3, MNK1/2, JAK1/2/3, Limk1/2, various CDKs, Haspin, ROCK1/2, TOPK, LRRK2, GSK3a/b, RSK1-4, ERK, P70S6K, AKT, PI3K, p38, PKC, PKA, FGFR1-4, VEGFR1-3, ALK, AXL, LIMK1/2, Aurora A/B, ABL1, AKT, CSF1R, CSNK1D, DCAMKL1, CSNK1G2, EPHA2, ERBB2, IKK-alpha, IKK-beta, JNK1/2/3, MARK3, MEK1/2, MET, MLK1, PAK1/2/4, PDGFRa/b, PIM1/2/3, PLK1/2/3/4, PRKCE, PRKX, RET, TAOK2, TRKA/B/C, ULK2, and receptor-interacting protein kinase 4 (RIPK4).

In some illustrative embodiments, the present invention relates to a method for treating diseases mediated by a kinase and/or histone demethylases, including inflammation, cancer, viral and bacterial infections, gastrointestinal disorders, eye diseases, neurological, cardiovascular and immunological disorders, comprising the step of administering a therapeutically effective amount of one or more compounds disclosed herein, and one or more carriers, diluents, or excipients, to a patient in need of relief from said cancer.

In some illustrative embodiments, the present invention relates to a method for treating diseases mediated by a kinase and histone demethylases, including inflammation, cancer, viral and bacterial infections, gastrointestinal disorders, eye diseases, neurological, cardiovascular and immunological disorders, comprising the step of administering a therapeutically effective amount of a compound disclosed herein in combination with one or more other compounds of the same

or different mode of action, and one or more carriers, diluents, or excipients, to a patient in need of relief from said cancer.

In some other illustrative embodiments, the present invention relates to a drug conjugate, either small molecule or biologic conjugate, comprising one or more compounds disclosed herein, wherein the conjugate confers cell-type or tissue type targeting or the conjugate targets another pathway that synergies the action of the compounds.

In some illustrative embodiments, the present invention relates to a drug conjugate, either small molecule or biologic conjugate, comprising one or more compounds disclosed herein, wherein the conjugate confers aqueous solubility or low clearance.

In some illustrative embodiments, the present invention relates to a drug conjugate containing one or more compounds disclosed herein, and a moiety that aids the degradation of target proteins via systems including but not limited to the ubiquitin ligase/proteosome degradation system.

In some illustrative embodiments, the present invention relates to a pharmaceutical composition comprising nanoparticles of one or more compounds disclosed herein, together with one or more diluents, excipients or carriers.

In some illustrative embodiments, the present invention relates to a prodrug comprising one or more compounds disclosed herein, wherein the prodrug moiety is removed at specific location, such as gastrointestinal or in blood or in tissues or in cancer specific.

In some illustrative embodiments, the present invention relates to an analogs of compounds disclosed herein whereby specific metabolic hot spots are modified with groups such as deuterium or fluorine.

In addition, it is appreciated herein that the compounds described herein may be used in combination with other

## 163

compounds that are administered to treat other symptoms of cancer, such as compounds administered to relieve pain, nausea, vomiting, and the like.

The following non-limiting exemplary embodiments are included herein to further illustrate the invention. These exemplary embodiments are not intended and should not be interpreted to limit the scope of the invention in any way. It is also to be understood that numerous variations of these exemplary embodiments are contemplated herein.

## Experimental Section and Characterization:

General Procedure for the Multicomponent Reaction:<sup>10</sup>

Method A: A mixture of amine (1 mmol) and aldehyde (1 mmol) in 3 mL of absolute ethanol was refluxed for 2 h followed by addition of cyclic ketone or acetaldehyde (2.1 mmol) to the reaction mixture. A catalytic amount of cone, hydrochloric acid was added and the reaction was continued to reflux for 6-12 h. Reaction mixture concentrated and dissolved in DCM (50 mL), washed with brine solution (20 mL×2). The organic layer was dried ( $\text{Na}_2\text{SO}_4$ ), concentrated under reduced pressure, and purified by silica gel chromatography (dichloromethane:methanol (99:01 to 80:20) to give the desired cyclized compound.

Method B: A mixture of amine (1 mmol) and aldehyde (1 mmol) in 3 mL acetonitrile was refluxed for 2 h. The reaction mixture allowed to cool to room temperature followed by addition of alkene (2 mmol) and  $\text{Y}(\text{OTf})_3$  (30 mol %). The reaction continued to reflux for overnight. Reaction mixture concentrated and purified by silica gel chromatography dichloromethane:methanol (99:01) to give the desired cyclized compound.

Method C: A mixture of amine (1 mmol), aldehyde (1 mmol) and cyclic ketone (2 mmol) in 6 mL tetrahydrofuran in presence of iodine (10 mol %) was refluxed for 6-12 h. After completion of reaction, reaction mixture was concentrated and purified by silica gel chromatography ethyl acetate:hexane (80:20) or dichloromethane:methanol (99:01) to give the desired cyclized compound. (Note: Sometime product may get precipitated out, which was filtered, washed with absolute ethanol and further purified by column chromatography).

Kinase assay: HotSpot kinase screening assay (Reaction Biology) was used to measure kinase/inhibitor interactions. Kinase and substrate were mixed in a buffer containing 20 mM HEPES pH 7.5, 10 mM  $\text{MgCl}_2$ , 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mM  $\text{Na}_3\text{VO}_4$ , 2 mM DTT and 1% DMSO. Single-dose of compounds (500 nM) were then added to each reaction mixture. After 20-minute incubation, ATP (Sigma) and [ $\gamma$ -<sup>33</sup>P] ATP (Perkin Elmer) were added at a final total concentration of 100  $\mu\text{M}$  for addition 2 hours at room temperature, followed by spotting onto P81 ion exchange cellulose chromatography paper (Whatman, Inc.).

Filter paper was washed in 0.75% phosphoric acid to remove unincorporated ATP. Percent remaining kinase activity of a vehicle (DMSO) containing kinase reaction was calculated for each kinase/inhibitor pair using Prism 5 (GraphPad).

## LSD1 Assay:


The LSD1 Assay Kit was used to measure LSD1 activity of purified LSD1 enzyme. In a 96 well plate was added LSD1 buffer, 10  $\mu\text{M}$  Histone H3(1-21)K4me2 peptide, and the test compound or DMSO control. The reaction was initiated with LSD1 enzyme. After 30 min incubation at room temperature, peroxidase and Amplex Red reagents are added and fluorescence ( $\lambda_{\text{ex}}=530\pm13$  nm.  $\lambda_{\text{cm}}=590\pm18$  nm) is measured after 5 min, using a plate reader. Percentage inhibition is calculated as fluorescence intensity in the presence of inhibitor divided by DMSO control times 100%.

## 164

IC<sub>50</sub> Proliferation Assay


Cell lines and primary cells were seeded into 96-well plates the afternoon prior to treatment. Approximately 18 hours later, compounds were semi-serially diluted in dimethyl sulfoxide (DMSO) and then growth medium, and added to cells. Plates were incubated for 72 hours prior to addition of Alamar Blue (Life Technologies, Carlsbad, CA). Plates were read after 4 additional hours of incubation at 37° C. using a Bio-Tek Synergy HT plate reader (Bio-Tek, Winooski, VT). Data was analyzed and graphed using GraphPad Prism Software (Graphpad, La Jolla, CA).

## 4-(8,9,10,11-Tetrahydro-3H-pyrrolo[3,2-a]phenanthridin-7-yl)phenol




Yellow solid (195 mg, 62%). <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) δ 10.35 (s, 1H), 8.20 (d, J=9.0 Hz, 1H), 8.02 (d, J=9.0 Hz, 1H), 7.79 (s, 1H), 7.58 (d, J=8.2 Hz, 2H), 7.31 (s, 1H), 7.05 (d, J=8.2 Hz, 2H), 3.56 (d, J=6.6 Hz, 2H), 2.80 (t, J=6.3 Hz, 2H), 2.02 (d, J=8.4 Hz, 2H), 1.87-1.61 (m, 2H), <sup>13</sup>C NMR (126 MHz, DMSO-d<sub>6</sub>) δ 160.28, 150.26, 133.77, 131.92, 129.82, 127.07, 123.08, 121.33, 119.87, 115.98, 106.80, 31.35, 28.22, 22.01, 21.65; HRMS (ESI) m/z calcd for C<sub>21</sub>H<sub>19</sub>N<sub>2</sub>O [M+H]<sup>+</sup> 315.1497, found 315.1499.

## 4-(8,9,10,11-Tetrahydro-3H-pyrazolo[4,3-a]phenanthridin-7-yl)phenol




Method A: Off white solid (189 mg, 60%). <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) δ 10.46 (s, 1H), 8.67 (s, 1H), 8.16 (d, J=9.5 Hz, 1H), 7.60 (d, J=8.1 Hz, 2H), 7.06 (d, J=5 Hz, 1H), 3.31 (s, 1H), 2.80 (s, 1H), 2.00 (s, 1H), 1.74 (s, 1H); <sup>13</sup>C NMR (126 MHz, DMSO-d<sub>6</sub>) δ 160.40, 152.79, 151.09, 134.91, 132.09, 131.87, 122.67, 122.43, 119.96, 115.95, 114.66, 30.85, 28.21, 21.72, 21.66; HRMS (ESI) m/z calcd for C<sub>20</sub>H<sub>18</sub>N<sub>2</sub>O [M+H]<sup>+</sup> 316.1449, found 316.1458.

**165**4-(8,9-Dihydro-3H-cyclobuta[c]pyrrolo[3,2-f]quino-  
lin-7-yl)phenol


HSD-02-91

5

**166**4-(9-Methyl-8,9,10,11-tetrahydro-3H-pyrrolo[3,2-a]  
phenanthridin-7-yl)phenol

HSD-02-93

Method C: Yellow solid (166 mg, 58%). <sup>1</sup>H NMR (500 MHz, Methanol-d<sub>4</sub>) δ 8.12 (d, J=9.1 Hz, 1H), 8.00 (d, J=8.5 Hz, 2H), 7.97 (d, J=9.2 Hz, 2H), 7.65 (d, J=3.0 Hz, 1H), 7.14-7.04 (m, 2H), 3.92 (t, J=3.7 Hz, 2H), 3.85 (t, J=3.8 Hz, 2H); <sup>13</sup>C NMR (126 MHz, DMSO) δ 161.86, 154.45, 143.71, 135.70, 134.66, 132.88, 131.33, 127.84, 123.68, 120.93, 119.32, 118.50, 116.87, 109.93, 103.31, 31.49. HRMS (ESI) m/z calcd for C<sub>19</sub>H<sub>15</sub>N<sub>2</sub>O [M+H]<sup>+</sup> 287.1184, found 287.1184.

4-(3,8,9,10-Tetrahydrocyclopenta[c]pyrrolo[3,2-f]  
quinolin-7-yl)phenol

HSD-02-92

40

45

50


55

Method A: Yellow solid (181 mg, 60%). <sup>1</sup>H NMR (500 MHz, Methanol-d<sub>4</sub>) δ 8.18 (dd, J=9.0, 0.9 Hz, 1H), 7.92 (d, J=9.0 Hz, 1H), 7.79-7.72 (m, 2H), 7.70 (d, J=3.1 Hz, 1H), 7.27 (dd, J=3.1, 0.9 Hz, 1H), 7.11-7.04 (m, 2H), 3.92-3.79 (m, 2H), 3.37 (t, J=7.6 Hz, 2H), 2.49 (p, J=7.7 Hz, 2H); <sup>13</sup>C NMR (126 MHz, Methanol-d<sub>4</sub>) δ 160.89, 146.91, 136.04, 135.25, 133.22, 130.80, 126.63, 122.44, 121.08, 120.85, 120.21, 115.78, 112.16, 104.20, 35.16, 31.66, 24.38; HRMS (ESI) m/z calcd for C<sub>20</sub>H<sub>17</sub>N<sub>2</sub>O [M+H]<sup>+</sup> 301.1340, found 301.1340.

Method A: Yellow solid (277 mg, 59%). <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) δ 11.80 (s, 1H), 10.10 (s, 1H), 7.80 (d, J=8.9 Hz, 0H), 7.73 (s, 1H), 7.64 (d, J=8.9 Hz, 0H), 7.51 (t, J=2.7 Hz, 0H), 7.13 (t, J=2.5 Hz, 1H), 3.37 (t, J=6.5 Hz, 1H), 2.79 (t, J=6.1 Hz, 1H), 2.03-1.89 (m, 1H), 1.74 (dq, J=6.3, 3.2 Hz, 1H); <sup>13</sup>C NMR (126 MHz, DMSO) δ 152.61, 150.86, 142.79, 135.62, 133.32, 127.69, 124.22, 123.48, 122.70, 120.25, 116.95, 116.65, 111.87, 106.37, 30.09, 28.90, 22.72, 22.48; HRMS (ESI) m/z calcd for C<sub>21</sub>H<sub>17</sub>Br<sub>2</sub>N<sub>2</sub>O [M+H]<sup>+</sup> 470.9707, found 470.9705.

**167**


7-(4-Bromophenyl)-8,9,10,11-tetrahydro-3H-pyrrolo[3,2-a]phenanthridine



HSD-02-95

**168**


7-(3,4,5-Trimethoxyphenyl)-8,9,10,11-tetrahydro-3H-pyrrolo[3,2-a]phenanthridine



HSD-02-97

Method A: Off white solid (207 mg, 55%). <sup>1</sup>H NMR (500 MHz, Methanol-d<sub>4</sub>) δ 7.80 (dd, J=8.9, 0.9 Hz, 1H), 7.70 (d, J=8.9 Hz, 1H), 7.66 (d, J=8.4 Hz, 2H), 7.44-7.40 (m, 3H), 7.20 (dd, J=3.3, 0.9 Hz, 1H), 3.53-3.45 (m, 2H), 2.74 (t, J=6.2 Hz, 2H), 2.13-2.01 (m, 2H), 1.87-1.76 (m, 2H); <sup>13</sup>C NMR (126 MHz, Methanol-d<sub>4</sub>) δ 154.80, 143.92, 142.60, 140.03, 133.30, 131.01, 130.67, 127.22, 122.92, 122.85, 121.94, 121.71, 120.23, 116.08, 105.79, 29.93, 28.51, 22.43, 22.09; HRMS (ESI) m/z calcd for C<sub>21</sub>H<sub>18</sub>BrN<sub>2</sub> [M+H]<sup>+</sup> 377.0653, found 377.0653.


4-(9-Methyl-3H-pyrrolo[3,2-f]quinolin-7-yl)phenol



HSD-02-96

4-(9,9-dimethyl-8,9,10,11-tetrahydro-3H-pyrrolo[3,2-a]phenanthridin-7-yl)phenol

35



HSD-02-99

Method A: Yellow solid (173 mg, 63%). <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) δ 10.57 (s, 1H), 8.24 (d, J=6.4 Hz, 3H), 8.09 (d, J=8.8 Hz, 1H), 7.80 (s, OH), 7.28 (s, 1H), 7.07 (d, J=8.8 Hz, 1H), 3.14 (s, 3H); <sup>13</sup>C NMR (126 MHz, DMSO-d<sub>6</sub>) δ 161.75, 149.00, 133.54, 131.40, 127.61, 122.28, 121.80, 121.28, 120.94, 116.69, 105.84, 24.33; HRMS (ESI) m/z calcd for C<sub>18</sub>H<sub>15</sub>N<sub>2</sub>O [M+H]<sup>+</sup> 275.1184, found 275.1192.


55

Method A: White crystalline solid (188 mg, 53%). <sup>1</sup>H NMR (500 MHz, Methanol-d<sub>4</sub>) δ 7.79 (d, J=8.9 Hz, 1H), 7.71 (d, J=8.9 Hz, 1H), 7.43 (d, J=3.1 Hz, 1H), 7.32 (d, J=8.1 Hz, 2H), 7.21 (d, J=3.1 Hz, 1H), 6.92 (d, J=8.1 Hz, 2H), 3.50 (t, J=6.8 Hz, 2H), 2.56 (s, 2H), 1.80 (t, J=6.7 Hz, 2H), 0.97 (s, 6H); <sup>13</sup>C NMR (126 MHz, Methanol-d<sub>4</sub>) δ 157.35, 156.02, 143.16, 141.88, 133.19, 131.52, 130.07, 126.84, 122.96, 122.26, 121.28, 120.30, 116.11, 114.60, 105.73, 48.11, 48.05, 47.94, 47.77, 47.60, 47.43, 47.26, 47.09, 42.06, 34.69, 28.29, 27.71, 26.60; HRMS (ESI) m/z calcd for C<sub>23</sub>H<sub>23</sub>N<sub>2</sub>O [M+H]<sup>+</sup> 343.1810, found 343.1808.

US 12,384,782 B2

**169**


5-(8,9,10,11-Tetrahydro-3H-pyrrolo[3,2-a]phenanthridin-7-yl)benzene-1,2,3-triol



HSD-02-910

**170**

7-(2,2-Difluorobenzo[d][1,3]dioxol-5-yl)-8,9,10,11-tetrahydro-3H-pyrrolo[4,3-a]phenanthridine




ND-02-912

Method A: Yellow solid (246 mg, 71%). <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) δ 9.52 (s, 2H), 9.01 (s, 1H), 8.17 (d, J=8.9 Hz, 1H), 7.95 (d, J=8.9 Hz, 1H), 7.78 (s, 1H), 7.27 (s, 1H), 6.65 (s, 2H), 3.50 (t, J=6.4 Hz, 2H), 2.80 (t, J=6.2 Hz, 2H), 2.03-1.98 (m, 2H), 1.83-1.73 (m, 2H); <sup>13</sup>C NMR (126 MHz, DMSO-d<sub>6</sub>) δ 154.17, 150.35, 146.76, 136.24, 133.69, 129.63, 127.03, 122.96, 122.04, 121.27, 119.85, 113.64, 109.26, 109.26, 106.74, 31.31, 28.26, 21.99, 21.58; HRMS (ESI) m/z calcd for C<sub>21</sub>H<sub>19</sub>N<sub>2</sub>O<sub>3</sub> [M+H]<sup>+</sup> 347.1395, found 347.1390.


4-(6,7,8,9-Tetrahydro-1H-pyrrolo[2,3-c]phenanthridin-5-yl)phenol

Method A: Off-white solid (57 mg, 15%) <sup>1</sup>H NMR (500 MHz, Methanol-d<sub>4</sub>) δ 7.78 (dd, J=9.0, 3.6 Hz, 1H), 7.68 (dd, J=9.1, 3.6 Hz, 1H), 7.36 (dt, J=40.7, 3.0 Hz, 2H), 7.32-7.20 (m, 2H), 7.15 (d, J=3.5 Hz, 1H), 3.42 (q, J=5.7 Hz, 2H), 2.69 (q, J=5.4 Hz, 2H), 2.05-1.94 (m, 2H), 1.82-1.69 (m, 2H); <sup>13</sup>C NMR (126 MHz, MeOD) δ 154.25, 144.03, 143.32, 143.22, 142.52, 137.40, 133.29, 131.73, 127.27, 124.87, 122.96, 122.87, 121.94, 120.19, 116.15, 110.39, 108.94, 105.81, 29.90, 28.49, 22.35, 22.03; HRMS (ESI) m/z calcd for C<sub>21</sub>H<sub>16</sub>F<sub>2</sub>N<sub>3</sub>O<sub>2</sub> [M+H]<sup>+</sup> 380.1211, found 380.1216.

7-(1-Methyl-1H-imidazol-5-yl)-8,9,10,11-tetrahydro-3H-pyrrolo[3,2-a]phenanthridine



HSD-02-911



HSD-02-913


Method A: Yellow solid (163 mg, 52%). <sup>1</sup>H NMR (500 MHz, Methanol-d<sub>4</sub>) δ 8.05-7.92 (m, 2H), 7.58-7.52 (m, 3H), 7.48 (d, J=3.2 Hz, 1H), 7.07 (d, J=8.3 Hz, 2H), 3.51 (t, J=6.5 Hz, 2H), 2.82 (d, J=6.4 Hz, 2H), 2.06 (dd, J=7.7, 4.3 Hz, 2H), 1.92-1.77 (m, 2H); <sup>13</sup>C NMR (126 MHz, Methanol-d<sub>4</sub>) δ 160.10, 155.63, 152.51, 137.17, 131.84, 130.93, 128.03, 125.79, 122.79, 122.70, 116.47, 116.22, 115.74, 115.44, 101.89, 27.60, 27.36, 21.68, 21.30; HRMS (ESI) m/z calcd for C<sub>21</sub>H<sub>19</sub>N<sub>2</sub>O [M+H]<sup>+</sup> 315.1497, found 315.1495.

Method A: Off-white solid (151 mg, 50%). <sup>1</sup>H NMR (500 MHz, Methanol-d<sub>4</sub>) δ 7.79 (d, J=7.9 Hz, 2H), 7.66 (d, J=8.9 Hz, 1H), 7.40 (d, J=3.1 Hz, 1H), 7.18 (s, 1H), 7.12 (d, J=3.1 Hz, 1H), 3.60 (s, 3H), 3.38 (t, J=6.5 Hz, 2H), 2.75 (t, J=6.3 Hz, 2H), 2.00-1.94 (m, 2H), 1.81 (q, J=6.0, 5.6 Hz, 2H); <sup>13</sup>C NMR (126 MHz, Methanol-d<sub>4</sub>) δ 144.67, 144.01, 142.83, 138.47, 133.43, 130.97, 129.25, 128.07, 122.97, 122.14, 120.11, 116.34, 105.94, 31.45, 29.82, 27.83, 22.28, 21.90; HRMS (ESI) m/z calcd for C<sub>19</sub>H<sub>19</sub>N<sub>4</sub> [M+H]<sup>+</sup> 303.1609, found 303.1599.

US 12,384,782 B2

**171**


4-(8,9,10,11-Tetrahydro-3H-pyrrolo[3,2-a]phenanthridin-7-yl)benzene-1,3-diol



HSD-02-914

**172**


4-(8,9,10,11-Tetrahydro-3H-[1,2,3]triazolo[4,5-a]phenanthridin-7-yl)phenol



HSD-02-916

Method A: Yellow solid (142 mg, 43%).  $^1\text{H}$  NMR (500 MHz, Methanol- $d_4$ )  $\delta$  7.77 (dd,  $J=8.9, 0.8$  Hz, 1H), 7.68 (d,  $J=8.9$  Hz, 1H), 7.42 (d,  $J=3.1$  Hz, 1H), 7.19 (dd,  $J=3.2, 0.9$  Hz, 1H), 7.09 (d,  $J=8.9$  Hz, 1H), 6.46-6.42 (m, 2H), 3.49 (t,  $J=6.5$  Hz, 2H), 2.80 (t,  $J=6.3$  Hz, 2H), 2.09-2.02 (m, 2H), 1.87-1.78 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, Methanol- $d_4$ )  $\delta$  158.65, 156.16, 154.02, 143.81, 141.57, 133.18, 130.73, 129.43, 122.78, 122.59, 121.13, 120.30, 118.60, 115.81, 106.34, 105.68, 102.35, 29.99, 27.42, 22.52, 22.05; HRMS (ESI) m/z calcd for  $C_{21}\text{H}_{19}\text{N}_2\text{O}_2$  [M+H] $^+$  331.1446, found 331.1440.


4-(3,8,9,10,11,12-Hexahydrocyclohepta[c]pyrrolo[3,2-f]quinolin-7-yl)phenol



HSD-02-915

Method A: Off white solid (237 mg, 75%).  $^1\text{H}$  NMR (500 MHz, DMSO- $d_6$ )  $\delta$  9.73 (s, 1H), 8.04 (d,  $J=9.1$  Hz, 1H), 7.89 (d,  $J=9.1$  Hz, 1H), 7.44 (d,  $J=8.3$  Hz, 2H), 6.89 (d,  $J=8.4$  Hz, 2H), 3.67 (s, 2H), 2.81 (s, 1H), 2.03-1.88 (m, 2H), 1.82-1.59 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  158.08, 143.69, 131.01, 130.34, 118.90, 115.25, 30.03, 28.96, 26.90, 24.76. HRMS (ESI) m/z calcd for  $C_{19}\text{H}_{17}\text{N}_4\text{O}$  [M+H] $^+$  317.1402, found 317.1408.

4-(2,3,4,8-Tetrahydro-1H-pyrrolo[3,2-b]phenanthridin-5-yl)phenol



HSD-02-917


Method A: Off white solid (187 mg, 57%).  $^1\text{H}$  NMR (500 MHz, DMSO- $d_6$ )  $\delta$  11.67 (s, 1H), 9.52 (s, 1H), 7.72 (s, 1H), 7.56 (d,  $J=8.9$  Hz, 1H), 7.45 (d,  $J=2.8$  Hz, 1H), 7.29 (d,  $J=8.1$  Hz, 2H), 7.07 (d,  $J=3.1$  Hz, 1H), 6.85 (s, 2H), 3.55 (dd,  $J=6.8, 3.3$  Hz, 2H), 3.08-2.96 (m, 2H), 1.88 (dq,  $J=16.5, 4.5$  Hz, 4H), 1.63 (p,  $J=5.1$  Hz, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO- $d_6$ )  $\delta$  157.25, 157.11, 154.98, 148.20, 144.09, 133.98, 133.26, 133.10, 132.98, 130.91, 124.12, 123.99, 123.82, 121.64, 120.00, 116.78, 116.72, 115.09, 115.00, 105.09, 31.64, 30.68, 30.11, 27.75, 25.12; HRMS (ESI) m/z calcd for  $C_{22}\text{H}_{21}\text{N}_2\text{O}$  [M+H] $^+$  329.1653, found 329.1652.

Method A: Off white solid (185 mg, 59%).  $^1\text{H}$  NMR (500 MHz, Methanol- $d_4$ )  $\delta$  7.87 (d,  $J=8.7$  Hz, 1H), 7.62 (d,  $J=8.7$  Hz, 1H), 7.43 (d,  $J=3.1$  Hz, 1H), 7.34 (d,  $J=8.5$  Hz, 1H), 6.92 (d,  $J=8.5$  Hz, 2H), 6.70 (d,  $J=3.1$  Hz, 1H), 3.50 (t,  $J=6.5$  Hz, 2H), 2.78 (t,  $J=6.3$  Hz, 2H), 2.13-2.05 (m, 2H), 1.86-1.80 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, MeOD)  $\delta$  157.34, 156.57, 143.27, 141.29, 131.70, 130.00, 128.49, 127.57, 125.52, 124.19, 123.50, 119.83, 117.04, 114.57, 102.65, 29.32, 28.61, 22.41, 22.04; HRMS (ESI) m/z calcd for  $C_{21}\text{H}_{19}\text{N}_2\text{O}$  [M+H] $^+$  315.1497, found 315.1495.

## US 12,384,782 B2

**173**


4-(2,3,4,8-Tetrahydro-1H-pyrrolo[3,2-b]phenanthridin-5-yl)phenol



HSD-02-918

**174**

2-Fluoro-4-(8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridin-7-yl)phenol



HSD-02-920


Method A: Off white solid (178 mg, 54%).  $^1\text{H}$  NMR (500 MHz, DMSO-d<sub>6</sub>)  $\delta$  11.81 (s, 1H), 8.85 (s, 2H), 7.81 (d, J=8.9 Hz, 1H), 7.66 (d, J=8.8 Hz, 1H), 7.51 (t, J=2.8 Hz, 1H), 7.13 (t, J=2.5 Hz, 1H), 3.99 (s, 3H), 3.37 (t, J=6.5 Hz, 2H), 2.84 (t, J=6.2 Hz, 2H), 1.99-1.91 (m, 2H), 1.75 (dd, J=7.5, 4.3 Hz, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  164.77, 159.82, 149.96, 143.68, 142.81, 133.37, 129.18, 127.97, 124.12, 124.09, 122.80, 120.25, 116.84, 106.43, 55.22, 29.96, 28.70, 22.75, 22.49; HRMS (ESI) m/z calcd for C<sub>20</sub>H<sub>19</sub>N<sub>4</sub>O [M+H]<sup>+</sup> 331.1558, found 331.1553.

2,2'-(2,3,4,8-tetrahydro-3H-pyrrolo[3,2-a]phenanthridin-7-yl)phenyl)azanediyl)diethanol


Method A: Off white solid (207 mg, 62%).  $^1\text{H}$  NMR (500 MHz, DMSO-d<sub>6</sub>)  $\delta$  10.81 (s, 1H), 8.83 (s, 1H), 8.26 (d, J=9.2 Hz, 1H), 8.21 (d, J=9.2 Hz, 1H), 7.66 (dd, J=11.8, 2.2 Hz, 1H), 7.42 (dd, J=8.4, 2.1 Hz, 1H), 7.26 (t, J=8.6 Hz, 1H), 3.49 (t, J=6.4 Hz, 2H), 2.83 (t, J=6.2 Hz, 2H), 2.07-2.00 (m, 2H), 1.85-1.76 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  151.89, 149.96, 147.88, 135.32, 132.02, 127.33, 123.16, 120.36, 118.65, 118.49, 118.29, 114.87, 30.92, 28.11, 21.80, 21.69; HRMS (ESI) m/z calcd for C<sub>20</sub>H<sub>17</sub>FN<sub>3</sub>O [M+H]<sup>+</sup> 334.1355, found 334.1352.

7-(Pyridin-4-yl)-8,9,10,11-tetrahydro-3H-pyrrolo[3,2-a]phenanthridine

35



35



55



Method A: Yellow solid (209 mg, 70%).  $^1\text{H}$  NMR (500 MHz, Methanol-d<sub>4</sub>)  $\delta$  8.00 (d, J=8.9 Hz, 1H), 7.77 (d, J=8.9 Hz, 1H), 7.59 (d, J=3.1 Hz, 1H), 7.48-7.43 (m, 2H), 7.28 (d, J=3.2 Hz, 1H), 6.95 (d, J=8.9 Hz, 2H), 3.79 (t, J=6.0 Hz, 4H), 3.65 (t, J=6.0 Hz, 4H), 2.90 (t, J=6.2 Hz, 2H), 2.12-2.06 (m, 2H), 1.84 (td, J=6.2, 3.2 Hz, 2H);  $^{13}\text{C}$  NMR (126 MHz, MeOD)  $\delta$  152.36, 151.09, 149.41, 136.32, 133.50, 130.36, 129.04, 124.91, 122.68, 121.37, 120.18, 118.91, 115.34, 111.33, 106.08, 58.85, 53.41, 30.85, 28.37, 21.94, 21.66; HRMS (ESI) m/z calcd for C<sub>25</sub>H<sub>28</sub>N<sub>3</sub>O<sub>2</sub> [M+H]<sup>+</sup> 402.2181, found 402.2179.

Method A: Off white solid (183 mg, 61%).  $^1\text{H}$  NMR (500 MHz, DMSO-d<sub>6</sub>)  $\delta$  11.81 (s, 1H), 8.67 (dt, J=4.4, 1.5 Hz, 2H), 7.81 (d, J=8.8 Hz, 1H), 7.65 (d, J=8.9 Hz, 1H), 7.60-7.55 (m, 2H), 7.54-7.48 (m, 1H), 7.14 (s, 1H), 3.40 (t, J=6.6 Hz, 2H), 2.77 (t, J=6.1 Hz, 2H), 2.01-1.94 (m, 2H), 1.75 (q, J=5.9 Hz, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  153.34, 149.84, 149.10, 143.44, 142.78, 133.41, 127.19, 124.49, 124.16, 124.08, 122.90, 120.26, 116.87, 106.42, 29.94, 28.67, 22.76, 22.39; HRMS (ESI) m/z calcd for C<sub>20</sub>H<sub>18</sub>N<sub>3</sub> [M+H]<sup>+</sup> 300.1500, found 300.1508.

US 12,384,782 B2

**175**


4-(2,3,4,9-Tetrahydro-1H-indolo[3,2-a]phenanthridin-5-yl)phenol



Method A: Brown solid (175 mg, 48%). <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) δ 8.52 (d, J=8.5 Hz, 1H), 8.25 (dd, J=8.0, 3.7 Hz, 2H), 7.73 (dd, J=8.5, 4.1 Hz, 1H), 7.58 (ddd, J=8.3, 5.4, 2.6 Hz, 2H), 7.51 (td, J=7.7, 2.5 Hz, 1H), 7.33 (t, J=7.7 Hz, 1H), 7.09-7.00 (m, 2H), 3.86 (t, J=6.0 Hz, 2H), 2.89 (t, J=6.7 Hz, 2H), 1.91 (p, J=6.6 Hz, 2H), 1.81 (q, J=6.3 Hz, 2H); <sup>13</sup>C NMR (126 MHz, DMSO) δ 159.66, 151.29, 145.82, 140.03, 139.23, 132.51, 131.70, 130.16, 128.83, 125.54, 125.33, 125.13, 123.01, 120.08, 116.30, 115.84, 113.14, 112.73, 110.76, 33.12, 26.84, 21.64, 21.36; HRMS (ESI) m/z calcd for C<sub>25</sub>H<sub>21</sub>N<sub>2</sub>O [M+H]<sup>+</sup> 365.1653, found 365.1647.

4-(3-Methyl-8,9,10,11-tetrahydro-3H-pyrrolo[3,2-a]phenanthridin-7-yl)phenol

Method A: Off white solid (158 mg, 50%). <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) δ 11.86 (s, 1H), 8.53 (s, 1H), 7.83 (d, J=9.0 Hz, 1H), 7.80-7.73 (m, 2H), 7.65 (d, J=2.6 Hz, 1H), 6.42 (d, J=9.4 Hz, 1H), 3.25 (t, J=6.6 Hz, 2H), 2.84 (t, J=6.1 Hz, 2H), 2.01-1.92 (m, 2H), 1.80-1.68 (m, 2H); <sup>13</sup>C NMR (126 MHz, DMSO) δ 162.21, 152.68, 143.74, 142.84, 142.59, 136.37, 129.51, 129.43, 121.76, 119.38, 118.73, 116.21, 29.69, 28.78, 22.59, 22.54; HRMS (ESI) m/z calcd for C<sub>19</sub>H<sub>17</sub>N<sub>4</sub>O [M+H]<sup>+</sup> 317.1402, found 317.1403.




Method A: Yellow solid (246 mg, 75%). <sup>1</sup>H NMR (500 MHz, Methanol-d<sub>4</sub>) δ 8.23 (d, J=9.0 Hz, 1H), 7.89 (d, J=9.1 Hz, 1H), 7.66 (d, J=3.1 Hz, 1H), 7.54 (d, J=8.5 Hz, 2H), 7.35 (d, J=3.1 Hz, 1H), 7.06 (d, J=8.4 Hz, 2H), 4.08 (s, 3H), 3.65 (t, J=6.4 Hz, 2H), 2.92 (t, J=6.2 Hz, 2H), 2.14 (dq, J=8.6, 5.9, 4.6 Hz, 2H), 1.94-1.85 (n, 2H); <sup>13</sup>C NMR (126 MHz, MeOD) δ 160.06, 154.70, 150.64, 134.12, 133.70, 130.78, 130.35, 129.85, 123.15, 122.88, 120.71, 118.64, 115.50, 112.77, 105.58, 32.40, 31.23, 27.96, 21.60, 21.28; HRMS (ESI) m/z calcd for C<sub>22</sub>H<sub>21</sub>N<sub>2</sub>O [M+H]<sup>+</sup> 329.1653, found 329.1645.

Method A: Orange solid (192 mg, 61%). <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) δ 8.73 (s, 1H), 8.16 (t, J=11.5 Hz, 2H), 7.45 (d, J=8.5 Hz, 2H), 6.79 (d, J=8.3 Hz, 2H), 3.46 (s, 2H), 2.98-2.78 (m, 2H'), 2.09-1.92 (m, 2H), 1.82-1.63 (m, 2H); <sup>13</sup>C NMR (126 MHz, DMSO) δ 162.75, 154.28, 150.08, 138.83, 136.20, 131.25, 130.62, 129.84, 124.50, 121.76, 115.68, 114.96, 113.80, 111.38, 30.33, 28.84, 22.22; HRMS (ESI) m/z calcd for C<sub>21</sub>H<sub>19</sub>N<sub>4</sub> [M+H]<sup>+</sup> 315.1609, found 315.1619.

US 12,384,782 B2

**177**

5-(8,9,10,11-Tetrahydro-3H-pyrrolo[3,2-a]phenanthridin-7-yl)pyridin-2-ol



Method A: Off-white solid (245 mg, 74%).  $^1\text{H}$  NMR (500 MHz, DMSO-d<sub>6</sub>)  $\delta$  9.96 (s, 1H), 8.36 (d, J=8.9 Hz, 1H), 8.32 (d, J=5.6 Hz, 1H), 8.08 (d, J=5.5 Hz, 1H), 7.97 (d, J=8.9 Hz, 1H), 7.46 (d, J=8.5 Hz, 2H), 6.94 (d, J=8.5 Hz, 2H), 3.49 (q, J=6.5 Hz, 2H), 2.80 (t, J=6.2 Hz, 2H), 1.94 (dp, J=6.6, 4.6, 2.8 Hz, 2H), 1.79-1.65 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  158.82, 139.74, 133.74, 131.22, 130.02, 128.68, 127.46, 125.78, 123.88, 115.49, 31.70, 29.13, 22.58, 21.88; HRMS (ESI) m/z calcd for C<sub>21</sub>H<sub>18</sub>NOS [M+H]<sup>+</sup> 332.1109, found 332.1118.


**178**

Method A: Off-white solid (245 mg, 74%).  $^1\text{H}$  NMR (500

MHz, DMSO-d<sub>6</sub>)  $\delta$  9.96 (s, 1H), 8.36 (d, J=8.9 Hz, 1H), 8.32 (d, J=5.6 Hz, 1H), 8.08 (d, J=5.5 Hz, 1H), 7.97 (d, J=8.9 Hz, 1H), 7.46 (d, J=8.5 Hz, 2H), 6.94 (d, J=8.5 Hz, 2H), 3.49 (q, J=6.5 Hz, 2H), 2.80 (t, J=6.2 Hz, 2H), 1.94 (dp, J=6.6, 4.6, 2.8 Hz, 2H), 1.79-1.65 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  158.82, 139.74, 133.74, 131.22, 130.02, 128.68, 127.46, 125.78, 123.88, 115.49, 31.70, 29.13, 22.58, 21.88; HRMS (ESI) m/z calcd for C<sub>21</sub>H<sub>18</sub>NOS [M+H]<sup>+</sup> 332.1109, found 332.1118.

2,6-Difluoro-4-(8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridin-7-yl)phenol


15



Method A: Off-white solid (170 mg, 54%).  $^1\text{H}$  NMR (500 MHz, DMSO-d<sub>6</sub>)  $\delta$  10.47 (s, 1H), 8.47 (d, J=2.1 Hz, 1H), 8.36 (q, J=9.2 Hz, 2H), 7.79 (d, J=2.2 Hz, 1H), 7.66-7.56 (m, 2H), 7.10-6.98 (m, 2H), 3.56 (t, J=6.4 Hz, 2H), 2.82 (t, J=6.2 Hz, 2H), 2.00 (dq, J=8.7, 5.8, 4.5 Hz, 2H), 1.85-1.65 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  160.63, 153.59, 153.01, 148.23, 132.05, 131.37, 122.86, 121.34, 119.47, 116.00, 110.37, 30.67, 28.32, 21.74, 21.57; HRMS (ESI) m/z calcd for C<sub>20</sub>H<sub>18</sub>N<sub>3</sub>O [M+H]<sup>+</sup> 316.1449, found 316.1455.

4-(8,9,10,11-Tetrahydrofuro[3,2-a]phenanthridin-7-yl)phenol


25



Method A: Off-white solid (221 mg, 63%).  $^1\text{H}$  NMR (500 MHz, DMSO-d<sub>6</sub>)  $\delta$  8.76 (s, 1H), 8.22 (S, 2H), 7.66-7.43 (m, 2H), 3.43 (t, J=6.4 Hz, 2H), 2.83 (t, J=6.1 Hz, 2H), 2.19-1.94 (m, 2H), 1.88-1.50 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  153.27, 151.34, 151.28, 136.31, 131.82, 123.22, 114.73, 114.52, 30.79, 27.97, 21.80, 21.69; HRMS (ESI) m/z calcd for C<sub>20</sub>H<sub>18</sub>F<sub>2</sub>N<sub>3</sub>O [M+H]<sup>+</sup> 352.1261, found 352.1260.

4-(8,9,10,11-Tetrahydro-3H-pyrrolo[3,2-a]phenanthridin-7-yl)aniline


30



Method A: Off-white solid (218 mg, 69%).  $^1\text{H}$  NMR (500 MHz, DMSO-d<sub>6</sub>)  $\delta$  8.47 (d, J=2.1 Hz, 1H), 8.36 (q, J=9.2 Hz, 2H), 7.79 (d, J=2.2 Hz, 1H), 7.61 (d, J=8.6 Hz, 2H), 7.06 (d, J=8.6 Hz, 2H), 3.56 (t, J=6.4 Hz, 2H), 2.82 (t, J=6.2 Hz, 2H), 2.00 (dq, J=8.7, 5.8, 4.5 Hz, 2H), 1.86-1.65 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  160.63, 153.59, 153.01, 148.23, 132.05, 131.37, 122.86, 121.34, 119.47, 116.00, 110.37, 30.67, 28.32, 21.74, 21.57; HRMS (ESI) m/z calcd for C<sub>21</sub>H<sub>18</sub>NO<sub>2</sub> [M+H]<sup>+</sup> 316.1337, found 316.1343.

4-(8,9,10,11-Tetrahydrothieno[3,2-a]phenanthridin-7-yl)phenol

45




Method A: Bright yellow solid (194 mg, 62%).  $^1\text{H}$  NMR (500 MHz, DMSO-d<sub>6</sub>)  $\delta$  8.09 (d, J=8.9 Hz, 1H), 7.93 (d, J=8.8 Hz, 1H), 7.72 (s, 1H), 7.40 (d, J=8.2 Hz, 2H), 7.26 (s, 1H), 6.75 (d, J=8.3 Hz, 2H), 5.79 (s, 2H), 3.51 (t, J=6.5 Hz, 2H), 3.32 (s, 2H), 2.85 (t, J=6.2 Hz, 2H), 2.09-1.95 (m, 2H), 1.81-1.68 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  151.31, 133.58, 133.58, 131.48, 129.37, 129.33, 127.94, 126.34, 122.49, 120.03, 118.73, 113.57, 106.60, 31.13, 28.60, 22.25, 21.94; HRMS (ESI) m/z calcd for C<sub>21</sub>H<sub>20</sub>N<sub>3</sub> [M+H]<sup>+</sup> 314.1657, found 314.1651.

## US 12,384,782 B2

**179**


2,6-Difluoro-4-(8,9,10,11-tetrahydro-3H-pyrrolo[3,2-a]phenanthridin-7-yl)phenol



HSD-02-935

**180**


2-Chloro-4-(8,9,10,11-tetrahydro-3H-pyrrolo[3,2-a]phenanthridin-7-yl)phenol



HSD-02-937

Method A: Yellow solid (161 mg, 46%).  $^1\text{H}$  NMR (500 MHz, DMSO- $d_6$ )  $\delta$  12.43 (s, 1H), 10.91 (s, 1H), 8.13 (d,  $J=9.0$  Hz, 1H), 7.95 (d,  $J=8.9$  Hz, 1H), 7.73 (s, 1H), 7.50 (d,  $J=7.2$  Hz, 2H), 7.28 (s, 1H), 3.52 (t,  $J=6.5$  Hz, 2H), 2.81 (t,  $J=6.1$  Hz, 2H), 2.03-1.99 (m, 2H), 1.78 (dd,  $J=6.2$ , 2.7 Hz, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  153.28, 153.22, 151.35, 151.29, 148.78, 135.89, 133.70, 132.12, 129.36, 126.45, 123.30, 120.58, 119.86, 114.37, 106.78, 31.05, 28.08, 22.12, 21.76; HRMS (ESI) m/z calcd for  $C_{21}\text{H}_{17}\text{F}_2\text{N}_2\text{O} [\text{M}+\text{H}]^+$  351.1308, found 351.1302.

2-Methyl-4-(8,9,10,11-tetrahydro-3H-pyrrolo[3,2-a]phenanthridin-7-yl)phenol




HSD-02-936

Method A: Yellow solid (226 mg, 65%).  $^1\text{H}$  NMR (500 MHz, DMSO- $d_6$ )  $\delta$  11.74 (s, 1H), 7.77 (dd,  $J=8.9$ , 0.7 Hz, 1H), 7.62 (d,  $J=8.8$  Hz, 1H), 7.50 (d,  $J=2.1$  Hz, 1H), 7.48 (t,  $J=2.6$  Hz, 1H), 7.34 (dd,  $J=8.3$ , 2.1 Hz, 1H), 7.13-7.10 (m, 1H), 7.04 (d,  $J=8.3$  Hz, 1H), 3.37 (d,  $J=6.6$  Hz, 2H), 2.78 (t,  $J=6.1$  Hz, 2H), 1.97 (pd,  $J=6.1$ , 2.6 Hz, 2H), 1.77-1.68 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  154.51, 153.28, 143.38, 142.36, 133.59, 133.20, 130.91, 129.36, 127.54, 124.08, 123.92, 122.39, 120.33, 119.60, 116.47, 116.41, 106.27, 29.99, 29.17, 22.87, 22.60; HRMS (ESI) m/z calcd for  $C_{21}\text{H}_{18}\text{ClN}_2\text{O} [\text{M}+\text{H}]^+$  349.1107, found 349.1112.

7-(4-Hydroxyphenyl)-8,9,10,11-tetrahydro-3H-pyrrolo[3,2-a]phenanthridine-9-carbonitrile

35



HSD-02-938

Method A: Yellow solid (260 mg, 79%).  $^1\text{H}$  NMR (500 MHz, DMSO- $d_6$ )  $\delta$  10.31 (s, 1H), 8.19 (d,  $J=9.0$  Hz, 1H), 8.03 (d,  $J=9.0$  Hz, 1H), 7.78 (t,  $J=2.9$  Hz, 1H), 7.47 (t,  $J=1.5$  Hz, 1H), 7.41 (dd,  $J=8.3$ , 2.4 Hz, 1H), 7.29 (d,  $J=2.5$  Hz, 1H), 7.10 (d,  $J=8.3$  Hz, 1H), 3.54 (t,  $J=6.4$  Hz, 2H), 2.82 (t,  $J=6.2$  Hz, 2H), 2.06-1.97 (m, 2H), 1.78 (qd,  $J=6.2$ , 3.0 Hz, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  158.45, 154.02, 150.34, 133.74, 132.54, 129.76, 129.19, 127.02, 124.97, 122.99, 122.46, 121.27, 119.85, 115.10, 113.79, 106.76, 31.34, 28.25, 22.01, 21.65, 16.42; HRMS (ESI) m/z calcd for  $C_{22}\text{H}_{21}\text{N}_2\text{O} [\text{M}+\text{H}]^+$  329.1653, found 329.1645.


55

Method A: Yellow solid (190 mg, 56%).  $^1\text{H}$  NMR (500 MHz, DMSO- $d_6$ )  $\delta$  10.46 (s, 1H), 8.21 (d,  $J=8.9$  Hz, 1H), 8.05 (d,  $J=9.0$  Hz, 1H), 7.81 (s, 1H), 7.62 (d,  $J=8.6$  Hz, 2H), 7.29 (s, 1H), 7.08 (d,  $J=8.6$  Hz, 2H), 3.63 (q,  $J=5.8$  Hz, 2H), 3.40-3.36 (m, 0H), 3.17 (qd,  $J=16.6$ , 6.4 Hz, 2H), 2.42-2.35 (m, 1H), 2.32-2.24 (m, 1H);  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  160.52, 151.84, 150.21, 134.27, 133.81, 132.07, 127.33, 126.12, 122.49, 122.38, 122.15, 121.66, 119.70, 116.10, 114.00, 106.64, 30.73, 29.32, 24.59, 23.97; HRMS (ESI) m/z calcd for  $C_{22}\text{H}_{18}\text{N}_3\text{O} [\text{M}+\text{H}]^+$  340.1449, found 340.1445.

US 12,384,782 B2


**181**

4-(1,2,4,9-Tetrahydropyrano[3,4-c]pyrrolo[3,2-f]quinolin-5-yl)phenol



**182**

4-(8,9,10,11-Tetrahydro-3H-pyrrolo[3,2-a]phenanthridin-7-yl)benzoic acid





Method A: Yellow solid (193 mg, 61%).  $^1\text{H}$  NMR (500 MHz, DMSO-d<sub>6</sub>) δ 10.36 (s, 1H), 8.22 (d, J=9.0 Hz, 1H), 8.03 (d, J=9.0 Hz, 1H), 7.81 (t, J=2.9 Hz, 1H), 7.59 (d, J=8.5 Hz, 2H), 7.30 (t, J=2.4 Hz, 1H), 7.03 (d, J=8.5 Hz, 2H), 4.17 (t, J=5.7 Hz, 2H), 3.61 (t, J=5.8 Hz, 2H), 3.42 (s, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO) δ 159.90, 149.19, 133.51, 132.49, 131.49, 130.87, 127.07, 126.51, 122.13, 120.36, 119.93, 116.30, 115.93, 115.62, 105.92, 66.43, 64.15, 29.76; HRMS (ESI) m/z calcd for C<sub>20</sub>H<sub>17</sub>N<sub>2</sub>O<sub>2</sub> [M+H]<sup>+</sup> 317.1290, found 317.1290.

6-(8,9,10,11-tetrahydro-3H-pyrrolo[3,2-a]phenanthridin-7-yl)pyridin-3-ol

20 Method A: Yellow solid (212 mg, 62%).  $^1\text{H}$  NMR (500 MHz, Methanol-d<sub>4</sub>) δ 88.17 (d, J=8.1 Hz, 2H), 7.87 (d, J=8.9 Hz, 1H), 7.73 (d, J=8.9 Hz, 1H), 7.62 (d, J=8.1 Hz, 2H), 7.49 (d, J=3.1 Hz, 1H), 7.24 (d, J=3.2 Hz, 1H), 3.53 (t, J=6.5 Hz, 2H), 2.76 (t, J=6.2 Hz, 2H), 2.11-2.04 (m, 2H), 1.88-1.79 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, MeOD) δ 153.85, 146.36, 142.90, 140.67, 133.41, 132.50, 129.30, 128.80, 127.65, 123.56, 123.12, 120.18, 119.96, 117.15, 105.96, 47.93, 30.20, 28.28, 22.22, 21.85; HRMS (ESI) m/z calcd for C<sub>22</sub>H<sub>19</sub>N<sub>2</sub>O<sub>2</sub> [M+H]<sup>+</sup> 343.1446, found 343.1438.

5-(8,9,10,11-Tetrahydro-3H-pyrrolo[3,2-a]phenanthridin-7-yl)benzene-1,3-diol

35




Method A: Yellow solid (98 mg, 31%).  $^1\text{H}$  NMR (500 MHz, DMSO-d<sub>6</sub>) δ 11.74 (s, 1H), 10.03 (s, 1H), 8.18 (d, J=2.8 Hz, 1H), 7.77 (d, J=8.9 Hz, 1H), 7.64 (dd, J=12.0, 8.7 Hz, 2H), 7.49 (t, J=2.8 Hz, 1H), 7.29 (dd, J=8.5, 2.9 Hz, 1H), 7.12 (d, J=2.5 Hz, 1H), 3.40-3.35 (m, 2H), 2.95 (t, J=6.3 Hz, 2H), 1.96-1.92 (m, 2H), 1.78-1.69 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO) δ 153.80, 153.32, 151.06, 142.98, 142.40, 136.29, 133.31, 128.21, 125.55, 124.11, 123.92, 123.07, 122.67, 120.36, 116.37, 106.28, 30.10, 28.50, 22.89, 22.51; HRMS (ESI) m/z calcd for C<sub>20</sub>H<sub>18</sub>N<sub>2</sub>O [M+H]<sup>+</sup> 316.1450, found 316.1453.

Method A: Yellow solid (231 mg, 70%).  $^1\text{H}$  NMR (500 MHz, DMSO-d<sub>6</sub>) δ 9.96 (s, 2H), 8.20 (d, J=8.9 Hz, 1H), 7.96 (d, J=9.0 Hz, 1H), 7.80 (s, 1H), 7.31 (d, J=2.4 Hz, 1H), 6.59-6.47 (m, 3H), 3.54 (t, J=6.5 Hz, 2H), 2.77 (t, J=6.2 Hz, 2H), 2.05-1.97 (m, 2H), 1.82-1.77 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO) δ 159.29, 154.49, 149.99, 133.76, 129.45, 127.13, 123.34, 121.54, 119.85, 113.69, 107.84, 106.82, 104.94, 40.48, 40.31, 40.14, 39.98, 39.81, 39.64, 39.48, 31.31, 27.91, 21.94, 21.44; HRMS (ESI) m/z calcd for C<sub>21</sub>H<sub>19</sub>N<sub>2</sub>O<sub>2</sub> [M+H]<sup>+</sup> 331.1446, found 331.1450.

**183**

5-(8,9,10,11-Tetrahydro-3H-pyrazolo[4,3-a]phenanthridin-7-yl)pyridin-2-amine




HSD-02-944

5

**184**

5-(8,9,10,11-Tetrahydro-3H-pyrazolo[4,3-a]phenanthridin-7-yl)thiazol-2-amine



HSD-02-946

10

15


20

Method A: Yellow solid (205 mg, 65%).  $^1\text{H}$  NMR (500 MHz, Methanol-d<sub>4</sub>)  $\delta$  8.51 (s, 1H), 8.16 (d, J=2.1 Hz, 1H), 8.14 (dd, J=9.0, 2.2 Hz, 1H), 7.88 (d, J=9.1 Hz, 1H), 7.83 (d, J=9.2 Hz, 1H), 7.09 (d, J=9.0 Hz, 1H), 3.26 (t, J=6.6 Hz, 2H), 2.87 (t, J=6.1 Hz, 2H), 2.06 (ddt, J=9.2, 6.5, 3.2 Hz, 2H), 1.86 (dp, J=9.3, 3.1 Hz, 2H);  $^{13}\text{C}$  NMR (126 MHz, MeOD)  $\delta$  155.32, 150.42, 145.84, 143.67, 143.48, 141.93, 138.13, 130.19, 126.90, 123.86, 122.70, 119.27, 115.60, 111.95, 29.80, 28.11, 21.86, 21.86; HRMS (ESI) m/z calcd for C<sub>19</sub>H<sub>18</sub>N<sub>5</sub> [M+H]<sup>+</sup> 316.1562, found 316.1555.

7-Pyrimidin-5-yl)-8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridine

Method A: Yellow solid (166 mg, 52%).  $^1\text{H}$  NMR (500 MHz, DMSO-d<sub>6</sub>)  $\delta$  8.50 (s, 1H), 7.79 (d, J=9.1 Hz, 1H), 7.66 (d, J=9.4 Hz, 1H), 7.51 (s, 1H), 7.23 (s, 2H), 3.28-3.22 (m, 2H), 2.96 (t, J=6.2 Hz, 2H), 1.99-1.93 (m, 2H), 1.90-1.82 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  170.46, 148.47, 143.26, 142.39, 140.03, 138.39, 136.08, 129.21, 128.99, 128.03, 120.39, 116.44, 114.43, 29.95, 28.90, 22.52, 22.24; HRMS (ESI) m/z calcd for C<sub>17</sub>H<sub>16</sub>N<sub>5</sub>S [M+H]<sup>+</sup> 322.1126, found 322.1127.

2-Fluoro-4-(8,9,10,11-tetrahydro-3H-pyrrolo[3,2-a]phenanthridin-7-yl)phenol



HSD-02-945


35

40

45

50

55



HSD-02-947


Method A: Yellow solid (144 mg, 48%).  $^1\text{H}$  NMR (500 MHz, DMSO-d<sub>6</sub>)  $\delta$  1H NMR (500 MHz, DMSO-d<sub>6</sub>)  $\delta$  9.26 (s, 1H), 9.07 (s, 2H), 8.55 (s, 1H), 7.89 (d, J=9.0 Hz, 1H), 7.84 (d, J=11.9 Hz, 2H), 3.31 (s, 4H), 2.84 (t, J=6.1 Hz, 2H), 2.03-1.94 (m, 2H), 1.80-1.71 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  158.00, 157.25, 150.89, 143.91, 142.97, 138.83, 136.49, 134.77, 129.84, 129.50, 122.42, 116.25, 114.94, 29.62, 28.44, 22.43, 22.38; HRMS (ESI) m/z calcd for C<sub>19</sub>H<sub>17</sub>N<sub>4</sub> [M+H]<sup>+</sup> 301.1453, found 301.1457.

Method A: Yellow solid (196 mg, 59%).  $^1\text{H}$  NMR (500 MHz, DMSO-d<sub>6</sub>)  $\delta$  11.75 (s, 2H), 7.85-7.71 (m, 2H), 7.67-7.56 (m, 2H), 7.48 (t, J=2.8 Hz, 1H), 7.10 (t, J=2.4 Hz, 1H), 6.40 (d, J=9.4 Hz, 1H), 3.35 (t, J=6.6 Hz, 2H), 2.84 (t, J=6.1 Hz, 2H), 1.97 (td, J=8.6, 7.2, 4.5 Hz, 2H), 1.75 (tq, J=8.5, 5.4, 3.9 Hz, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  162.16, 151.74, 143.46, 142.97, 142.51, 136.05, 133.19, 127.71, 123.97, 122.39, 120.28, 119.30, 116.56, 106.27, 30.00, 28.90, 22.83, 22.63; HRMS (ESI) m/z calcd for C<sub>21</sub>H<sub>18</sub>FN<sub>2</sub>O [M+H]<sup>+</sup> 333.1405, found 333.1403.

US 12,384,782 B2

**185**

5-(8,9,10,11-Tetrahydro-3H-pyrrolo[3,2-a]phenanthridin-7-yl)thiazol-2-amine




HSD-02-948

**186**

2H), 2.78 (t, J=6.1 Hz, 2H), 2.06-1.91 (m, 2H), 1.77 (tt, J=8.9, 5.5 Hz, 2H); <sup>13</sup>C NMR (126 MHz, DMSO) δ 168.54, 168.54, 168.32, 161.15, 151.10, 150.72, 136.76, 132.49, 132.29, 131.52, 124.82, 122.96, 121.86, 118.10, 117.86, 115.02, 114.60, 53.03, 30.66, 28.23, 21.85, 21.79; HRMS (ESI) m/z calcd for C<sub>22</sub>H<sub>20</sub>N<sub>3</sub>O<sub>3</sub> [M+H]<sup>+</sup> 374.1505, found 374.1508.

10 3-(8,9,10,11-Tetrahydro-3H-pyrrolo[3,2-a]phenanthridin-7-yl)pyridin-2(1H)-one


HSD-02-951



Method A: Yellow solid (112 mg, 35%). <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) δ 12.21 (s, 1H) 8.12 (d, J=9.0 Hz, 1H), 8.04-7.94 (m, 1H) 7.56-7.50 (m, 2H), 6.96 (s, 1H), 5.98 (t, J=2.4 Hz, 1H), 3.29 (t, J=6.4 Hz, 2H), 2.84 (s, 2H), 1.96-1.88 (m, 2H), 1.83 (q, J=6.0, 5.3 Hz, 2H); HRMS (ESI) m/z calcd for C<sub>18</sub>H<sub>17</sub>N<sub>4</sub>S [M+H]<sup>+</sup> 321.1174, found 321.1177.

25 2-Hydroxy-5-(8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridin-7-yl)benzoic acid


HSD-02-949



Method A: Yellow solid (204 mg, 65%). Yellow solid (217 mg, 70%). <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) δ 11.76 (s, 1H), 7.80-7.72 (m, 2H), 7.64-7.58 (m, 2H), 7.48 (t, J=2.7 Hz, 1H), 7.10 (t, J=2.3 Hz, 1H), 6.41 (d, J=9.4 Hz, 1H), 3.36 (d, J=6.6 Hz, 2H), 2.84 (t, J=6.2 Hz, 2H), 2.02-1.94 (m, 2H), 1.75 (dp, J=9.3, 3.4, 2.9 Hz, 2H); <sup>13</sup>C NMR (126 MHz, DMSO) δ 162.19, 151.74, 143.47, 142.98, 142.52, 136.07, 133.20, 127.72, 123.98, 122.40, 120.30, 119.29, 116.56, 106.28, 30.01, 28.91, 22.83, 22.63; HRMS (ESI) m/z calcd for C<sub>20</sub>H<sub>18</sub>N<sub>3</sub>O [M+H]<sup>+</sup> 316.1450, found 316.1459.

40 Methyl 2-hydroxy-5-(8,9,10,11-tetrahydro-3H-pyrazolo[3,2-a]phenanthridin-7-yl)benzoate

HSD-02-952



HSD-02-950

45 Method A: Yellow solid (187 mg, 52%). <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) δ 10.10 (s, 1H), 8.67 (s, 1H), 8.09 (d, J=9.8 Hz, 4H), 3.38-3.31 (m, 2H), 2.78 (t, J=6.2 Hz, 2H), 2.06-1.93 (m, 2H), 1.83-1.72 (m, 2H); HRMS (ESI) m/z calcd for C<sub>21</sub>H<sub>18</sub>N<sub>3</sub>O<sub>3</sub> [M+H]<sup>+</sup> 360.1348, found 360.1351.

50 Methyl 2-hydroxy-5-(8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridin-7-yl)benzoate


55 Method A: White solid (189 mg, 51%). <sup>1</sup>H NMR (500 MHz, Methanol-d<sub>4</sub>) δ 8.01 (d, J=2.3 Hz, 1H), 7.79 (d, J=8.9 Hz, 1H), 7.71 (d, J=8.8 Hz, 1H), 7.66 (dt, J=8.5, 2.1 Hz, 1H), 7.43 (d, J=3.1 Hz, 1H), 7.20 (d, J=3.2 Hz, 1H), 7.09 (dd, J=8.3, 2.4 Hz, 1H), 3.96 (s, 3H), 3.49 (t, J=6.5 Hz, 2H), 2.77 (t, J=6.2 Hz, 2H), 2.11-2.03 (m, 2H), 1.83 (dp, J=9.4, 3.0 Hz, 2H); <sup>13</sup>C NMR (126 MHz, MeOD) δ 170.24, 161.08, 154.60, 143.93, 142.64, 136.22, 133.26, 132.11, 130.33, 127.42, 122.82, 121.91, 120.24, 116.86, 116.03, 111.93, 105.77, 51.58, 48.10, 29.95, 28.67, 22.45, 22.16; HRMS (ESI) m/z calcd for C<sub>23</sub>H<sub>21</sub>N<sub>2</sub>O<sub>3</sub> [M+H]<sup>+</sup> 373.1552, found 373.1557.

60 Method A: White solid (208 mg, 56%). <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) δ 10.93 (s, 1H), 8.73 (s, 1H), 8.20-8.12 (m, 2H), 8.09 (d, J=2.3 Hz, 1H), 7.87 (dd, J=8.6, 2.4 Hz, 1H), 7.24 (d, J=8.6 Hz, 1H), 3.89 (s, 3H), 3.40 (td, J=6.9, 4.0 Hz,

US 12,384,782 B2

**187**

2-(7-(4-Hydroxyphenyl)-8,9,10,11-tetrahydro-3H-pyrrolo[3,2-a]phenanthridin-9-yl)isoindoline-1,3-dione 12.11



HSD-02-953


**188**

128.27, 127.75, 127.12, 122.61, 122.34, 121.41, 119.89, 116.02, 113.72, 106.77, 65.77, 45.47, 33.92, 29.80, 27.29; HRMS (ESI) m/z calcd for  $C_{29}H_{26}N_3O_3[M+H]^+$  464.1974 found 464.1970.

5

7-(4-Hydroxyphenyl)-8,9,10,11-tetrahydro-3H-pyrrolo[3,2-a]phenanthridin-9-ol

10



HSD-02-955


Method A: Yellow solid (197 mg, 43%).  $^1H$  NMR (500 MHz, DMSO- $d_6$ )  $\delta$  11.85 (s, 1H), 7.81 (tt,  $J=4.4, 1.9$  Hz, 5H), 7.64 (d,  $J=8.9$  Hz, 1H), 7.50 (d,  $J=3.1$  Hz, 1H), 7.37-7.29 (m, 2H), 7.12 (d,  $J=3.3$  Hz, 1H), 6.85-6.78 (m, 2H), 4.44-4.33 (m, 1H), 3.78-3.69 (m, 1H), 3.69-3.57 (m, 1H), 3.54-3.44 (m, 1H), 2.89-2.81 (m, 1H), 2.79-2.68 (m, 1H), 2.34-2.26 (m, 1H);  $^{13}C$  NMR (126 MHz, DMSO)  $\delta$  168.40, 157.71, 155.84, 143.60, 141.02, 134.77, 133.23, 132.00, 130.64, 125.66, 124.08, 123.99, 123.38, 121.75, 120.41, 116.72, 115.24, 106.26, 47.58, 32.31, 30.31, 26.40; HRMS (ESI) m/z calcd for  $C_{29}H_{22}N_3O_3 [M+H]^+$  460.1661, found 460.1665.

Benzyl (7-(4-hydroxyphenyl)-8,9,10,11-tetrahydro-3H-pyrrolo[3,2-a]phenanthridin-9-yl)carbamate


Method A: Yellow solid (172 mg, 52%).  $^1H$  NMR (500 MHz, DMSO-d)  $\delta$  10.43 (s, 1H), 8.19 (d,  $J=8.9$  Hz, 1H), 8.04 (d,  $J=8.9$  Hz, 1H), 7.78 (t,  $J=2.9$  Hz, 1H), 7.65-7.51 (m, 2H), 7.29 (t,  $J=2.4$  Hz, 1H), 7.12-7.00 (m, 2H), 4.05 (tt,  $J=7.0, 3.1$  Hz, 1H), 3.70-3.60 (m, 1H), 3.52 (dt,  $J=19.2, 6.8$  Hz, 1H), 2.99 (dd,  $J=16.6, 4.1$  Hz, 1H), 2.75 (dd,  $J=16.6, 6.7$  Hz, 1H), 2.19-2.09 (m, 1H), 1.99 (dq,  $J=13.9, 7.0$  Hz, 1H);  $^{13}C$  NMR (126 MHz, DMSO)  $\delta$  160.37, 153.53, 150.30, 133.89, 133.72, 132.01, 127.94, 127.08, 122.53, 121.38, 119.84, 115.99, 113.73, 106.74, 63.25, 36.67, 29.46, 29.03; HRMS (ESI) m/z, calcd for  $C_{21}H_{19}N_2O_2 [M+H]^+$  331.1447, found 331.1452.

4-(8,9,10,11-Tetrahydro-3H-pyrrolo[3,2-a]phenanthridin-7-yl)-2-(trifluoromethoxy)phenol

HSD-02-954



40



HSD-02-956

Method A: Yellow solid (240 mg, 52%).  $^1H$  NMR (500 MHz, DMSO- $d_6$ )  $\delta$  10.46 (s, 1H), 8.20 (d,  $J=9.0$  Hz, 1H), 8.07 (d,  $J=8.9$  Hz, 1H), 7.78 (d,  $J=3.0$  Hz, 1H), 7.55 (d,  $J=8.4$  Hz, 2H), 7.37-7.19 (m, 6H), 7.08 (s, 1H), 4.97 (d,  $J=3.2$  Hz, 2H), 3.84 (t,  $J=7.4$  Hz, 1H), 3.69 (dt,  $J=19.6, 5.6$  Hz, 1H), 3.56 (dt,  $J=19.2, 7.4$  Hz, 1H), 3.01 (dd,  $J=16.9, 4.6$  Hz, 1H), 2.81 (dd,  $J=16.6, 8.4$  Hz, 1H), 2.31-2.18 (m, 1H), 2.06-1.95 (m, 1H);  $^{13}C$  NMR (126 MHz, DMSO)  $\delta$  160.39, 156.05, 153.02, 150.33, 137.46, 133.91, 133.75, 131.95, 128.79,

Method A: off-white solid (242 mg, 61%).  $^1H$  NMR (500 MHz, DMSO- $\delta$ ) 11.16 (s, 1H), 8.22 (d,  $J=8.9$  Hz, 1H), 8.01 (d,  $J=9.0$  Hz, 1H), 7.86-7.75 (m, 2H), 7.60 (dd,  $J=8.4, 2.2$  Hz, 1H), 7.41-7.29 (m, 2H), 1.83-1.76 (m, 2H);  $^{13}C$  NMR (126 MHz, DMSO)  $\delta$  152.73, 148.65, 136.08, 134.20, 133.76, 130.85, 129.77, 126.94, 125.54, 123.93 (q,  $J=257$  Hz), 123.31, 121.29, 119.80, 118.25, 114.31, 106.81, 31.29, 28.01, 21.96, 21.63; HRMS (ESI) m/z calcd for  $C_{22}H_{18}F_3N_2O [M+H]^+$  399.1320, found 399.1321.

**189**


3-(8,9,10,11-Tetrahydro-3H-pyrrolo[3,2-a]phenanthridin-7-yl)phenol

**190**

2-((Dimethylamino)methyl)-4-(8,9,10,11-tetrahydro-3H-pyrrolo[3,2-a]phenanthridin-7-yl)phenol


5

HSD-02-957



10

HSD-02-959



15

20

Method A: Yellow solid (188 mg, 60%).  $^1\text{H}$  NMR (500 MHz, DMSO-d<sub>6</sub>)  $\delta$  10.28 (s, 1H), 8.17 (d, J=8.9 Hz, 1H), 7.97 (d, J=8.9 Hz, 1H), 7.77 (t, J=2.9 Hz, 1H), 7.43 (t, J=7.9 Hz, 1H), 7.27-7.16 (m, 2H), 7.09 (td, J=5.2, 2.2 Hz, 2H), 3.45 (t, J=6.5 Hz, 2H), 2.73 (t, J=6.2 Hz, 2H), 2.03-1.95 (m, 2H), 1.81-1.72 (m, 2H),  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  158.18, 154.01, 149.81, 133.69, 130.40, 129.35, 126.95, 123.26, 121.30, 120.36, 119.72, 118.04, 116.76, 113.98, 106.74, 31.22, 27.99, 21.92, 21.47; HRMS (ESI) m/z calcd for C<sub>21</sub>H<sub>19</sub>N<sub>2</sub>O [M+H]<sup>+</sup> 315.1497, found 315.1499.


5-(8,9,10,11-tetrahydro-3H-pyrrolo[3,2-a]phenanthridin-7-yl)pyrimidin-2-amine

Method A: Pale yellow solid (170 mg, 46%).  $^1\text{H}$  NMR (500 MHz, Methanol-d<sub>4</sub>)  $\delta$  7.77 (d, J=8.9 Hz, 1H), 7.69 (d, J=9.0 Hz, 1H), 7.41 (s, 1H), 7.33 (dd, J=8.2, 2.2 Hz, 1H), 7.26 (d, J=2.2 Hz, 1H), 7.19-7.15 (m, 1H), 6.92 (d, J=8.2 Hz, 1H), 3.88 (s, 2H), 3.46 (t, J=6.5 Hz, 2H), 2.75 (t, J=6.2 Hz, 2H), 2.05-2.01 (m, 2H), 1.82-1.76 (m, 2H); HRMS (ESI) n/z calcd for C<sub>24</sub>H<sub>26</sub>N<sub>3</sub>O [M+H]<sup>+</sup> 372.2076, found 372.2082.

2,6-Diiodo-4-(8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridin-7-yl)phenol


30

ND-02-958



40

HSD-02-960



45

50

55


Method A: Pale yellow solid (185 mg, 59%).  $^1\text{H}$  NMR (500 MHz, Methanol-d<sub>4</sub>)  $\delta$  8.07 (dd, J=2.4, 0.9 Hz, 1H), 7.77 (dd, J=8.9, 0.9 Hz, 1H), 7.69 (d, J=8.9 Hz, 1H), 7.63 (dd, J=8.5, 2.4 Hz, 1H), 7.40 (d, J=3.1 Hz, 1H), 7.14 (dd, J=3.2, 0.9 Hz, 1H), 6.70 (dd, J=8.5, 0.8 Hz, 1H), 3.42 (t, J=6.4 Hz, 2H), 2.78 (t, J=6.2 Hz, 2H), 2.05-1.96 (m, 2H), 1.83-1.75 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  163.22, 158.63, 158.15, 152.27, 144.04, 142.51, 134.14, 129.66, 129.58, 123.56, 123.39, 121.80, 116.22, 29.69, 28.81, 22.63, 22.56; HRMS (ESI) m/z calcd for C<sub>19</sub>H<sub>18</sub>N<sub>5</sub> [M+H]<sup>+</sup> 316.1562, found 316.1565.

Method A: Yellow solid (272 mg, 48%).  $^1\text{H}$  NMR (500 MHz, DMSO-d<sub>6</sub>)  $\delta$  9.79 (s, 1H), 8.57 (s, 1H), 7.94 (s, 2H), 7.92-7.78 (m, 3H), 3.29 (s, 2H), 2.03-1.95 (m, 2H), 1.78-1.70 (m, 2H); HRMS (ESI) m/z calcd for C<sub>20</sub>H<sub>16</sub>I<sub>2</sub>N<sub>3</sub>O [M+H]<sup>+</sup> 567.9383, found 567.9388.

US 12,384,782 B2

**191**

3-(8,9,10,11-Tetrahydro-3H-pyrazolo[4,3-a]phenanthridin-7-yl)phenol




HSD-02-962

5  
10  
15  
20

**192**


Benzyl (7-(4-hydroxyphenyl)-8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridin-9-yl)carbamate




HSD-02-964

Method A: Off-white solid (241 mg, 52%). <sup>1</sup>H NMR (500 MHz, Methanol-d<sub>4</sub>) δ 8.66 (d, J=9.1 Hz, 1H), 8.08 (dd, J=9.2, 6.3 Hz, 1H), 7.93 (dd, J=9.3, 5.3 Hz, 1H), 7.50 (d, J=8.2 Hz, 2H), 7.29-7.20 (m, 5H), 7.02 (d, J=8.2 Hz, 2H), 5.01 (s, 2H), 3.97-3.84 (m, 1H), 3.67-3.56 (m, 1H), 3.54-3.41 (m, 1H), 3.18-3.08 (m, 1H), 2.95-2.82 (m, 1H), 2.42-2.29 (m, 1H), 2.11-2.01 (m, 1H), <sup>13</sup>C NMR (126 MHz, MeOD) δ 161.72, 159.87, 156.89, 152.70, 150.63, 139.58, 136.84, 136.35, 130.82, 129.46, 128.03, 127.56, 127.34, 123.73, 122.33, 120.83, 119.33, 118.00, 115.47, 114.97, 66.04, 48.13, 48.08, 47.96, 47.79, 47.62, 47.45, 47.28, 47.11, 45.66, 33.71, 29.28, 26.87; HRMS (ESI) m/z calcd for C<sub>28</sub>H<sub>25</sub>N<sub>4</sub>O<sub>3</sub> [M+H]<sup>+</sup> 465.1927, found 465.1927.

3-(8,9,10,11-Tetrahydro-3H-pyrazolo[4,3-a]phenanthridin-7-yl)pyridin-2(1H)-one



HSD-02-963



HSD-02-965


Method A: Off-white solid (211 mg, 64%). <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) δ 9.87 (s, 1H), 8.57 (s, 1H), 7.97-7.80 (m, 2H), 7.45 (d, J=8.1 Hz, 2H), 6.93 (d, J=8.1 Hz, 2H), 4.92 (s, 1H), 3.95 (tt, J=7.8, 3.3 Hz, 1H), 3.41 (dt, J=20.7, 4.7 Hz, 1H), 3.27 (p, J=7.1 Hz, 1H), 2.96 (dd, J=16.6, 4.2 Hz, 1H), 2.74 (dd, J=16.5, 7.4 Hz, 1H), 2.13 (dt, J=13.1, 6.2 Hz, 1H), 1.90 (dq, J=15.0, 7.8 Hz, 1H), <sup>13</sup>C NMR (126 MHz, DMSO) δ 158.44, 155.40, 144.50, 141.23, 138.96, 136.06, 131.24, 129.27, 128.15, 126.83, 121.32, 115.90, 115.38, 64.42, 37.63, 30.18, 28.16; HRMS (ESI) m/z calcd for C<sub>20</sub>H<sub>18</sub>N<sub>4</sub>O<sub>2</sub> [M+H]<sup>+</sup> 332.1399, found 332.1402.

Method A: Off-white solid (214 mg, 67%). <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) δ 8.53 (s, 1H), 7.83 (d, J=9.0 Hz, 1H), 7.81-7.73 (m, 2H), 7.65 (d, J=2.7 Hz, 1H), 6.42 (d, J=9.4 Hz, 1H), 3.25 (t, J=6.5 Hz, 2H), 2.84 (t, J=6.0 Hz, 2H), 1.97 (dq, J=8.4, 5.7 Hz, 2H), 1.78-1.69 (m, 2H); <sup>13</sup>C NMR (126 MHz, DMSO) δ 162.24, 152.74, 143.82, 142.86, 142.53, 140.86, 139.70, 136.38, 134.04, 129.50, 121.76, 119.36, 118.81, 116.19, 115.37, 29.69, 28.79, 22.61, 22.55; HRMS (ESI) m/z calcd for C<sub>19</sub>H<sub>17</sub>N<sub>4</sub>O [M+H]<sup>+</sup> 317.1402, found 317.1411.

## US 12,384,782 B2


**193**

2-(7-(4-Hydroxyphenyl)-8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridin-9-yl)isoindoline-1,3-dione



Method A: Off-white solid (239 mg, 52%).  $^1\text{H}$  NMR (500 MHz, DMSO-d<sub>6</sub>)  $\delta$  9.56 (s, 1H), 8.57 (s, 1H), 7.89-7.84 (m, 2H), 7.83-7.78 (m, 4H), 7.36 (d, J=8.6 Hz, 1H), 6.82 (d, J=8.6 Hz, 1H), 4.45-4.33 (m, 1H), 3.73-3.59 (m, 2H), 3.53-3.39 (m, 1H), 2.92-2.85 (m, 1H), 2.82-2.69 (m, 1H), 2.36-2.26 (m, 1H);  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  168.38, 157.66, 156.88, 143.84, 141.13, 138.66, 136.38, 134.76, 132.01, 131.67, 130.75, 129.58, 127.50, 123.38, 121.10, 116.54, 115.25, 114.60, 47.46, 32.19, 31.15, 26.15; HRMS (ESI) m/z calcd for C<sub>22</sub>H<sub>21</sub>N<sub>4</sub>O<sub>3</sub> [M+H]<sup>+</sup> 461.1614, found 461.1619.


2-Chloro-4-(8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridin-7-yl)phenol



Method A: Off-white solid (191 mg, 55%).  $^1\text{H}$  NMR (500 MHz, DMSO-d<sub>6</sub>)  $\delta$  11.20 (s, 1H), 8.74 (s, 1H), 8.25-8.12 (m, 2H), 7.80 (d, J=2.1 Hz, 1H), 7.56 (dd, J=8.4, 2.2 Hz, 1H), 7.30 (d, J=8.4 Hz, 1H), 3.40 (d, J=6.7 Hz, 2H), 2.81 (t, J=6.1 Hz, 2H), 2.07-1.98 (m, 2H), 1.81-1.75 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  155.92, 152.58, 149.60, 135.00, 131.94, 131.83, 130.50, 123.67, 122.81, 120.32, 120.19, 116.98, 114.53, 30.78, 28.06, 21.65, 21.61; HRMS (ESI) m/z calcd for C<sub>20</sub>H<sub>17</sub>ClN<sub>3</sub>O [M+H]<sup>+</sup> 350.1060, found 350.1066.


**194**

4-(1-Bromo-8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridin-7-yl)phenol




Method A: Yellow solid (110 mg, 28%). Off-white solid (153 mg, 39%).  $^1\text{H}$  NMR (500 MHz, Methanol-d<sub>4</sub>)  $\delta$  8.18 (d, J=9.1 Hz, 1H), 8.06 (d, J=9.2 Hz, 1H), 7.57 (d, J=8.3 Hz, 2H), 7.07 (d, J=8.3 Hz, 2H), 3.99 (s, 2H), 2.97 (s, 2H), 1.97 (t, J=3.5 Hz, 4H);  $^{13}\text{C}$  NMR (126 MHz, MeOD)  $\delta$  160.37, 155.96, 151.79, 141.59, 135.37, 132.94, 130.83, 123.46, 121.93, 120.38, 119.36, 115.60, 114.56, 36.01, 27.02, 20.91, 20.80.  $^{13}\text{C}$  NMR (126 MHz, MeOD)  $\delta$  160.37, 155.96, 154.60, 151.79, 141.55, 135.37, 132.94, 130.83, 127.59, 123.46, 121.93, 120.38, 119.25, 115.60, 114.56, 36.01, 27.02, 20.91, 20.80; HRMS (ESI) m/z calcd for C<sub>20</sub>H<sub>17</sub>BrN<sub>3</sub>O [M+H]<sup>+</sup> 394.0555, found 394.0556.

7-(6-Chloropyridin-3-yl)-8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridine



Method A: White solid (210 mg, 63%).  $^1\text{H}$  NMR (500 MHz, DMSO-d<sub>6</sub>)  $\delta$  8.69 (d, J=2.4 Hz, 1H), 8.64 (s, 1H), 8.17 (dd, J=8.2, 2.5 Hz, 1H), 8.02-7.91 (m, 2H), 7.70 (d, J=8.2 Hz, 1H), 3.33 (t, J=6.6 Hz, 2H), 2.78 (t, J=6.2 Hz, 2H), 2.02-1.97 (m, 2H), 1.80-1.73 (m, 2H); HRMS (ESI) m/z calcd for C<sub>19</sub>H<sub>16</sub>ClN<sub>4</sub> [M+H]<sup>+</sup> 335.1063, found 335.1063.

4-(8,9,10,11-Tetrahydro-3H-pyrazolo[4,3-a]phenanthridin-7-yl)-2-(trifluoromethyl)phenol




US 12,384,782 B2

**195**


Method A: white solid (233 mg, 61%).  $^1\text{H}$  NMR (500 MHz, DMSO-d<sub>6</sub>) δ 10.77 (s, 1H), 8.52 (s, 1H), 7.82 (d, J=2.2 Hz, 2H), 7.72-7.64 (m, 2H), 7.12 (d, J=8.3 Hz, 1H), 3.32-3.25 (m, 2H), 2.78 (t, J=6.1 Hz, 2H), 2.02-1.92 (m, 2H), 1.77-1.67 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO) δ 155.93, 155.43, 143.63, 142.52, 138.66, 136.33, 134.92, 131.78, 129.60, 129.39, 127.78, 127.73, 125.63 (q, J=273.42 Hz), 121.78, 116.87, 116.43, 115.61 (q, J=30.24 Hz), 114.39, 29.69, 29.00, 22.55; HRMS (ESI) m/z calcd for C<sub>21</sub>H<sub>17</sub>F<sub>3</sub>N<sub>3</sub>O [M+H]<sup>+</sup> 384.1324, found 384.1329.

2-Methoxy-4-(8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridin-7-yl)phenol



Method A: White solid (231 mg, 67%).  $^1\text{H}$  NMR (500 MHz, DMSO-d<sub>6</sub>) δ 9.57 (s, 1H), 8.63 (s, 1H), 8.03 (s, 2H), 7.24 (d, J=2.1 Hz, 1H), 7.08 (dd, J=8.0, 2.0 Hz, 1H), 6.98 (d, J=8.0 Hz, 1H), 3.83 (s, 3H), 3.35 (s, 2H), 2.82 (t, J=6.2 Hz, 2H), 2.04-1.98 (m, 2H), 1.79-1.71 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO) δ 148.62, 147.81, 138.57, 135.55, 131.11, 126.48, 123.12, 122.31, 115.71, 114.34, 56.35, 30.47, 28.55, 22.05; HRMS (ESI) m/z calcd for C<sub>21</sub>H<sub>20</sub>N<sub>3</sub>O<sub>2</sub> [M+H]<sup>+</sup> 346.1556, found 346.1562.


3-Fluoro-4-(8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridin-7-yl)phenol



Method A: White solid (186 mg, 56%).  $^1\text{H}$  NMR (500 MHz, DMSO-d<sub>6</sub>) δ 8.57 (s, 1H), 7.84 (dd, J=9.0, 0.9 Hz, 1H), 7.79 (d, J=9.1 Hz, 1H), 7.22 (t, J=8.6 Hz, 1H), 6.72 (dd, J=8.3, 2.3 Hz, 1H), 6.66 (dd, J=11.8, 2.3 Hz, 1H), 3.30 (t, J=6.6 Hz, 2H), 2.61 (t, J=6.0 Hz, 2H), 2.00-1.91 (m, 2H), 1.79-1.69 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO) δ 161.25 (J=245.11 Hz), 159.59, 159.50, 152.73, 143.80, 142.04, 132.20, 132.16, 130.53, 129.53, 122.03, 119.48, 119.35, 116.25, 112.08, 102.89, 102.70, 29.48, 27.50, 22.64, 22.24; HRMS (ESI) m/z calcd for C<sub>20</sub>H<sub>17</sub>FN<sub>3</sub>O [M+H]<sup>+</sup> 334.1356, found 334.1360.

**196**

4-(9-Methyl-8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridin-7-yl)phenol




HSD-02-973

HSD-02-971

Method A: Off-white solid (223 mg, 68%).  $^1\text{H}$  NMR (500 MHz, Methanol-d<sub>4</sub>) δ 8.81 (s, 1H), 8.22 (d, J=9.3 Hz, 1H), 8.02 (d, J=9.3 Hz, 1H), 7.58 (dd, J=8.5, 1.9 Hz, 2H), 7.07 (dd, J=8.6, 1.9 Hz, 2H), 3.75-3.68 (m, 1H), 3.56 (dt, J=18.6, 8.3 Hz, 1H), 2.91 (dt, J=17.3, 2.7 Hz, 1H), 2.65 (dd, J=17.1, 10.6 Hz, 1H), 2.38-2.21 (m, 1H), 1.99-1.85 (m, 1H), 1.79-1.64 (m, 1H), 1.14 (dd, J=6.5, 1.8 Hz, 3H);  $^{13}\text{C}$  NMR (126 MHz, MeOD) δ 160.23, 153.67, 151.60, 134.75, 132.00, 130.90, 124.14, 123.00, 123.00, 122.62, 121.61, 119.36, 119.08, 116.55, 115.54, 115.03, 35.98, 30.99, 29.34, 27.83, 20.20; HRMS (ESI) m/z calcd for C<sub>21</sub>H<sub>20</sub>N<sub>3</sub>O [M+H]<sup>+</sup> 330.1606, found 330.1609.

4-(3,8,9,10-Tetrahydrocyclopenta[c]pyrazolo[4,3-f]quinolin-7-yl)phenol



HSD-02-974


HSD-02-972

Method A: Off-white solid (168 mg, 56%).  $^1\text{H}$  NMR (500 MHz, DMSO-d<sub>6</sub>) δ 8.42 (s, 1H), 7.85 (d, J=9.2 Hz, 1H), 7.81 (dd, J=9.1, 0.9 Hz, 1H), 7.74 (d, J=8.6 Hz, 2H), 6.89 (d, J=8.6 Hz, 2H), 3.41 (t, J=7.6 Hz, 2H), 3.21 (t, J=7.4 Hz, 2H), 2.21 (p, J=7.6 Hz, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO) δ 158.20, 152.26, 149.32, 144.91, 135.59, 131.44, 130.38, 129.22, 118.73, 116.70, 115.46, 33.48, 33.40, 24.97; HRMS (ESI) m/z calcd for C<sub>19</sub>H<sub>16</sub>N<sub>3</sub>O [M+H]<sup>+</sup> 302.1293, found 302.1295.

US 12,384,782 B2

**197**

7-(4-Hydroxyphenyl)-8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridine-9-carbonitrile



HSD-02-976


**198**

Method A: Pale yellow solid (181 mg, 57%). <sup>1</sup>H NMR (500 MHz, Methanol-d<sub>4</sub>) δ 8.51 (s, 1H), 8.40 (d, J=2.4 Hz, 1H), 8.16 (td, J=8.0, 2.5 Hz, 1H), 7.83 (s, 2H), 7.22 (dd, J=8.4, 2.4 Hz, 1H), 3.27 (t, J=6.6 Hz, 2H), 2.76 (t, J=6.2 Hz, 2H), 2.09-2.02 (m, 2H), 1.86-1.78 (m, 2H); <sup>13</sup>C NMR (126 MHz, MeOD) δ 164.30, 162.39, 152.26, 147.56, 147.45, 144.47, 142.82, 142.68, 142.61, 133.99, 129.83, 127.94, 122.52, 115.69, 108.96, 108.67, 29.58, 28.25, 21.91, 21.87; HRMS (ESI) m/z calcd for C<sub>19</sub>H<sub>16</sub>FN<sub>4</sub> [M+H]<sup>+</sup> 319.1359, found 319.1366.

2-Iodo-4-(8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridin-7-yl)phenol

15

HSD-02-980




Method A: Yellow solid (207 mg, 61%). <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) δ 10.41 (s, 1H), 8.76 (s, 1H), 8.21 (d, J=9.2 Hz, 1H), 8.17 (d, J=9.2 Hz, 1H), 7.62 (d, J=8.2 Hz, 2H), 7.07 (d, J=8.2 Hz, 2H), 3.58-3.48 (m, 2H), 3.45-3.36 (m, 1H), 3.28-3.12 (m, 2H), 2.43-2.34 (m, 1H), 2.34-2.24 (m, 1H), <sup>13</sup>C NMR (126 MHz, DMSO) δ 157.87, 156.56, 144.05, 140.61, 138.62, 136.16, 131.33, 130.95, 129.54, 125.63, 122.86, 120.97, 116.21, 115.29, 114.74, 31.73, 27.64, 25.08, 24.57; HRMS (ESI) m/z calcd for C<sub>21</sub>H<sub>17</sub>N<sub>4</sub>O [M+H]<sup>+</sup> 341.1402, found 341.1410.

2-((Dimethylamino)methyl)-4-(8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridin-7-yl)phenol

30

HSD-02-977




Method A: White solid (198 mg, 45%). <sup>1</sup>H NMR (500 MHz, Methanol-d<sub>4</sub>) δ 8.87 (s, 1H), 8.28 (d, J=9.2 Hz, 1H), 8.11 (d, J=2.2 Hz, 1H), 8.06 (d, J=9.2 Hz, 1H), 7.60 (dd, J=8.4, 2.2 Hz, 1H), 7.10 (d, J=8.4 Hz, 1H), 3.65 (t, J=6.4 Hz, 2H), 2.95 (t, J=6.2 Hz, 2H), 2.31-2.09 (m, 2H), 2.03-1.69 (m, 2H); <sup>13</sup>C NMR (126 MHz, MeOD) δ 159.64, 154.77, 153.68, 149.57, 140.11, 134.50, 132.47, 130.75, 129.17, 123.97, 123.61, 118.95, 114.86, 114.28, 109.63, 83.68, 30.98, 27.82, 21.28, 21.20; HRMS (ESI) m/z calcd for C<sub>20</sub>H<sub>17</sub>IN<sub>3</sub>O [M+H]<sup>+</sup> 442.0416, found 442.0416.

4-(8,9,10,11-Tetrahydro-3H-pyrazolo[4,3-a]phenanthridin-7-yl)benzoic acid

40

HSD-02-981




Method A: Yellow solid (148 mg, 40%). <sup>1</sup>H NMR (500 MHz, Methanol-d<sub>4</sub>) δ 8.63 (s, 1H), 7.92 (s, 2H), 7.61-7.55 (m, 2H), 7.12 (d, J=8.1 Hz, 1H), 4.42 (s, 2H), 3.43 (d, J=6.2 Hz, 2H), 2.93 (s, 6H), 2.85 (t, J=6.2 Hz, 2H), 2.13-2.08 (m, 2H), 1.91-1.82 (m, 2H); HRMS (ESI) m/z calcd for C<sub>23</sub>H<sub>25</sub>N<sub>4</sub>O [M+H]<sup>+</sup> 373.2028, found 373.2033.

7-(6-Fluoropyridin-3-yl)-8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridine

50

HSD-02-978




Method A: Yellow solid (172 mg, 50%). <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) δ 8.62 (s, 1H), 8.12-8.08 (m, 2H), 8.02 (d, J=9.1 Hz, 1H), 7.95 (d, J=9.1 Hz, 1H), 7.80-7.73 (m, 2H), 3.29 (t, J=6.5 Hz, 2H), 2.75-2.68 (m, 2H), 2.00-1.94 (m, 2H), 1.76-1.66 (m, 2H), <sup>13</sup>C NMR (126 MHz, DMSO) δ 167.42, 152.75, 148.00, 140.96, 139.42, 135.00, 131.73, 130.39, 130.19, 129.66, 129.59, 124.86, 122.74, 118.09, 115.38, 30.20, 28.32, 22.04, 21.92; HRMS (ESI) m/z calcd for C<sub>21</sub>H<sub>18</sub>N<sub>3</sub>O<sub>2</sub> [M+H]<sup>+</sup> 344.1399, found 344.1401.

US 12,384,782 B2

**199**

4-(8,9-Dihydro-3H-cyclobuta[c]pyrazolo[4,3-f]quinolin-7-yl)phenol

HSD-02-982



Method A: Off-white solid (224 mg, 65%).  $^1\text{H}$  NMR (500 MHz, DMSO-d<sub>6</sub>)  $\delta$  8.56 (s, 1H), 8.12 (s, 1H), 7.92 (s, 1H), 7.83 (d, J=5.8 Hz, 2H), 7.61 (d, J=8.6 Hz, 1H), 7.55 (d, J=8.6 Hz, 1H), 3.32-3.26 (m, 2H), 2.78 (t, J=6.1 Hz, 2H), 2.01-1.92 (m, 2H), 1.74-1.65 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  157.30, 143.71, 142.28, 139.80, 138.66, 136.27, 134.45, 133.55, 129.66, 129.54, 128.17, 123.07, 121.71, 121.43, 116.44, 114.31, 109.93, 29.69, 29.22, 22.64, 22.59; HRMS (ESI) m/z calcd for C<sub>21</sub>H<sub>18</sub>N<sub>5</sub>[M+H]<sup>+</sup> 340.1562, found 340.1565.


**200**

Method A: Off-white solid (224 mg, 65%).  $^1\text{H}$  NMR (500 MHz, DMSO-d<sub>6</sub>)  $\delta$  8.56 (s, 1H), 8.12 (s, 1H), 7.92 (s, 1H), 7.83 (d, J=5.8 Hz, 2H), 7.61 (d, J=8.6 Hz, 1H), 7.55 (d, J=8.6 Hz, 1H), 3.32-3.26 (m, 2H), 2.78 (t, J=6.1 Hz, 2H), 2.01-1.92 (m, 2H), 1.74-1.65 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  157.30, 143.71, 142.28, 139.80, 138.66, 136.27, 134.45, 133.55, 129.66, 129.54, 128.17, 123.07, 121.71, 121.43, 116.44, 114.31, 109.93, 29.69, 29.22, 22.64, 22.59; HRMS (ESI) m/z calcd for C<sub>21</sub>H<sub>18</sub>N<sub>5</sub>[M+H]<sup>+</sup> 340.1562, found 340.1565.

7-(1H-Indazol-6-yl)-8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridine

15

HSD-02-985




Method A: Off-white solid (152 mg, 53%).  $^1\text{H}$  NMR (500 MHz, DMSO-d<sub>6</sub>)  $\delta$  9.80 (s, 1H), 8.32 (s, 1H), 8.01 (dd, J=8.6, 1.4 Hz, 2H), 7.82 (d, J=9.5 Hz, 1H), 7.78 (d, J=9.1 Hz, 1H), 6.91 (dd, J=8.6, 1.4 Hz, 2H), 3.73-3.64 (m, 2H), 3.62-3.54 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  159.12, 149.75, 148.04, 144.97, 137.96, 136.56, 134.42, 130.02, 129.03, 128.87, 116.88, 116.11, 115.24, 114.32, 32.33, 30.24; HRMS (ESI) m/z calcd for C<sub>18</sub>H<sub>14</sub>N<sub>3</sub>O [M+H]<sup>+</sup> 288.1137, found 288.1139.

4-(3,8-Dihydro-2H-furo[3,2-c]pyrazolo[4,3-f]quinolin-4-yl)phenol

20

HSD-02-983




Method A: Off-white solid (176 mg, 52%).  $^1\text{H}$  NMR (500 MHz, DMSO-d<sub>6</sub>)  $\delta$  8.52 (s, 1H), 7.87-7.77 (m, 2H), 7.61 (d, J=1.6 Hz, 1H), 7.48 (d, J=8.2 Hz, 1H), 7.38 (dd, J=8.2, 1.7 Hz, 1H), 3.27 (d, J=7.7 Hz, 2H), 2.75 (t, J=6.0 Hz, 2H), 1.97 (qd, J=6.5, 4.2, 2.9 Hz, 2H), 1.79-1.67 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  155.27, 143.48, 142.61, 138.71, 138.01, 136.36, 133.74, 131.74, 129.55, 129.36, 125.92, 122.00, 116.36, 114.53, 111.49, 110.02, 29.64, 28.80, 22.52, 22.44; HRMS (ESI) m/z calcd for C<sub>21</sub>H<sub>18</sub>N<sub>5</sub> [M+H]<sup>+</sup> 340.1562, found 340.1565.

35

5-(8,9,10,11-Tetrahydro-3H-pyrazolo[4,3-a]phenanthridin-7-yl)-1H-benzo[d]imidazol-2(3H)-one


40

HSD-02-986



50

HSD-02-984



Method A: Off-white solid (178 mg, 50%).  $^1\text{H}$  NMR (500 MHz, DMSO-d<sub>6</sub>)  $\delta$  8.55 (s, 1H), 7.84 (d, J=9.1 Hz, 1H), 7.78 (d, J=9.1 Hz, 1H), 7.16-7.09 (m, 2H), 7.00 (d, J=7.8 Hz, 1H), 3.28 (t, J=6.5 Hz, 2H), 2.77 (t, J=6.1 Hz, 2H), 2.00-1.95 (m, 2H), 1.73-1.66 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  157.16, 156.09, 143.72, 142.21, 139.73, 134.99, 133.77, 130.00, 129.94, 129.53, 129.35, 122.16, 121.65, 116.30, 115.27, 109.89, 108.18, 29.70, 29.28, 22.65, 22.62; HRMS (ESI) m/z calcd for C<sub>22</sub>H<sub>17</sub>N<sub>4</sub>O<sub>2</sub> [M+H]<sup>+</sup> 369.1352, found 369.1352.

60


65

US 12,384,782 B2

**201**

4-(8,9,10,11-Tetrahydro-1H-pyrazolo[3,4-a]phenanthridin-7-yl)phenol

HSD-02-987



Method A: Off-white solid (207 mg, 56%).  $^1\text{H}$  NMR (500 MHz, DMSO-d<sub>6</sub>) δ 8.59 (s, 1H), 8.22 (d, J=1.6 Hz, 1H), 7.97 (d, J=8.3 Hz, 1H), 7.86 (dd, J=9.0, 0.9 Hz, 1H), 7.82 (d, J=9.1 Hz, 1H), 7.65 (dd, J=8.3, 1.7 Hz, 1H), 3.36-3.33 (m, 3H), 2.83 (s, 3H), 2.81-2.78 (m, 2H), 2.04-1.98 (m, 2H), 1.78-1.70 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO) δ 168.24, 156.38, 152.90, 143.77, 142.53, 137.87, 135.52, 129.61, 129.48, 127.80, 122.99, 121.99, 121.67, 118.44, 116.26, 29.71, 29.02, 22.62, 22.54, 20.33; HRMS (ESI) m/z calcd for C<sub>22</sub>H<sub>19</sub>N<sub>4</sub>S [M+H]<sup>+</sup> 371.1330, found 371.1333.


**202**

Method A: Off-white solid (207 mg, 56%).  $^1\text{H}$  NMR (500 MHz, DMSO-d<sub>6</sub>) δ 8.59 (s, 1H), 8.22 (d, J=1.6 Hz, 1H), 7.97 (d, J=8.3 Hz, 1H), 7.86 (dd, J=9.0, 0.9 Hz, 1H), 7.82 (d, J=9.1 Hz, 1H), 7.65 (dd, J=8.3, 1.7 Hz, 1H), 3.36-3.33 (m, 3H), 2.83 (s, 3H), 2.81-2.78 (m, 2H), 2.04-1.98 (m, 2H), 1.78-1.70 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO) δ 168.24, 156.38, 152.90, 143.77, 142.53, 137.87, 135.52, 129.61, 129.48, 127.80, 122.99, 121.99, 121.67, 118.44, 116.26, 29.71, 29.02, 22.62, 22.54, 20.33; HRMS (ESI) m/z calcd for C<sub>22</sub>H<sub>19</sub>N<sub>4</sub>S [M+H]<sup>+</sup> 371.1330, found 371.1333.

3,5-Difluoro-4-(8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridin-7-yl)phenol

15


HSD-02-990



Method A: Off-white solid (126 mg, 40%).  $^1\text{H}$  NMR (500 MHz, DMSO-d<sub>6</sub>) δ 9.63 (s, 1H), 8.14 (s, 1H), 7.77 (d, J=8.9 Hz, 1H), 7.58 (d, J=9.0 Hz, 1H), 7.43 (d, J=8.5 Hz, 2H), 6.88 (d, J=8.6 Hz, 2H), 3.17 (t, J=6.6 Hz, 2H), 2.73 (t, J=6.1 Hz, 2H), 1.88 (qd, J=7.8, 6.4, 4.5 Hz, 2H), 1.73-1.63 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO) δ 158.72, 157.79, 142.88, 138.02, 134.71, 134.54, 131.87, 130.95, 129.09, 124.62, 121.76, 119.80, 116.13, 115.13, 28.93, 26.48, 22.74, 22.32; HRMS (ESI) m/z calcd for C<sub>20</sub>H<sub>18</sub>N<sub>3</sub>O [M+H]<sup>+</sup> 316.1449, found 316.1458.

5-(8,9,10,11-Tetrahydro-3H-pyrazolo[4,3-a]phenanthridin-7-yl)pyrimidine-2,4(1H,3H)-dione

HSD-02-988




Method A: White solid (168 mg, 48%).  $^1\text{H}$  NMR (500 MHz, DMSO-d<sub>6</sub>) δ 8.52 (s, 1H), 7.84 (d, J=9.0 Hz, 1H), 7.80 (d, J=9.5 Hz, 1H), 7.61 (d, J=1.6 Hz, 1H), 7.48 (d, J=8.2 Hz, 1H), 7.38 (dd, J=8.2, 1.7 Hz, 1H), 3.27 (d, J=7.7 Hz, 2H), 2.75 (t, J=6.0 Hz, 2H), 1.99-1.92 (m, 2H), 1.76-1.65 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO) δ 155.27, 143.48, 142.96, 142.76, 142.61, 138.71, 138.01, 136.36, 133.74, 131.74, 129.55, 129.36, 125.92, 122.00, 116.36, 114.53, 111.49, 110.02, 29.64, 28.80, 22.52, 22.44; HRMS (ESI) m/z calcd for C<sub>20</sub>H<sub>16</sub>FN<sub>3</sub>O [M+H]<sup>+</sup> 352.1261, found 352.1266.

7-(4-Hydroxyphenyl)-8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridine-9-carboxylic acid

40


HSD-02-991



Method A: Off-white solid (173 mg, 52%).  $^1\text{H}$  NMR (500 MHz, Methanol-d<sub>4</sub>) δ 8.77 (s, 1H), 8.18-8.10 (m, 1H), 8.02-7.85 (m, 1H), 7.74-7.17 (m, 2H), 3.60-3.48 (m, 2H), 3.02-2.89 (m, 2H), 2.20-2.09 (m, 1H), 2.04-1.90 (m, 1H); HRMS (ESI) m/z calcd for C<sub>18</sub>H<sub>16</sub>N<sub>5</sub>O<sub>2</sub> [M+H]<sup>+</sup> 334.1304, found 334.1305.

2-Methyl-6-(8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridin-7-yl)benzo[d]thiazole


HSD-02-989



Method A: Off-white solid (180 mg, 50%).  $^1\text{H}$  NMR (500 MHz, DMSO-d<sub>6</sub>) δ 8.56 (s, 1H), 7.83 (d, J=9.1 Hz, 1H), 7.78 (d, J=9.1 Hz, 1H), 7.38 (d, J=8.5 Hz, 2H), 6.87 (d, J=8.5 Hz, 2H), 3.48-3.39 (m, 1H), 3.36-3.23 (m, 1H), 3.05-2.97 (m, 1H), 2.95-2.87 (m, 1H), 2.62-2.56 (m, 1H), 2.38-2.30 (m, 1H), 2.01-1.91 (m, 1H);  $^{13}\text{C}$  NMR (126 MHz, DMSO) δ 177.11, 157.71, 156.96, 143.77, 141.52, 131.87, 130.83, 129.55, 128.25, 121.22, 116.27, 115.19, 31.66, 29.18, 25.49; HRMS (ESI) m/z calcd for C<sub>21</sub>H<sub>18</sub>N<sub>3</sub>O<sub>3</sub> [M+H]<sup>+</sup> 360.1348, found 360.1351.

**203**

5-(8,9,10,11-Tetrahydro-3H-pyrazolo[4,3-a]phenanthridin-7-yl)benzo[d]thiazol-2-amine




HSD-02-992

5

**204**

N-(7-(4-Hydroxyphenyl)-8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridin-9-yl)acetamide



HSD-02-994

10

15

30

35

40

45

50


55

Method A: Pale yellow solid (137 mg, 37%).  $^1\text{H}$  NMR (500 MHz, DMSO-d<sub>6</sub>)  $\delta$  8.55 (s, 1H), 7.88-7.78 (m, 3H), 7.55 (s, 2H), 7.45-7.36 (m, 2H), 3.32 (s, 2H), 2.82 (t, J=6.1 Hz, 2H), 1.99 (qq, J=5.2, 2.7 Hz, 2H), 1.74 (dp, J=9.1, 3.2, 2.8 Hz, 2H);  $^{13}\text{C}$  NMR (126 DMSO)  $\delta$  167.61, 156.90, 152.94, 143.53, 142.39, 138.63, 136.32, 133.93, 131.17, 129.60, 127.25, 122.13, 121.64, 117.32, 116.50, 114.34, 29.75, 29.18, 22.66, 22.62; HRMS (ESI) m/z calcd for C<sub>21</sub>H<sub>18</sub>N<sub>5</sub>S [M+H]<sup>+</sup> 372.1283, found 372.1285.


4-(3,8,10,11-Tetrahydropyrano[3,4-c]pyrazolo[4,3-f]quinolin-7-yl)phenol

Method A: Pale brownish solid (220 mg, 59%).  $^1\text{H}$  NMR (500 MHz, DMSO-d<sub>6</sub>)  $\delta$  8.57 (s, 1H), 7.97 (d, J=7.2 Hz, 1H), 7.84 (dd, J=9.0, 0.9 Hz, 1H), 7.79 (d, J=9.1 Hz, 1H), 7.40-7.35 (m, 2H), 6.89-6.80 (m, 2H), 3.96-3.88 (m, 1H), 3.52-3.46 (m, 1H), 3.34-3.29 (m, 1H), 2.98-2.90 (m, 1H), 2.75 (dd, J=16.6, 9.0 Hz, 1H), 2.24-2.16 (m, 1H), 1.95-1.83 (m, 1H), 1.77 (s, 3H);  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  169.29, 157.68, 157.02, 143.86, 141.35, 131.82, 130.82, 129.56, 127.39, 121.15, 116.35, 115.20, 44.69, 35.05, 28.48, 28.02, 23.15; HRMS (ESI) m/z calcd for C<sub>22</sub>H<sub>21</sub>N<sub>4</sub>O<sub>2</sub> [M+H]<sup>+</sup> 373.1665, found 373.1670.

4-(6,7,8,9-Tetrahydro-1H-pyrazolo[3,4-c]phenanthridin-5-yl)phenol



HSD-02-993



HSD-02-995


Method A: Off-white solid (206 mg, 65%).  $^1\text{H}$  NMR (500 MHz, DMSO-d<sub>6</sub>)  $\delta$  9.69 (s, 1H), 8.52 (s, 1H), 7.85 (q, J=9.2 Hz, 2H), 7.40 (d, J=8.5 Hz, 2H), 6.87 (d, J=8.6 Hz, 2H), 4.77 (s, 2H), 4.11 (t, J=5.9 Hz, 2H), 3.34 (d, J=6.8 Hz, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  158.09, 153.88, 144.20, 139.12, 138.55, 135.81, 130.66, 130.59, 129.53, 127.54, 120.80, 116.34, 115.40, 114.82, 67.17, 64.45, 28.70; HRMS (ESI) m/z calcd for C<sub>19</sub>H<sub>16</sub>N<sub>3</sub>O<sub>2</sub> [M+H]<sup>+</sup> 318.1243, found 318.1244.

Method A: Pale brownish solid (132 mg, 42%).  $^1\text{H}$  NMR (500 MHz, Methanol-d<sub>4</sub>)  $\delta$  8.90 (s, 1H), 8.28 (dd, J=11.6, 5.5 Hz, 2H), 8.05 (t, J=8.7 Hz, 2H), 7.62-7.54 (m, 2H), 7.11-7.05 (m, 2H), 3.57 (t, J=6.4 Hz, 2H), 2.88 (t, J=6.2 Hz, 2H), 2.14-2.05 (m, 2H), 1.93-1.85 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, MeOD)  $\delta$  160.37, 156.23, 153.72, 132.09, 130.99, 130.27, 123.52, 122.38, 122.21, 115.50, 111.83, 27.76, 27.47, 21.48, 21.18; HRMS (ESI) m/z calcd for C<sub>20</sub>H<sub>18</sub>N<sub>3</sub>O [M+H]<sup>+</sup> 316.1449, found 316.1456.


## US 12,384,782 B2

**205**

4-(6,7,8,9-Tetrahydro-3H-pyrazolo[4,3-c]phenanthridin-5-yl)phenol


5  
HSD-02-997**206**

4-(8,9,10,11-Tetrahydro-1H-pyrazolol[3,4-a]phenanthridin-7-yl)phenol

5  
HSD-02-999


Method A: Pale yellow solid (161 mg, 51%).  $^1\text{H}$  NMR (500 MHz, Methanol-d<sub>4</sub>)  $\delta$  8.49 (s, 1H), 8.11 (d, J=9.2 Hz, 1H), 7.89 (d, J=9.2 Hz, 1H), 7.65-7.56 (m, 2H), 7.12-7.03 (m, 2H), 3.53 (t, J=6.5 Hz, 2H), 2.92 (t, J=6.3 Hz, 2H), 2.14-2.05 (m, 2H), 1.95-1.83 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  162.75, 159.17, 154.29, 147.97, 140.25, 139.21, 136.17, 134.68, 130.81, 128.84, 127.83, 124.74, 122.97, 122.65, 122.32, 115.57, 110.49, 110.49, 30.27, 28.70, 22.16, 22.08; HRMS (ESI) m/z calcd for C<sub>20</sub>H<sub>18</sub>N<sub>3</sub>O [M+H]<sup>+</sup> 316.1449, found 316.1459.

7-(1H-Pyrrolo[2,3-b]pyridin-5-yl)-8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridine

35  
HSD-02-998

Method A: White solid (229 mg, 72%).  $^1\text{H}$  NMR (500 MHz, Methanol-d<sub>4</sub>)  $\delta$  8.92 (s, 1H), 8.35 (d, J=9.3 Hz, 1H), 8.06 (dd, J=9.2, 2.4 Hz, 1H), 3.71-3.64 (m, 2H), 2.86-2.77 (m, 2H), 2.45 (s, 3H), 2.25-2.20 (m, 5H), 2.06-1.98 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, MeOD)  $\delta$  170.18, 158.64, 155.86, 140.72, 140.00, 135.64, 134.42, 134.28, 124.70, 121.79, 118.93, 114.70, 108.54, 30.94, 26.68, 21.17, 20.88, 10.39, 8.99; HRMS (ESI) m/z calcd for C<sub>19</sub>H<sub>19</sub>N<sub>4</sub>O [M+H]<sup>+</sup> 319.1559, found 319.1563.

7-(4-Hydroxyphenyl)-8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridine-1-carbonitrile

55  
HSD-02-1013


Method A: Off-white solid (203 mg, 60%).  $^1\text{H}$  NMR (500 MHz, DMSO-d<sub>6</sub>)  $\delta$  12.09 (s, 1H), 8.78 (s, 1H), 8.54 (d, J=2.1 Hz, 1H), 8.37 (d, J=2.1 Hz, 1H), 8.17 (q, J=9.2 Hz, 2H), 7.65 (t, J=3.0 Hz, 1H), 6.61 (dd, J=3.5, 1.8 Hz, 1H), 3.51-3.44 (m, 2H), 2.86 (t, J=6.2 Hz, 2H), 2.09-2.01 (m, 2H), 1.86-1.73 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  151.20, 149.00, 143.45, 136.93, 132.02, 130.20, 128.42, 122.92, 122.10, 119.30, 115.16, 115.08, 101.14, 30.71, 28.46, 21.95, 21.88; HRMS (ESI) m/z calcd for C<sub>21</sub>H<sub>18</sub>N<sub>5</sub> [M+H]<sup>+</sup> 340.1562, found 340.1569.

US 12,384,782 B2

**207**

Method A: White solid (210 mg, 61%).  $^1\text{H}$  NMR 1500 MHz, Methanol-d<sub>4</sub>)  $\delta$  8.32 (d, J=9.3 Hz, 1H), 8.20 (d, J=9.2 Hz, 1H), 7.62 (d, J=8.6 Hz, 2H), 7.09 (d, J=8.5 Hz, 2H), 3.91 (t, J=6.3 Hz, 2H), 3.00 (t, J=6.3 Hz, 2H), 2.24-2.09 (m, 2H), 2.01-1.90 (m, 2H).  $^{13}\text{C}$  NMR (126 MHz, MeOD)  $\delta$  160.62, 155.55, 153.29, 139.97, 135.54, 133.16, 130.98, 122.63, 121.71, 121.08, 119.18, 115.88, 115.65, 115.28, 33.30, 27.88, 20.92, 20.63; HRMS (ESI) m/z calcd for C<sub>21</sub>H<sub>21</sub>N<sub>4</sub>O [M+H]<sup>+</sup> 345.1715, found 345.1720.


tert-Butyl (6-(8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridin-7-yl)pyridin-2-yl)carbamate



HSD-02-1022

Method A: White solid (270 mg, 65%).  $^1\text{H}$  NMR (500 MHz, Methanol-d<sub>4</sub>)  $\delta$  8.79 (s, 1H), 8.23 (d, J=9.3 Hz, 1H), 8.12-8.05 (m, 3H), 7.65 (dd, J=5.7, 2.6 Hz, 1H), 3.53 (d, J=6.0 Hz, 2H), 3.08 (t, J=6.1 Hz, 2H), 2.21-2.14 (m, 2H), 1.99-1.91 (m, 2H), 1.58 (s, 9H);  $^{13}\text{C}$  NMR (126 MHz, MeOD)  $\delta$  154.62, 153.09, 153.05, 147.37, 146.93, 140.49, 139.57, 134.87, 134.39, 132.10, 124.03, 120.98, 119.75, 119.68, 114.62, 114.29, 80.98, 30.97, 27.41, 27.15, 21.16, 21.06.


4-(5-Methoxy-8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridin-7-yl)phenol



HSD-02-1031

**208**


4-(3-Methyl-8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridin-7-yl)phenol



HSD-02-1036

Method A: Off-white solid (208 mg, 63%).  $^1\text{H}$  NMR (500 MHz, Methanol-d<sub>4</sub>)  $\delta$  8.74 (s, 1H), 8.34 (d, J=9.2 Hz, 1H), 8.11 (d, J=9.3 Hz, 1H), 7.63-7.56 (m, 2H), 7.10-7.03 (m, 2H), 4.30 (s, 3H), 3.64 (t, J=6.4 Hz, 2H), 2.96 (t, J=6.2 Hz, 2H), 2.23-2.14 (m, 2H), 1.98-1.88 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, MeOD)  $\delta$  160.36, 154.36, 151.77, 138.31, 134.95, 134.11, 132.57, 130.94, 123.00, 122.30, 118.94, 118.25, 116.10, 115.57, 35.20, 30.96, 27.98, 21.33, 21.26.


7-(1H-Pyrazol-4-yl)-8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridine



HSD-02-1077

Method A: White solid (220 mg, 76%).  $^1\text{H}$  NMR (500 MHz, DMSO-d<sub>6</sub>)  $\delta$  8.52 (s, 1H), 8.14 (s, 2H), 7.79 (d, J=5.4 Hz, 2H), 3.28 (d, J=6.7 Hz, 2H), 2.99 (t, J=6.1 Hz, 2H), 1.98 (ddt, J=9.0, 6.4, 3.2 Hz, 2H), 1.84 (dP, J=9.2, 3.4, 2.9 Hz, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  149.72, 143.79, 142.11, 138.53, 136.11, 129.61, 128.83, 121.65, 121.03, 116.45, 114.22, 29.85, 28.67, 22.64, 22.48; HRMS (ESI) m/z calcd for C<sub>17</sub>H<sub>16</sub>N<sub>5</sub> [M+H]<sup>+</sup> 290.1406, found 290.1406.

7-(1H-Indazol-5-yl)-8,9,10,11-tetrahydro-3H-pyrrolo[3,2-a]phenanthridine



HSD-02-1081


Method A: White solid (145 mg, 42%).  $^1\text{H}$  NMR (500 MHz, DMSO-d<sub>6</sub>)  $\delta$  10.16 (s, 1H), 8.60 (s, 1H), 7.53-7.39 (m, 3H), 7.03-6.92 (m, 2H), 4.05 (s, 3H), 3.37 (t, J=6.5 Hz, 2H), 2.75 (t, J=6.2 Hz, 2H), 1.99 (pd, J=6.4, 4.3, 2.6 Hz, 2H), 1.75 (dq, J=6.0, 2.9, 2.5 Hz, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  159.52, 152.70, 150.67, 150.36, 140.21, 132.48, 131.68, 130.23, 125.17, 123.07, 121.30, 115.56, 109.83, 96.56, 56.90, 30.79, 28.48, 21.93, 21.80; HRMS (ESI) m/z calcd for C<sub>21</sub>H<sub>20</sub>N<sub>3</sub>O<sub>2</sub> [M+H]<sup>+</sup> 346.1556, found 346.1559.

US 12,384,782 B2

**209**


Method A: White solid (173 mg, 51%).  $^1\text{H}$  NMR (500 MHz, DMSO-d<sub>6</sub>)  $\delta$  11.76 (s, 1H), 8.12 (s, 1H), 7.91 (s, 1H), 7.80 (d, J=8.8 Hz, 1H), 7.66 (d, J=8.8 Hz, 1H), 7.61 (d, J=8.5 Hz, 1H), 7.54 (dd, J=8.5, 1.5 Hz, 1H), 7.48 (t, J=2.8 Hz, 1H), 7.11 (t, J=2.6 Hz, 1H), 3.37 (d, J=6.9 Hz, 2H), 2.77 (t, J=6.2 Hz, 2H), 1.99-1.91 (m, 2H), 1.73-1.64 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  156.34, 143.43, 142.27, 139.73, 134.40, 134.08, 133.20, 128.24, 127.74, 124.12, 123.87, 123.10, 122.38, 121.28, 120.41, 116.42, 109.84, 106.27, 30.01, 29.35, 22.91, 22.62; HRMS (ESI) m/z calcd for C<sub>22</sub>H<sub>19</sub>N<sub>4</sub> [M+H]<sup>+</sup> 339.1610, found 339.1618.

7-(1H-Indol-2-yl)-8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridine



15  
HSD-02-1103

20




HSD-02-1105

25 Method A: Off-white solid (181 mg, 69%).  $^1\text{H}$  NMR (500 MHz, DMSO-d<sub>6</sub>)  $\delta$  8.45 (s, 1H), 7.73 (d, J=9.0 Hz, 1H), 7.64 (d, J=9.1 Hz, 1H), 3.18 (q, J=5.3, 4.6 Hz, 2H), 2.94 (t, J=6.2 Hz, 2H), 2.21 (tt, J=8.1, 4.9 Hz, 1H), 1.96-1.88 (m, 2H), 1.86-1.81 (m, 2H), 1.10-0.99 (m, 2H), 0.97-0.87 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  157.71, 143.33, 140.97, 138.28, 135.75, 129.57, 129.38, 120.82, 116.55, 113.67, 29.49, 26.38, 22.40, 22.37, 13.67, 9.14; HRMS (ESI) m/z calcd for C<sub>17</sub>H<sub>18</sub>N<sub>3</sub> [M+H]<sup>+</sup> 264.1501, found 264.1509.

2-(8,9,10,11-Tetrahydro-3H-pyrazolo[4,3-a]phenanthridin-7-yl)-4H-chromen-4-one


Method A: Yellow solid (264 mg, 78%).  $^1\text{H}$  NMR (500 MHz, DMSO-d<sub>6</sub>)  $\delta$  12.12 (s, 1H), 8.76 (s, 1H), 8.38-8.08 (m, 2H), 7.70 (d, J=8.0 Hz, 1H), 7.57 (dd, J=8.2, 1.0 Hz, 1H), 7.30-7.21 (m, 2H), 7.09 (td, J=7.4, 6.9, 1.0 Hz, 1H), 3.45 (t, J=6.4 Hz, 2H), 3.18-3.15 (m, 2H), 2.11-1.99 (m, 2H), 1.92-1.81 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  143.78, 137.55, 134.89, 131.22, 130.49, 128.14, 124.23, 122.63, 121.72, 120.53, 119.45, 115.27, 112.54, 108.05, 30.84, 28.26, 21.91, 21.86, 21.86; HRMS (ESI) m/z calcd for C<sub>22</sub>H<sub>19</sub>N<sub>4</sub> [M+H]<sup>+</sup> 339.1610, found 339.1618.

7-(1H-indol-3-yl)-8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridine



40  
HSD-02-1104

45




HSD-02-1106

Method A: White solid (183 mg, 54%).  $^1\text{H}$  NMR (500 MHz, Methanol-d<sub>4</sub>)  $\delta$  8.72 (s, 1H), 8.14 (d, J=8.7 Hz, 1H), 8.04-7.93 (m, 2H), 7.61-7.52 (m, 2H), 7.30-7.16 (m, 2H), 3.49 (t, J=6.2 Hz, 2H), 2.99 (t, J=6.1 Hz, 2H), 2.22-2.10 (m, 2H), 1.87 (q, J=5.7 Hz, 2H);  $^{13}\text{C}$  NMR (126 MHz, MeOD)  $\delta$  152.83, 147.51, 136.55, 135.07, 132.76, 128.62, 125.73, 122.77, 122.39, 120.99, 119.61, 118.86, 115.08, 112.11, 107.22, 30.80, 27.71, 21.46, 21.29; HRMS (ESI) m/z calcd for C<sub>22</sub>H<sub>19</sub>N<sub>4</sub> [M+H]<sup>+</sup> 339.1610, found 339.1618.


60 Method A: Off-white solid (92 mg, 25%).  $^1\text{H}$  NMR (500 MHz, DMSO-d<sub>6</sub>)  $\delta$  8.88 (s, 1H), 8.85 (s, 1H), 8.26 (d, J=9.2 Hz, 1H), 8.23 (d, J=9.2 Hz, 1H), 8.17 (dd, J=8.0, 1.7 Hz, 1H), 7.95 (dt, J=8.7, 7.1 Hz, 1H), 7.85-7.83 (d, J=8.2 Hz, 1H), 7.62 (t, J=8.0 Hz, 1H), 3.52 (t, J=6.4 Hz, 2H), 2.87 (t, J=6.3 Hz, 2H), 2.08-1.98 (m, 2H), 1.82 (dp, J=9.8, 3.9, 3.1 Hz, 2H); HRMS (ESI) m/z calcd for C<sub>23</sub>H<sub>18</sub>N<sub>3</sub>O<sub>2</sub> [M+H]<sup>+</sup> 368.1399, found 368.1400.

**211**

7-(Bicyclo[2.2.1]hept-5-en-2-yl)-8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridine

**212**

1-Bromo-7-(1H-indazol-5-yl)-8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridine





Method A: Off-white solid (110 mg, 34%). <sup>1</sup>H NMR (500 MHz, Methanol-d<sub>4</sub>) δ 8.82 (s, 1H), 8.34 (d, J=9.3 Hz, 1H), 8.23 (d, J=9.2 Hz, 1H), 6.71 (dd, J=5.8, 3.2 Hz, 1H), 6.44-6.36 (m, 1H), 5.68 (dd, J=5.7, 2.9 Hz, 1H), 4.34-4.28 (m, 1H), 3.64-3.59 (m, 2H), 3.43 (s, 1H), 3.24 (d, J=4.8 Hz, 2H), 2.42 (ddd, J=12.9, 9.3, 3.6 Hz, 1H), 2.24-2.16 (m, 1H), 2.14-2.03 (m, 4H), 1.76 (d, J=8.4 Hz, 1H), 1.74-1.66 (m, 2H); HRMS (ESI) m/z calcd for C<sub>23</sub>H<sub>22</sub>N<sub>3</sub> [M+H]<sup>+</sup> 316.1814, found 316.1819.

7-(1H-Indazol-5-yl)-1-iodo-8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridine

20 Method A: Off-white solid (234 mg, 56%). <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) δ 8.13 (d, J=1.0 Hz, 1H), 7.94-7.92 (m, 1H), 7.83-7.76 (m, 2H), 7.62 (dt, J=8.6, 1.0 Hz, 1H), 7.54 (dd, J=8.6, 1.6 Hz, 1H), 3.60 (t, J=5.9 Hz, 2H), 2.81 (t, J=6.2 Hz, 2H), 1.79-1.70 (m, 4H); <sup>13</sup>C NMR (126 MHz, DMSO) δ 157.76, 144.25, 143.42, 141.60, 139.90, 134.39, 133.10, 131.25, 129.53, 128.02, 123.10, 121.51, 121.45, 115.33, 114.67, 110.13, 34.34, 27.88, 22.29, 22.10; HRMS (ESI) m/z calcd for C<sub>19</sub>H<sub>18</sub>N<sub>5</sub> [M+H]<sup>+</sup> 316.1562, found 316.1555.

N-(7-(1H-Indazol-5-yl)-8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridin-9-yl)acetamide




Method A: Yellow solid (302 mg, 65%). <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) δ 8.13 (s, 1H), 7.94 (t, J=1.1 Hz, 1H), 7.79 (d, J=9.1 Hz, 1H), 7.76 (d, J=9.0 Hz, 1H), 7.62 (d, J=8.6 Hz, 1H), 7.55 (dd, J=8.6, 1.6 Hz, 1H), 3.70 (t, J=5.9 Hz, 2H), 2.82 (t, J=6.3 Hz, 2H), 1.76-1.72 (m, 4H); <sup>13</sup>C NMR (126 MHz, DMSO) δ 157.35, 144.29, 143.76, 141.32, 139.91, 134.39, 133.08, 130.70, 129.56, 129.31, 128.08, 123.10, 121.70, 121.50, 120.04, 114.80, 110.12, 37.07, 27.57, 22.22, 22.04; HRMS (ESI) m/z calcd for C<sub>21</sub>H<sub>17</sub>IN<sub>5</sub> [M+H]<sup>+</sup> 466.0529, found 466.0535.

Method A: Off-white solid (277 mg, 70%). <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) δ 8.71 (s, 1H), 8.23 (s, 1H), 8.09 (q, J=7.1, 5.1 Hz, 4H), 7.74 (d, J=8.6 Hz, 1H), 7.63 (dd, J=8.6, 1.6 Hz, 1H), 4.04-3.93 (m, 1H), 3.57 (dt, J=18.7, 5.5 Hz, 1H), 3.45 (dt, J=17.9, 7.4 Hz, 1H), 2.96 (dd, J=16.8, 4.7 Hz, 1H), 2.80 (dd, J=16.7, 8.7 Hz, 1H), 2.27-2.18 (m, 1H), 2.04-1.91 (m, 1H), 1.75 (s, 3H); <sup>13</sup>C NMR (126 MHz, DMSO) δ 169.40, 153.72, 140.39, 138.50, 134.76, 129.36, 127.67, 122.94, 122.22, 115.46, 110.75, 44.11, 34.25, 29.21, 27.36, 23.11; HRMS (ESI) m/z calcd for C<sub>23</sub>H<sub>21</sub>N<sub>6</sub>O [M+H]<sup>+</sup> 397.1777, found 397.1778.

US 12,384,782 B2

**213**


(7-(1H-Indazol-5-yl)-8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridin-9-amine



HSD-02-1111

**214**


4-(8,9,10,11-Tetrahydro-3H-pyrazolo[4,3-a]phenanthridin-7-yl)benzonitrile



HSD-02-1115

Method A: Pale yellow solid (227 mg, 64%).  $^1\text{H}$  NMR (500 MHz, DMSO-d<sub>6</sub>)  $\delta$  8.80 (s, 1H), 8.60-8.51 (m, 3H), 8.27 (s, 1H), 8.24 (s, 2H), 8.16 (s, 1H), 7.80 (d, J=8.5 Hz, 1H), 7.65 (dd, J=8.6, 1.6 Hz, 1H), 3.74-3.65 (m, 1H), 3.54 (q, J=9.8, 9.2 Hz, 2H), 3.15-3.09 (m, 2H), 2.55-2.51 (m, 1H), 2.20-2.10 (m, 1H);  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  157.40, 143.77, 141.82, 139.88, 139.65, 135.14, 134.42, 133.51, 133.35, 129.58, 128.37, 128.18, 123.04, 121.43, 121.35, 116.32, 115.26, 110.08, 46.76, 38.61, 31.48, 29.03; HRMS (ESI) m/z calcd for C<sub>21</sub>H<sub>19</sub>N<sub>6</sub> [M+H]<sup>+</sup> 355.1671, found 355.1673.

(4-(8,9,10,11-Tetrahydro-3H-pyrazolo[4,3-a]phenanthridin-7-yl)phenyl)boronic acid




HSD-02-1113

Method A: Off-white solid (182 mg, 56%).  $^1\text{H}$  NMR 500 MHz, DMSO-d<sub>6</sub>)  $\delta$  8.78 (s, 1H), 8.20 (t, J=7.4 Hz, 2H), 8.10 (d, J=8.1 Hz, 2H), 7.94 (d, J=8.2 Hz, 2H), 3.48-3.44 (m, 2H), 2.73 (t, J=6.2 Hz, 2H), 2.07-1.97 (m, 2H), 1.84-1.72 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  150.26, 140.30, 138.64, 136.93, 135.01, 132.87, 131.23, 130.97, 123.45, 122.31, 119.99, 118.89, 115.01, 113.13, 30.63, 28.01, 21.85, 21.68; HRMS (ESI) m/z calcd for C<sub>21</sub>H<sub>17</sub>N<sub>4</sub> [M+H]<sup>+</sup> 325.1453, found 325.1455.

4-(9-Amino-8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridin-7-yl)phenol

35




HSD-02-1116

Method A: Off-white solid (151 mg, 44%).  $^1\text{H}$  NMR (500 MHz, Methanol-d<sub>4</sub>)  $\delta$  8.84 (s, 1H), 8.25 (dd, J=9.3, 3.1 Hz, 1H), 8.04 (dd, J=9.2, 3.2 Hz, 2H), 7.95 (s, 1H), 7.68 (d, J=7.5 Hz, 2H), 3.67-3.59 (m, 2H), 2.96-2.85 (m, 2H), 2.24-2.13 (m, 2H), 1.95-1.89 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, MeOD)  $\delta$  154.13, 151.37, 135.10, 134.26, 134.02, 133.60, 132.07, 128.01, 123.67, 119.63, 114.91, 30.85, 27.73, 21.31, 21.16; HRMS (ESI) m/z calcd for C<sub>20</sub>H<sub>19</sub>BN<sub>3</sub>O<sub>2</sub> [M+H]<sup>+</sup> 344.1570, found 344.1577.

Method A: Off-white solid (205 mg, 62%).  $^1\text{H}$  NMR (500 MHz, Methanol-d<sub>4</sub>)  $\delta$  8.60-8.56 (m, 1H), 7.89 (d, J=9.2 Hz, 1H), 7.83 (dd, J=9.2, 0.9 Hz, 1H), 7.37 (d, J=8.6 Hz, 1H), 6.92 (d, J=8.6 Hz, 1H), 3.62-3.55 (m, 1H), 3.45-3.35 (m, 1H), 3.14-3.08 (m, 1H), 3.03-2.98 (m, 1H), 2.74-2.66 (m, 1H), 2.37-2.29 (m, 1H), 1.89-1.78 (m, 1H).  $^{13}\text{C}$  NMR (126 MHz, MeOD)  $\delta$  157.83, 157.59, 143.24, 142.36, 139.52, 134.57, 131.18, 130.07, 128.37, 128.06, 121.39, 116.01, 114.78, 114.55, 46.29, 37.35, 30.57, 28.84; HRMS (ESI) m/z calcd for C<sub>20</sub>H<sub>19</sub>N<sub>4</sub>O [M+H]<sup>+</sup> 331.1559, found 331.1561.

**215**

(2-Fluoro-3-(8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridin-7-yl)phenyl)boronic acid



HSD114A


**216**

Method A: Off-white solid (238 mg, 70%).  $^1\text{H}$  NMR (500 MHz, DMSO-d<sub>6</sub>)  $\delta$  8.58 (s, 1H), 8.28 (s, 1H), 7.85 (d, J=9.0, 0.8 Hz, 1H), 7.81 (d, J=9.1 Hz, 1H), 7.74 (s, 1H), 7.66 (d, J=8.3 Hz, 1H), 7.38 (dd, J=8.2, 1.6 Hz, 1H), 3.33 (t, J=6.6 Hz, 2H), 2.80 (t, J=6.1 Hz, 2H), 2.00 (td, J=9.0, 7.4, 4.6 Hz, 2H), 1.72 (ddt, J=9.2, 6.3, 3.8 Hz, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  157.66, 143.73, 143.21, 142.24, 135.19, 129.71, 129.58, 123.77, 121.72, 116.34, 29.72, 29.29, 22.67, 22.62; HRMS (ESI) m/z calcd for C<sub>21</sub>H<sub>18</sub>N<sub>5</sub> [M+H]<sup>+</sup> 340.1562, found 340.1570.

4-(1-Methyl-8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridin-7-yl)phenol

15

HSD-02-1171




Method A: Off-white solid (163 mg, 45%).  $^1\text{H}$  NMR (500 MHz, Methanol-d<sub>4</sub>)  $\delta$  8.77 (s, 1H), 8.10 (s, 1H), 7.94 (d, J=7.3 Hz, 1H), 7.77-7.55 (m, 2H), 7.52-7.34 (m, 1H), 3.52 (s, 2H), 2.77 (s, 2H), 2.13 (s, 2H), 1.91 (s, 2H);  $^{13}\text{C}$  NMR (126 MHz, MeOD)  $\delta$  150.62, 147.92, 138.23, 136.61, 132.21, 132.13, 131.10, 124.78, 124.63, 123.70, 122.50, 122.02, 115.93, 115.76, 30.40, 26.98, 21.61, 21.26.

7-(3-(Trifluoromethyl)-1H-pyrazol-4-yl)-8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridine

25

HSD-02-1169




30

Method A: Off-white solid (132 mg, 40%).  $^1\text{H}$  NMR (500 MHz, DMSO-d<sub>6</sub>)  $\delta$  10.37 (s, 1H), 8.24-8.03 (m, 2H), 7.56 (d, J=8.6 Hz, 2H), 7.04 (d, J=8.6 Hz, 2H), 3.62 (t, J=5.9 Hz, 2H), 2.94 (s, 3H), 2.81 (t, J=6.2 Hz, 2H), 1.93-1.73 (m, 4H);  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  163.50, 160.27, 153.31, 150.55, 135.81, 135.11, 131.86, 131.49, 125.28, 122.45, 119.96, 116.00, 112.81, 32.79, 27.62, 21.69, 21.32; HRMS (ESI) m/z calcd for C<sub>21</sub>, H<sub>20</sub>N<sub>3</sub>O [M+H]<sup>+</sup> 330.1606, found 330.1606.

Methyl 7-(4-hydroxyphenyl)-8,9,10,11-tetrahydro-3H-pyrrolo[3,2-a]phenanthridine-2-carboxylate

35

HSD-02-1173




50

Method A: Off-white solid (161 mg, 45%).  $^1\text{H}$  NMR (500 MHz, DMSO-d<sub>6</sub>)  $\delta$  8.55 (s, 1H), 8.22 (s, 1H), 7.85 (d, J=9.1 Hz, 1H), 7.77 (d, J=9.1 Hz, 1H), 3.26 (t, J=6.4 Hz, 2H), 2.68 (t, J=6.2 Hz, 2H), 1.98-1.86 (m, 2H), 1.80-1.69 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  148.52, 143.61, 141.99, 139.65, 139.37 (q, J=35.28 Hz), 135.14, 131.28, 130.36, 129.53, 123.56 (q, J=25-269.64 Hz), 121.99, 119.73, 116.21, 115.24, 29.48, 28.17, 22.51, 22.29; HRMS (ESI) m/z calcd for C<sub>18</sub>H<sub>15</sub>F<sub>3</sub>N<sub>5</sub> [M+H]<sup>+</sup> 358.1280, found 358.1286.

7-(1H-Benzo[d]imidazol-5-yl)-8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridine

55

HSD-02-1170




Method A: Yellow solid (146 mg, 39%).  $^1\text{H}$  NMR (500 MHz, DMSO-d<sub>6</sub>)  $\delta$  9.79 (s, 1H), 7.83 (t, J=7.1 Hz, 2H), 7.71 (d, J=2.3 Hz, 1H), 7.42 (dd, J=8.6, 2.3 Hz, 2H), 6.90 (dd, J=8.4, 2.2 Hz, 2H), 3.35-3.32 (m, 8H), 2.77 (t, J=6.1 Hz, 2H), 2.02-1.92 (m, 2H), 1.78-1.65 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  161.47, 158.28, 155.16, 135.67, 131.12, 129.38, 126.63, 122.76, 119.77, 118.05, 115.31, 112.07, 30.25, 29.02, 22.48, 22.24; HRMS (ESI) m/z calcd for C<sub>23</sub>H<sub>23</sub>N<sub>2</sub>O<sub>3</sub> [M+H]<sup>+</sup> 375.1709, found 375.1711.

US 12,384,782 B2

**217**

7-(4-Fluorophenyl)-8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridine




HSD-02-1174

5

**218**

7-Phenyl-8,9,10,11-tetrahydro-3H-pyrrolo[3,2-a]phenanthridine



HSD-02-1176

10

15

20

Method A: Off-white solid (190 mg, 59%).  $^1\text{H}$  NMR (500 MHz, DMSO-d<sub>6</sub>)  $\delta$  8.80 (s, 1H), 8.24 (d, J=9.1 Hz, 1H), 8.20 (d, J=9.2 Hz, 1H), 7.85-7.77 (m, 2H), 7.52-7.44 (m, 2H), 3.47 (t, J=6.4 Hz, 2H), 2.76 (t, J=6.2 Hz, 2H), 2.07-1.98 (m, 2H), 1.83-1.71 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  164.66, 162.69, 150.54, 132.78, 132.71, 131.76, 129.72, 123.29, 121.12, 116.26, 116.08, 114.93, 111.46, 101.25, 30.79, 28.10, 21.80, 21.67; HRMS (ESI) m/z calcd for C<sub>20</sub>H<sub>21</sub>FN<sub>3</sub> [M+H]<sup>+</sup> 322.1720, found 322.1724.

7-(4-Fluorophenyl)-8,9,10,11-tetrahydro-3H-pyrrolo[3,2-a]phenanthridine


Method A: Off-white solid (235 mg, 78%).  $^1\text{H}$  NMR (500 MHz, DMSO-d<sub>6</sub>)  $\delta$  8.56 (s, 1H), 7.84 (dd, J=9.1, 0.9 Hz, 1H), 7.80 (d, J=9.1 Hz, 1H), 7.54-7.51 (m, 2H), 7.48-7.44 (m, 2H), 7.44-7.39 (m, 1H), 3.29 (t, J=6.5 Hz, 2H), 2.74 (t, J=6.1 Hz, 2H), 2.02-1.91 (m, 2H), 1.77-1.64 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  156.89, 143.73, 142.34, 141.33, 139.70, 135.12, 129.62, 129.45, 129.22, 128.39, 128.15, 121.89, 116.26, 115.24, 29.64, 28.95, 22.59, 22.49; HRMS (ESI) m/z calcd for C<sub>20</sub>H<sub>18</sub>N<sub>3</sub> [M+H]<sup>+</sup> 300.1501, found 300.1501.

7-Phenyl-8,9,10,11-tetrahydro-3H-pyrrolo[3,2-a]phenanthridine

35


40

HSD-02-1175



HSD-02-1177

45



50

55

Method A: Off-white solid (144 mg, 45%).  $^1\text{H}$  NMR (500 MHz, DMSO-d<sub>6</sub>)  $\delta$  11.76 (s, 1H), 7.78 (dd, J=8.9, 0.8 Hz, 1H), 7.63 (d, J=8.8 Hz, 1H), 7.61-7.54 (m, 2H), 7.49 (t, J=2.8 Hz, 1H), 7.32-7.24 (m, 2H), 7.12 (ddd, J=3.1, 2.0, 0.9 Hz, 1H), 3.38 (t, J=6.5 Hz, 2H), 2.74 (t, J=6.1 Hz, 2H), 2.01-1.92 (m, 2H), 1.72 (ddd, J=9.0, 7.1, 4.1 Hz, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  163.08, 161.14, 154.88, 143.35, 142.44, 138.19, 133.25, 131.61, 131.54, 127.45, 124.06, 123.98, 122.53, 120.32, 116.56, 115.24, 115.07, 106.29, 29.96, 29.06, 22.84, 22.53; HRMS (ESI) m/z calcd for C<sub>21</sub>H<sub>22</sub>FN<sub>2</sub> [M+H]<sup>+</sup> 321.1767, found 321.1768.

Method A: Yellow solid (180 ng, 60%).  $^1\text{H}$  NMR (500 MHz, Methanol-d<sub>4</sub>)  $\delta$  8.19 (d, J=8.9 Hz, 1H), 7.84 (d, J=8.9 Hz, 1H), 7.72 (d, J=3.2 Hz, 1H), 7.69 (s, 5H), 7.42 (d, J=3.1 Hz, 1H), 3.71 (t, J=6.5 Hz, 2H), 2.87 (t, J=6.3 Hz, 2H), 2.16 (p, J=6.3 Hz, 3H), 1.92 (p, J=6.1 Hz, 2H);  $^{13}\text{C}$  NMR (126 MHz, MeOD)  $\delta$  154.99, 150.08, 133.99, 133.82, 132.55, 130.58, 129.45, 128.93, 128.81, 126.02, 123.68, 120.84, 120.09, 112.92, 106.45, 31.23, 27.74, 21.57, 21.19; HRMS (ESI) m/z calcd for C<sub>21</sub>H<sub>21</sub>N<sub>2</sub> [M+H]<sup>+</sup> 301.1705, found 301.1713.


**219**

7-(4-Hydroxyphenyl)-8,9,10,11-tetrahydro-3H-pyr-  
rolo[3,2-a]phenanthridine-2-carboxylic acid

**220**

7-(4-Ethynylphenyl)-8,9,10,11-tetrahydro-3H-pyra-  
zolo[4,3-a]phenanthridine

5



20


Method A: Yellow solid (220 mg, 61%).  $^1\text{H}$  NMR (500 MHz, DMSO-d<sub>6</sub>)  $\delta$  10.44 (s, 1H), 8.29-7.84 (m, 2H), 7.77-7.44 (m, 3H), 7.06 (d, J=8.2 Hz, 2H), 3.56-3.32 (m, 2H), 2.94-2.62 (m, 2H), 2.14-1.89 (m, 2H), 1.75-1.55 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  162.48, 160.31, 153.04, 150.98, 135.29, 131.99, 130.84, 129.33, 123.31, 122.54, 121.26, 121.09, 119.04, 117.85, 115.91, 111.63, 31.11, 28.30, 21.81, 21.55; HRMS (ESI) m/z calcd for C<sub>22</sub>H<sub>21</sub>N<sub>2</sub>O<sub>3</sub> [M+H]<sup>+</sup> 361.1552, found 361.1552.

7-(2-Bromo-4-fluorophenyl)-8,9,10,11-tetrahydro-  
3H-pyrazolo[4,3-a]phenanthridine

Method A: Off-white solid (160 mg, 49%).  $^1\text{H}$  NMR (500 MHz, DMSO-d<sub>6</sub>)  $\delta$  8.54 (d, J=1.0 Hz, 1H), 7.88-7.84 (m, 1H), 7.79 (d, J=9.1 Hz, 1H) 7.64 (t, J=1.7 Hz, 1H), 7.58 (dt, J=7.6, 1.5 Hz, 1H), 7.54 (dt, J=7.7, 1.4 Hz, 1H), 7.47 (t, J=7.7 Hz, 1H), 4.21 (s, 1H), 3.25 (t, J=6.6 Hz, 2H), 2.73 (t, J=6.2 Hz, 2H), 1.99-1.92 (m, 2H), 1.70 (tdd, J=9.0, 5.6, 2.8 Hz, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  155.63, 143.76, 142.49, 141.73, 139.83, 135.09, 132.65, 131.45, 130.16, 129.47, 129.13, 128.86, 122.07, 121.97, 116.19, 115.47, 83.85, 81.41, 29.63, 28.83, 22.52, 22.45; HRMS (ESI) m/z calcd for C<sub>22</sub>H<sub>20</sub>N<sub>3</sub> [M+H]<sup>+</sup> 326.1657, found 326.1657.

7-(4-Chlorophenyl)-8,9,10,11-tetrahydro-3H-naph-  
tho[1,2-e]indazole

40



55


Method A: Off-white solid (163 mg, 41%).  $^1\text{H}$  NMR (500 MHz, Methanol-d<sub>4</sub>)  $\delta$  8.56 (s, 1H), 7.84 (s, 2H), 7.55 (dd, J=8.5, 2.6 Hz, 1H), 7.42 (dd, J=8.5, 5.9 Hz, 1H), 7.29 (td, J=8.4, 2.6 Hz, 1H), 3.36-3.29 (m, 1H), 2.66-2.44 (m, 2H), 2.06-1.98 (m, 2H), 1.89-1.79 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, MeOD)  $\delta$  163.31 (J=250.74 Hz), 155.51, 143.71, 142.87, 137.54, 135.92, 131.53, 131.46, 130.07, 128.21, 122.77, 122.69, 122.62, 119.51, 119.32, 114.72, 114.55, 29.42, 27.22, 22.02, 21.75; HRMS (ESI) m/z calcd for C<sub>20</sub>H<sub>18</sub>BrFN<sub>3</sub> [M+H]<sup>+</sup> 398.0668, found 398.0673.

Method A: Off-white solid (171 mg, 51%).  $^1\text{H}$  NMR (500 MHz, DMSO-d<sub>6</sub>)  $\delta$  8.54 (s, 1H), 7.85 (d, J=9.1 Hz, 1H), 7.81 (d, J=9.1 Hz, 1H), 7.61-7.55 (m, 2H), 7.55-7.47 (m, 2H), 3.30 (t, J=6.5 Hz, 2H), 2.74 (t, J=6.1 Hz, 2H), 2.01-1.91 (m, 2H), 1.76-1.66 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  155.62, 143.60, 143.11, 142.56, 140.08, 138.71, 136.38, 134.90, 133.05, 131.42, 129.61, 129.49, 129.30, 128.62, 128.43, 121.95, 116.41, 114.51, 29.67, 28.86, 22.54, 22.47; HRMS (ESI) m/z calcd for C<sub>20</sub>H<sub>19</sub>ClN<sub>3</sub> [M+H]<sup>+</sup> 336.1268, found 336.1271.

US 12,384,782 B2

**221**

7-(4-Chlorophenyl)-8,9,10,11-tetrahydro-3H-pyrrolo  
[3,2-a]phenanthridine



HSD-02-1189


**222**

Method A: Off-white solid (160 mg, 50%).  $^1\text{H}$  NMR (500 MHz, Methanol-d<sub>4</sub>)  $\delta$  7.78 (ddd, J=8.9, 2.1, 0.8 Hz, 1H), 7.69 (dd, J=8.9, 3.8 Hz, 1H), 7.55-7.42 (m, 2H), 7.41 (dd, J=3.1, 1.2 Hz, 1H), 7.29 (dt, J=7.6, 1.2 Hz, 1H), 7.26-7.16 (m, 1H), 7.17 (dd, J=3.2, 1.0 Hz, 1H), 3.50-3.41 (m, 2H), 2.71 (t, J=6.3 Hz, 2H), 2.07-1.96 (m, 2H), 1.82-1.72 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, MeOD)  $\delta$  163.57 (J=245.70 Hz), 154.58, 143.91, 143.32, 142.54, 133.29, 130.38, 129.74, 129.68, 127.97, 127.14, 124.73, 122.96, 122.84, 121.97, 120.21, 116.09, 115.71, 115.54, 114.41, 114.24, 105.80, 29.89, 28.41, 22.39, 22.03; HRMS (ESI) m/z calcd for C<sub>21</sub>H<sub>20</sub>FN<sub>2</sub> [M+H]<sup>+</sup> 319.1611, found 319.1618.


4-(8,9,10,11-Tetrahydro-3H-8,11-methanopyrazolo  
[4,3-a]phenanthridin-7-yl)phenol 1193

Method A: Off-white solid (180 mg, 54%).  $^1\text{H}$  NMR (500 MHz, Methanol-d<sub>4</sub>)  $\delta$  7.75 (d, J=45.8 Hz, 2H), 7.46 (d, J=32.4 Hz, 5H), 7.20 (s, 1H), 3.50 (s, 2H), 2.74 (s, 2H), 2.06 (s, 2H), 1.83 (s, 2H);  $^{13}\text{C}$  NMR (126 MHz, MeOD)  $\delta$  154.78, 20 143.91, 142.58, 139.60, 133.67, 133.29, 130.38, 127.99, 127.27, 122.84, 121.93, 120.21, 116.07, 105.77, 29.93, 28.51, 22.42, 22.09; HRMS (ESI) m/z calcd for C<sub>21</sub>H<sub>20</sub>ClN<sub>2</sub> [M+H]<sup>+</sup> 335.1315, found 335.1322.

7-(3-Fluorophenyl)-8,9,10,11-tetrahydro-3H-pyra-  
zolo[4,3-a]phenanthridine




HSD-02-1190



HSD1193


Method A: Off-white solid (195 mg, 61%).  $^1\text{H}$  NMR (500 MHz, DMSO-d<sub>6</sub>)  $\delta$  8.56 (s, 1H), 7.85 (dd, J=9.1, 0.9 Hz, 1H), 7.79 (d, J=9.1 Hz, 1H), 7.50 (td, J=8.0, 6.1 Hz, 1H), 7.42-7.36 (m, 2H), 7.30-7.22 (m, 1H), 3.27 (t, J=6.5 Hz, 2H), 2.75 (t, J=6.1 Hz, 2H), 2.01-1.92 (m, 2H), 1.78-1.66 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  163.27, 161.33, 155.43, 143.69, 143.64, 142.56, 130.42, 130.36, 129.58, 129.19, 125.72, 122.10, 116.43, 116.26, 116.19, 115.11, 114.94, 29.63, 28.75, 22.52, 22.43; HRMS (ESI) m/z calcd for C<sub>20</sub>H<sub>19</sub>FN<sub>3</sub> [M+H]<sup>+</sup> 320.1563, found 320.1569.

7-(3-Fluorophenyl)-8,9,10,11-tetrahydro-3H-pyrrolo  
[3,2-a]phenanthridine



HSD-02-1191

4-(2-Methyl-8,9,10,11-tetrahydro-3H-pyrrolo[3,2-a]  
phenanthridin-7-yl)phenol




HSD-02-1195

Method A: Off-white solid (135 mg, 41%).  $^1\text{H}$  NMR (500 MHz, Methanol-d<sub>4</sub>)  $\delta$  7.66 (d, J=8.9 Hz, 1H), 7.61 (d, J=8.9 Hz, 1H), 7.34-7.29 (m, 2H), 6.93-6.88 (m, 2H), 6.85 (s, 1H), 3.42 (t, J=6.6 Hz, 2H), 2.73 (t, J=6.3 Hz, 2H), 2.53 (s, 3H), 2.06-1.97 (m, 2H), 1.83-1.73 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, MeOD)  $\delta$  157.11, 155.96, 143.48, 142.28, 133.63, 133.06, 132.20, 129.97, 127.27, 122.10, 121.13, 120.58, 115.11, 114.50, 103.96, 29.91, 28.69, 22.53, 22.23, 12.07; HRMS (ESI) m/z calcd for C<sub>22</sub>H<sub>23</sub>N<sub>2</sub>O [M+H]<sup>+</sup> 331.1810, found 331.1813.

**223**

6-(8,9,10,11-Tetrahydro-3H-pyrazolo[4,3-a]phenanthridin-7-yl)pyridin-3-ol




HSD-02-1196

5

**224**

7-(Pyridin-3-yl)-8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridine



HSD1199

10

15


20

Method A: Off-white solid (124 mg, 39%).  $^1\text{H}$  NMR (500 MHz, Methanol-d<sub>4</sub>)  $\delta$  8.57 (s, 1H), 8.22 (d, J=2.8 Hz, 1H), 7.90 (d, J=9.8 Hz, 1H), 7.83 (d, J=9.0 Hz, 1H), 7.55 (d, J=8.4 Hz, 1H), 7.41 (dd, J=8.5, 2.8 Hz, 1H), 3.38 (s, 2H), 2.82 (t, J=6.2 Hz, 2H), 2.12-2.04 (m, 2H), 1.89-1.80 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, MeOD)  $\delta$  154.85, 154.08, 149.15, 143.75, 142.80, 138.71, 136.11, 135.86, 130.19, 128.51, 125.23, 123.37, 122.48, 116.10, 113.81, 29.62, 27.62, 22.09, 21.91; HRMS (ESI) m/z calcd for C<sub>19</sub>H<sub>17</sub>N<sub>4</sub>O [M+H]<sup>+</sup> 317.1402, found 317.1397.

Method A: Off-white solid (135 mg, 45%).  $^1\text{H}$  NMR (500 MHz, Methanol-d<sub>4</sub>)  $\delta$  9.06 (s, 2H), 8.73 (s, 1H), 8.42 (d, J=7.3 Hz, 1H), 8.11 (d, J=8.4 Hz, 1H), 7.96 (d, J=8.8 Hz, 2H), 3.55-3.46 (m, 2H), 2.95-2.81 (m, 2H), 2.20-2.08 (m, 2H), 1.99-1.84 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, MeOD)  $\delta$  150.86, 148.85, 148.27, 147.36, 140.15, 138.36, 131.44, 123.81, 122.94, 119.15, 115.51, 30.47, 27.89, 21.51, 21.42; HRMS (ESI) m/z calcd for C<sub>19</sub>H<sub>17</sub>N<sub>4</sub> [M+H]<sup>+</sup> 301.1453, found 301.1453.

7-(6-Fluoropyridin-3-yl)-8,9,10,11-tetrahydro-3H-pyrrolo[3,2-a]phenanthridine

35




HSD-02-1197

40

45

50

HSD-02-1200




Method A: Off-white solid (223 mg, 59%).  $^1\text{H}$  NMR (500 MHz, Methanol-d<sub>4</sub>)  $\delta$  7.81 (dd, J=8.9, 0.8 Hz, 1H), 7.73 (dd, J=8.5, 1.2 Hz, 1H), 7.69 (d, J=8.9 Hz, 1H), 7.51 (td, J=7.5, 1.2 Hz, 1H), 7.44 (d, J=3.1 Hz, 1H), 7.40-7.36 (m, 2H), 7.21 (dd, J=3.2, 0.9 Hz, 1H), 3.50 (td, J=6.4, 1.4 Hz, 2H), 2.57 (ddt, J=68.3, 17.0, 6.3 Hz, 2H), 2.08-1.98 (m, 2H), 1.92-1.78 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, MeOD)  $\delta$  155.07, 143.75, 142.37, 141.72, 133.32, 132.31, 130.23, 130.19, 129.54, 129.50, 127.66, 127.44, 123.14, 122.89, 122.52, 121.82, 120.27, 116.01, 105.69, 29.80, 27.36, 22.39, 21.88; HRMS (ESI) m/z, calcd for C<sub>21</sub>H<sub>20</sub>BrN<sub>2</sub> [M+H]<sup>+</sup> 379.0810, found 379.0817.

Method A: Off-white solid (201 mg, 61%).  $^1\text{H}$  NMR (500 MHz, Methanol-d<sub>4</sub>)  $\delta$  8.31 (d, J=2.4 Hz, 1H), 8.04 (td, J=8.0, 2.5 Hz, 1H), 7.78 (d, J=8.9 Hz, 1H), 7.68 (d, J=8.9 Hz, 1H), 7.40 (d, J=3.1 Hz, 1H), 7.17 (dd, J=8.4, 2.3 Hz, 1H), 7.12 (d, J=3.1 Hz, 1H), 3.36 (t, J=6.5 Hz, 2H), 2.66 (t, J=6.2 Hz, 2H), 1.95 (ddt, J=12.5, 9.1, 4.6 Hz, 2H), 1.79-1.71 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, MeOD)  $\delta$  164.07, 162.16, 151.30, 147.35, 147.24, 144.14, 142.80, 142.65, 142.58, 134.95, 134.91, 133.32, 127.42, 123.11, 122.96, 122.05, 120.13, 116.37, 116.32, 108.83, 108.54, 105.95, 105.90, 29.82, 28.39, 22.24, 21.95; HRMS (ESI) m/z calcd for C<sub>20</sub>H<sub>19</sub>FN<sub>3</sub> [M+H]<sup>+</sup> 320.1563, found 320.1566.

US 12,384,782 B2


**225**

3-Fluoro-4-(8,9,10,11-tetrahydro-3H-pyrrolo[3,2-a]phenanthridin-7-yl)phenol



Method A: Off-white solid (184 mg, 55%).  $^1\text{H}$  NMR (500 MHz, Methanol-d<sub>4</sub>)  $\delta$  11.65 (s, 1H), 9.02 (d, J=8.9 Hz, 1H), 8.80 (d, J=9.0 Hz, 1H), 8.60 (s, 1H), 8.34 (t, J=8.5 Hz, 1H), 8.13 (s, 1H), 7.72 (d, J=8.1 Hz, 2H), 4.37 (s, 2H), 3.52 (d, J=6.3 Hz, 2H), 2.93-2.78 (m, 2H), 2.61 (s, 2H),  $^{13}\text{C}$  NMR (126 MHz, MeOD)  $\delta$  163.03, 162.14, 160.18, 134.61, 133.62, 131.43, 127.83, 124.37, 122.33, 120.67, 113.54, 107.72, 104.37, 104.18, 31.98, 28.02, 22.84, 22.19; HRMS (ESI) m/z calcd for C<sub>21</sub>H<sub>20</sub>FN<sub>2</sub>O [M+H]<sup>+</sup> 335.1560, found 335.1566.

2-Fluoro-4-(2-methyl-8,9,10,11-tetrahydro-3H-pyrrolo[3,2-a]phenanthridin-7-yl)phenol



Method A: Off-white solid (164 mg, 47%).  $^1\text{H}$  NMR (500 MHz, Methanol-d<sub>4</sub>)  $\delta$  7.66 (d, J=8.9 Hz, 1H), 7.61 (d, J=8.9 Hz, 1H), 7.20 (dd, J=11.8, 2.0 Hz, 1H), 7.13-7.08 (m, 1H), 7.05-7.00 (m, 1H), 6.84 (s, 1H), 3.39 (t, J=6.5 Hz, 2H), 2.72 (t, J=6.2 Hz, 2H), 2.52 (s, 3H), 2.04-1.94 (m, 2H), 1.82-1.70 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, MeOD)  $\delta$  154.57, 152.03, 150.11, 144.90, 143.84, 142.21, 133.78, 133.12, 132.62, 127.08, 125.12, 122.26, 121.10, 120.50, 117.06, 116.55, 116.40, 115.35, 104.03, 29.91, 28.58, 22.44, 22.15, 12.08; HRMS (ESI) m/z calcd for C<sub>22</sub>H<sub>22</sub>FN<sub>2</sub>O [M+H]<sup>+</sup> 349.1716, found 349.1720.

**226**

4-(8,9,10,11-Tetrahydro-3H-pyrazolo[4,3-a]phenanthridin-7-yl)benzimidamide hydrochloride

5 HSD-02-1204

10 HSD-02-1202

15 HSD-02-1204

Method A: Off-white solid (172 mg, 50%).  $^1\text{H}$  NMR (500 MHz, DMSO-d<sub>6</sub>)  $\delta$  9.69 (s, 2H), 9.47 (s, 2H), 8.71 (s, 1H), 8.16-8.06 (m, 4H), 7.94 (d, J=8.0 Hz, 2H), 3.42-3.33 (m, 2H), 2.76 (t, J=6.2 Hz, 2H), 2.07-1.97 (m, 2H), 1.81-1.65 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  165.63, 151.52, 140.26, 134.84, 130.64, 130.34, 129.16, 128.63, 123.10, 115.22, 30.40, 28.25, 21.97, 21.83; HRMS (ESI) m/z calcd for C<sub>21</sub>H<sub>22</sub>N<sub>5</sub> [M+H]<sup>+</sup> 344.1875, found 344.1879.

N-hydroxy-4-(8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridin-7-yl)benzimidamide

30 HSD-02-1115

35 HSD-02-1203

40 HSD-02-1115

45 HSD-02-1207

50 HSD-02-1207

55 In a solution of NH<sub>2</sub>OH-H<sub>2</sub>O (1.5 equiv) in DMSO (3 mL), KOTBu (3 equiv) was added slowly at 0° C. and the suspension was stirred for 30 min. After this 4-(8,9,10,11-Tetrahydro-3H-pyrazolo[4,3-a]phenanthridin-7-yl)benzonitrile(0.5 mmol) was added to the mixture and reaction was continued for 4 h at room temperature. After completion of reaction cold water was added to the reaction mixture and the resulting precipitate was filtered and washed with water and dried. Solid was recrystallized with ethanol to get the desired product.


60 Off-white solid (162 mg, 90%).  $^1\text{H}$  NMR (500 MHz, DMSO-d<sub>6</sub>)  $\delta$  9.71 (s, 1H), 8.56 (s, 1H), 7.88-7.82 (m, 2H),

US 12,384,782 B2

**227**

7.79-7.76 (m, 2H), 7.59-7.54 (m, 2H), 5.89 (s, 2H), 2.79 (t, J=6.1 Hz, 2H), 2.00 (ddt, J=9.3, 6.5, 3.1 Hz, 2H), 1.74 (tt, J=8.6, 5.4 Hz, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  156.48, 151.11, 145.66, 143.64, 142.45, 141.74, 138.70, 136.39, 133.15, 129.67, 129.32, 125.43, 121.88, 116.46, 114.44, 29.69, 28.96, 22.60, 22.52; HRMS (ESI) m/z calcd for  $\text{C}_{21}\text{H}_{22}\text{N}_5$  [M+H] $^+$  360.1824, found 360.1827.

N-(4-(8,9,10,11-Tetrahydro-3H-pyrazolo[4,3-a]phenanthridin-7-yl)phenyl)acetamide



10

HSD 02-1209

20

25


Method A: Off-white solid (201 mg, 51%).  $^1\text{H}$  NMR (500 MHz, DMSO-d<sub>6</sub>)  $\delta$  10.08 (s, 1H), 8.50 (s, 1H), 7.81 (s, 2H), 7.70 (d, J=8.4 Hz, 2H), 7.49 (d, J=8.5 Hz, 2H), 3.24 (t, J=6.0 Hz, 2H), 2.75 (t, J=6.1 Hz, 2H), 2.08 (s, 3H), 1.96-1.89 (m, 2H), 1.67 (tt, J=8.3, 5.4 Hz, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  168.87, 156.52, 143.62, 142.22, 139.37, 138.62, 136.27, 135.92, 129.99, 129.62, 129.35, 121.66, 118.79, 116.48, 114.22, 29.63, 29.05, 24.54, 22.59, 22.54; HRMS (ESI) m/z calcd for  $\text{C}_{22}\text{H}_{23}\text{N}_4\text{O}$  [M+H] $^+$  359.1872, found 359.1875.

30

Method B: Off-white solid (76 mg, 25%).  $^1\text{H}$  NMR (500 MHz, Methanol-d<sub>4</sub>)  $\delta$  8.62 (s, 1H), 7.77 (d, J=9.0 Hz, 1H), 7.67 (d, J=9.0 Hz, 1H), 7.42-7.32 (m, 3H), 7.11 (d, J=3.0 Hz, 1H), 6.96-6.89 (m, 2H), 3.71 (t, J=7.0 Hz, 2H), 3.07 (t, J=7.1 Hz, 2H);  $^{13}\text{C}$  NMR (126 MHz, MeOD)  $\delta$  157.38, 156.71, 133.00, 132.35, 131.76, 130.10, 129.51, 123.71, 122.39, 121.62, 120.57, 116.48, 114.65, 106.36, 100.91, 61.71, 35.83; HRMS (ESI) m/z calcd for  $\text{C}_{19}\text{H}_{17}\text{N}_2\text{O}_2$  [M+H] $^+$  305.1290, found 305.1299.

4-(3,8-Dihydro-2H-furo[3,2-c]pyrrolo[3,2-f]quino- lin-4-yl)phenol

40



45

HSD 02-1210

50

55

Method A: Off-white solid (171 mg, 48%).  $^1\text{H}$  NMR (500 MHz, DMSO-d<sub>6</sub>)  $\delta$  11.74 (t, J=2.4 Hz, 1H), 10.05 (s, 1H), 7.78 (d, J=8.8 Hz, 1H), 7.68 (d, J=8.3 Hz, 2H), 7.63 (d, J=8.8 Hz, 1H), 7.51-7.46 (m, 3H), 7.10 (d, J=2.8 Hz, 1H), 3.38-3.35 (m, 2H), 2.77 (t, J=6.2 Hz, 2H), 2.08 (s, 3H), 1.99-1.92 (m, 2H), 1.71 (ddt, J=12.3, 9.5, 4.4 Hz, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  168.82, 155.57, 143.41, 142.25, 139.16, 136.45, 133.19, 129.95, 127.55, 124.10, 123.88, 122.36, 120.37, 118.76, 116.42, 106.27, 29.98, 29.18, 24.55, 22.90, 22.61; HRMS (ESI) m/z calcd for  $\text{C}_{23}\text{H}_{24}\text{N}_3\text{O}$  [M+H] $^+$  358.1919, found 358.1922.


60

Method A: Off-white solid (157 mg, 45%).  $^1\text{H}$  NMR (500 MHz, Methanol-d<sub>4</sub>)  $\delta$  7.76 (s, 1H), 7.71 (d, J=8.6 Hz, 1H), 7.21 (d, J=11.7 Hz, 1H), 7.12 (d, J=8.4 Hz, 1H), 7.04 (t, J=8.5 Hz, 1H), 3.51-3.40 (m, 2H), 2.89 (s, 3H), 2.84-2.76 (m, 2H), 1.92-1.80 (m, 4H);  $^{13}\text{C}$  NMR (126 MHz, MeOD)  $\delta$  157.03, 155.85, 152.11, 150.19, 144.98, 143.53, 132.05, 128.98, 128.70, 125.04, 123.95, 117.20, 116.48, 116.32, 113.04, 31.86, 27.70, 22.03, 21.87; HRMS (ESI) m/z calcd for  $\text{C}_{21}\text{H}_{21}\text{FN}_3\text{O}$  [M+H] $^+$  350.1669, found 350.1677.


**228**

4-(3,8-Dihydro-2H-furo[3,2-c]pyrrolo[3,2-f]quino- lin-4-yl)phenol

HSD 02-1211




HSD 02-1213



**229**

4-(8,9,10,11-Tetrahydro-3H-pyrrolo[3,2-a]phenanthridin-7-yl)benzonitrile




HSD 02-1214

5

**230**

4-(8,9,10,11-Tetrahydro-3H-pyrazolo[4,3-a]phenanthridin-7-yl)benzamide



HSD 02-1217

10

15


20

Method A: Off-white solid (195 mg, 60%).  $^1\text{H}$  NMR (500 MHz, DMSO-d<sub>6</sub>)  $\delta$  11.80 (s, 1H), 7.92 (d, J=8.5 Hz, 1H), 7.81 (dd, J=8.9, 0.8 Hz, 1H), 7.75 (d, J=8.9 Hz, 2H), 7.64 (d, J=8.9 Hz, 1H), 7.51 (t, J=2.8 Hz, 1H), 7.15-7.11 (m, 1H), 3.38 (t, J=6.1 Hz, 2H), 2.73 (t, J=6.1 Hz, 2H), 2.00-1.93 (m, 3H), 1.76-1.68 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  154.08, 146.45, 143.42, 142.77, 133.40, 132.39, 130.61, 127.28, 124.14, 124.07, 122.82, 120.26, 119.41, 116.85, 110.74, 106.41, 29.95, 28.81, 22.76, 22.41; HRMS (ESI) m/z calcd for C<sub>22</sub>H<sub>20</sub>N<sub>3</sub>[M+H]<sup>+</sup> 326.1657, found 326.1662.

Methyl 4-(8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridin-7-yl)benzoate

Method A: Off-white solid (172 mg, 50%).  $^1\text{H}$  NMR (500 MHz, DMSO-d<sub>6</sub>)  $\delta$  8.60 (s, 1H), 8.05 (s, 1H), 7.97 (d, J=8.0 Hz, 2H), 7.86 (d, J=9.1 Hz, 1H), 7.81 (d, J=9.1 Hz, 1H), 7.63 (d, J=8.0 Hz, 2H), 7.41 (S, 1H), 3.39-3.34 (m, 2H), 2.77 (t, J=6.1 Hz, 2H), 2.04-1.98 (m, 2H), 1.79-1.69 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  168.13, 156.17, 144.02, 143.77, 142.55, 133.95, 129.63, 129.40, 129.29, 127.64, 122.07, 116.23, 29.68, 28.86, 22.58, 22.49; HRMS (ESI) m/z calcd for C<sub>21</sub>H<sub>21</sub>N<sub>4</sub>O [M+H]<sup>+</sup> 345.1715, found 345.1719.

Methyl 4-(8,9,10,11-tetrahydro-3H-pyrazolo[3,2-a]phenanthridin-7-yl)benzoate



HSD 02-1215

35


40

45

50

55

HSD 02-1218




Method A: Off-white solid (198 ng, 55%).  $^1\text{H}$  NMR (500 MHz, DMSO-d<sub>6</sub>)  $\delta$  8.69 (s, 1H), 8.14 (dd, J=10.7, 7.0 Hz, 4H), 7.87 (d, J=7.6 Hz, 2H), 3.90 (s, 3H), 3.35 (d, J=6.2 Hz, 2H), 2.73 (t, J=5.8 Hz, 2H), 2.06-1.96 (m, 2H), 1.75 (d, J=7.1 Hz, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  166.53, 155.59, 145.92, 143.71, 142.57, 138.77, 136.40, 130.03, 129.92, 129.65, 129.55, 129.25, 129.09, 122.12, 116.33, 114.56, 52.63, 29.59, 28.75, 22.48, 22.38; HRMS (ESI) m/z calcd for C<sub>22</sub>H<sub>22</sub>N<sub>3</sub>O<sub>2</sub> [M+H]<sup>+</sup> 360.1712, found 360.1718.

Method A: Off-white solid (105 mg, 30%).  $^1\text{H}$  NMR (500 MHz, Methanol-d<sub>4</sub>)  $\delta$  7.68 (dd, J=8.9, 0.8 Hz, 1H), 7.62 (d, J=8.9 Hz, 1H), 7.22 (dd, J=11.8, 2.0 Hz, 1H), 7.13 (ddd, J=8.2, 2.1, 0.9 Hz, 1H), 7.03 (dt, J=8.9, 8.2 Hz, 1H), 6.87 (s, 1H), 3.48-3.40 (m, 2H), 2.76 (t, J=6.2 Hz, 2H), 2.54 (s, 3H), 2.07-1.99 (m, 2H), 1.86-1.75 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, MeOD)  $\delta$  154.38, 152.03 (J=241.92 Hz), 144.97, 144.23, 141.91, 133.92, 133.16, 132.30, 127.16, 125.13, 122.28, 121.10, 120.18, 117.07, 116.57, 116.41, 115.50, 104.05, 29.98, 28.55, 22.44, 22.14, 12.07; HRMS (ESI) m/z calcd for C<sub>22</sub>H<sub>22</sub>FN<sub>2</sub>O [M+H]<sup>+</sup> 349.1716, found 349.1717.

## US 12,384,782 B2

**231**


Methyl 4-(8,9,10,11-tetrahydro-3H-pyrrolo[3,2-a]phenanthridin-7-yl)benzoate



HSD 02-1219

**232**


116.54, 106.31, 29.97, 29.08, 22.87, 22.54; HRMS (ESI) m/z calcd for  $C_{22}H_{23}N_4O$   $[M+H]^+$  359.1872, found 359.1872.




HSD 02-1221

Method A: Off-white solid (179 mg, 50%).  $^1H$  NMR (500 MHz, DMSO-d<sub>6</sub>)  $\delta$  12.38 (s, 1H), 8.13 (d, J=8.0 Hz, 2H), 8.08 (d, J=8.7 Hz, 1H), 7.92 (d, J=8.9 Hz, 1H), 7.82 (d, J=8.0 Hz, 2H), 7.69 (t, J=2.7 Hz, 1H), 7.25-7.22 (m, 1H), 3.90 (s, 3H), 3.48 (t, J=6.5 Hz, 2H), 2.72 (t, J=6.2 Hz, 2H), 2.06-1.94 (m, 2H), 1.85-1.67 (m, 3H);  $^{13}C$  NMR (126 MHz, DMSO)  $\delta$  166.31, 150.76, 140.46, 137.32, 133.66, 130.77, 130.49, 130.13, 129.56, 129.56, 129.45, 128.64, 126.02, 123.33, 119.96, 117.68, 106.71, 52.90, 30.82, 28.26, 22.22, 21.82; HRMS (ESI) m/z calcd for  $C_{23}H_{23}N_2O_2$   $[M+H]^+$  359.1760, found 359.1767.

N-Hydroxy-4-(8,9,10,11-tetrahydro-3H-pyrrolo[3,2-a]phenanthridin-7-yl)benzimidamide




HSD-02-1214




HSD 02-1222

Method A: Off-white solid (147 mg, 43%);  $^1H$  NMR (500 MHz, DMSO-d<sub>6</sub>)  $\delta$  11.77 (t, J=2.3 Hz, 1H), 8.05 (s, 1H), 7.97 (d, J=8.3 Hz, 2H), 7.79 (d, J=8.9 Hz, 1H), 7.64 (d, J=8.9 Hz, 1H), 7.61 (d, J=8.2 Hz, 2H), 7.50 (t, J=2.8 Hz, 1H), 7.41 (s, 1H), 7.13 (t, J=2.5 Hz, 1H), 3.39 (t, J=6.5 Hz, 2H), 2.75 (t, J=6.1 Hz, 2H), 1.98 (q, J=4.3, 3.0 Hz, 3H), 1.73 (ddt, J=9.4, 6.5, 2.8 Hz, 2H);  $^{13}C$  NMR (126 MHz, DMSO)  $\delta$  168.20, 155.18, 144.56, 143.40, 142.47, 133.73, 133.30, 129.39, 127.59, 127.40, 124.11, 124.02, 122.62, 120.33, 116.62, 106.34, 29.97, 28.98, 22.84, 22.50; HRMS (ESI) m/z calcd for  $C_{22}H_{22}N_3O$   $[M+H]^+$  344.1763, found 344.1769.



HSD-02-1220




Method A: Yellow solid (166 mg, 47%).  $^1H$  NMR (500 MHz, DMSO-d<sub>6</sub>)  $\delta$  11.40 (s, 1H), 8.23 (d, J=8.9 Hz, 1H), 8.05 (d, J=8.9 Hz, 1H), 7.80 (t, J=2.9 Hz, 1H), 7.41-7.34 (m, 1H), 7.31 (t, J=2.4 Hz, 1H), 7.15 (t, J=8.2 Hz, 1H), 3.55 (t, J=6.4 Hz, 2H), 2.72 (s, 2H), 2.13-1.96 (m, 2H), 1.81 (dd, J=7.8, 4.1 Hz, 2H);  $^{13}C$  NMR (126 MHz, DMSO)  $\delta$  149.88, 147.97, 147.88, 143.40, 141.12, 141.01, 139.18, 139.07, 134.54, 133.83, 130.60, 127.12, 126.30, 123.79, 121.80, 119.78, 113.94, 111.57, 106.98, 31.22, 27.17, 21.96, 21.33; HRMS (ESI) m/z calcd for  $C_{21}H_{19}F_2N_2O$   $[M+H]^+$  353.1465, found 353.1468.

Synthesized by following general procedure for 1207. Off-white solid (163 mg, 91%);  $^1H$  NMR (500 MHz, DMSO-d<sub>6</sub>)  $\delta$  11.76 (d, J=2.3 Hz, 1H), 9.69 (s, 1H), 7.78 (t, J=8.9 Hz, 3H), 7.63 (d, J=8.8 Hz, 1H), 7.56-7.52 (m, 2H), 7.49 (t, J=2.8 Hz, 1H), 7.13 (d, J=2.5 Hz, 1H), 5.86 (s, 2H), 3.39 (t, J=6.5 Hz, 3H), 2.77 (t, J=6.2 Hz, 2H), 2.01-1.92 (m, 2H), 1.79-1.69 (m, 2H).  $^{13}C$  NMR (126 MHz, DMSO)  $\delta$  155.44, 151.17, 143.41, 142.38, 142.28, 133.25, 132.92, 129.31, 127.45, 125.38, 124.12, 123.98, 122.52, 120.34,

## US 12,384,782 B2

**233**

2,3-Difluoro-4-(8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridin-7-yl)phenol




HSD 02-1223

5

**234**

2-Fluoro-5-(8,9,10,11-tetrahydro-3H-pyrrolo[3,2-a]phenanthridin-7-yl)benzonitrile



HSD 02-1225

10

15


20

Method A: Off-white solid (177 mg, 50%).  $^1\text{H}$  NMR (500 MHz, DMSO- $d_6$ )  $\delta$  10.56 (s, 1H), 8.56 (s, 1H), 7.92-7.76 (m, 2H), 7.05 (td,  $J=8.2$ , 2.0 Hz, 1H), 6.90 (td,  $J=8.3$ , 1.6 Hz, 1H), 3.32 (d,  $J=7.6$  Hz, 2H), 2.62 (t,  $J=6.1$  Hz, 2H), 1.96 (dt,  $J=11.1$ , 5.9 Hz, 2H), 1.75 (p,  $J=5.8$  Hz, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  151.48, 149.77, 147.83, 147.75, 147.03, 143.67, 142.40, 141.06, 140.95, 139.02, 138.74, 136.40, 130.47, 129.50, 125.40, 122.18, 120.81, 120.70, 116.39, 114.56, 113.32, 29.50, 27.48, 22.58, 22.19; HRMS (ESI) m/z calcd for  $C_{20}\text{H}_{16}\text{F}_2\text{N}_3\text{O}$  [M+H] $^+$  352.1261, found 352.1256.

Method A: Off-white solid (131 mg, 38%).  $^1\text{H}$  NMR (500 MHz, Methanol- $d_4$ )  $\delta$  8.09 (dd,  $J=6.1$ , 2.3 Hz, 1H), 8.04 (d,  $J=9.0$  Hz, 1H), 8.00 (ddd,  $J=8.7$ , 5.1, 2.3 Hz, 1H), 7.78 (d,  $J=9.0$  Hz, 1H), 7.63-7.58 (m, 2H), 7.35-7.32 (m, 1H), 3.62 (t, 2H), 2.80 (t,  $J=6.2$  Hz, 2H), 2.13-2.09 (m, 2H), 1.93-1.87 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, MeOD)  $\delta$  164.50, 162.42, 149.33, 138.09, 136.46, 134.57, 133.67, 128.43, 124.75, 123.69, 120.09, 119.05, 117.10, 116.70, 116.53, 112.81, 106.28, 101.63, 30.66, 27.94, 21.86, 21.54; HRMS (ESI) m/z calcd for  $C_{22}\text{H}_{19}\text{FN}_3$  [M+H] $^+$  344.1563, found 344.1565.

2-Fluoro-5-(8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridin-7-yl)benzonitrile

3-Methoxy-4-(8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridin-7-yl)phenol



HSD 02-1224

35

40


45

50

55

Method A: Off-white solid (169 mg, 49%).  $^1\text{H}$  NMR (500 MHz, DMSO- $d_6$ )  $\delta$  8.52 (s, 1H), 8.14 (dd,  $J=6.3$ , 2.3 Hz, 1H), 8.01-7.95 (m, 1H), 7.85 (d,  $J=9.0$  Hz, 1H), 7.81 (d,  $J=9.3$  Hz, 1H), 7.61 (t,  $J=9.0$  Hz, 1H), 3.26 (d,  $J=6.7$  Hz, 2H), 2.75 (t,  $J=6.1$  Hz, 2H), 2.03-1.92 (m, 2H), 1.79-1.68 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  163.50 ( $J=257.04$  Hz), 153.77, 143.56, 142.81, 138.70, 137.36, 137.29, 136.44, 134.73, 129.49, 122.20, 116.85, 116.69, 116.30, 114.70, 114.42, 100.43, 100.31, 29.62, 28.60, 22.47, 22.40; HRMS (ESI) m/z calcd for  $C_{21}\text{H}_{18}\text{FN}_4$  [M+H] $^+$  345.1515, found 345.1519.


Method A: Off-white solid (87 mg, 25%).  $^1\text{H}$  NMR (500 MHz, DMSO- $d_6$ )  $\delta$  9.59 (s, 1H), 8.53 (s, 1H), 7.84-7.74 (m, 2H), 6.97 (d,  $J=8.1$  Hz, 1H), 6.50 (d,  $J=2.2$  Hz, 1H), 6.45 (dd,  $J=8.1$ , 2.2 Hz, 1H), 3.63 (s, 3H), 3.34-3.31 (m, 1H), 3.29-3.20 (m, 1H), 2.72-2.62 (m, 1H), 2.47-2.38 (m, 1H), 2.02-1.87 (m, 2H), 1.83-1.62 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  159.02, 157.89, 155.92, 143.53, 141.09, 138.58, 136.19, 131.12, 129.60, 121.67, 121.44, 116.57, 113.84, 107.41, 99.24, 55.49, 29.45, 27.19, 22.74, 22.27; HRMS (ESI) m/z calcd for  $C_{21}\text{H}_{22}\text{N}_3\text{O}_2$  [M+H] $^+$  348.1712, found 348.1717.



HSD 02-1228

**235**

4-(8,9,10,11-Tetrahydro-3H-pyrrolo[3,2-a]phenanthridin-7-yl)-2-(trifluoromethyl)phenol




HSD 02-1232

5

**236**

7-(3-(Trifluoromethyl)-1H-pyrazol-4-yl)-8,9,10,11-tetrahydro-3H-pyrrolo[3,2-a]phenanthridine



HSD 02-1234

10

15


20

Method A: Yellow solid (219 mg, 57%).  $^1\text{H}$  NMR (500 MHz, DMSO-d<sub>6</sub>)  $\delta$  11.75 (s, 1H), 10.73 (s, 1H), 7.78 (d, J=8.9 Hz, 1H), 7.67 (dq, J=3.7, 2.2 Hz, 2H), 7.63 (d, J=8.8 Hz, 1H), 7.49 (t, J=2.8 Hz, 1H), 7.14-7.08 (m, 2H), 3.37 (t, J=6.6 Hz, 3H), 2.77 (t, J=6.1 Hz, 2H), 2.03-1.93 (m, 2H), 1.78-1.68 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  155.74, 154.41, 143.42, 142.51, 134.89, 133.22, 132.30, 127.65, 127.50, 125.67 (q, J=273.42 Hz), 124.05, 123.95, 122.46, 120.32, 116.82, 116.55, 115.52, 115.28, 106.29, 29.99, 29.12, 22.83, 22.58; HRMS (ESI) n/z calcd for C<sub>22</sub>H<sub>20</sub>F<sub>3</sub>N<sub>2</sub>O [M+H]<sup>+</sup> 385.1528, found 385.1530.

2,5-Difluoro-4-(8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridin-7-yl)phenol


Method A: Off-white solid (135 mg, 38%).  $^1\text{H}$  NMR (500 MHz, Methanol-d<sub>4</sub>)  $\delta$  7.92 (s, 1H), 7.79 (d, J=9.0 Hz, 1H), 7.71-7.65 (m, 1H), 7.45-7.40 (m, 1H), 7.18 (d, J=3.2 Hz, 1H), 3.46 (t, J=6.4 Hz, 2H), 2.65 (t, J=6.3 Hz, 2H), 2.01 (dp, J=9.8, 3.3 Hz, 2H), 1.85 (qd, J=6.5, 3.2 Hz, 2H);  $^{13}\text{C}$  NMR (126 MHz, MeOD)  $\delta$  146.73, 143.44, 142.52, 133.34, 130.08, 129.00, 123.12, 122.85, 121.93, 120.17, 119.38, 116.04, 105.77, 29.74, 27.88, 22.38, 21.90; HRMS (ESI) m/z calcd for C<sub>19</sub>H<sub>16</sub>F<sub>3</sub>N<sub>4</sub> [M+H]<sup>+</sup> 357.1327, found 357.1327.

7-(3-methyl-1H-pyrazol-4-yl)-8,9,10,11-tetrahydro-3H-pyrrolo[3,2-a]phenanthridine



HSD 02-1233

40



HSD 02-1235

45

50


55

Method A: Off-white solid (159 mg, 45%).  $^1\text{H}$  NMR (500 MHz, Methanol-d<sub>4</sub>)  $\delta$  8.57 (s, 1H), 7.86 (q, J=9.1 Hz, 2H), 7.15 (dd, J=10.8, 6.7 Hz, 1H), 6.81 (dd, J=10.5, 7.1 Hz, 1H), 3.38 (s, 2H), 2.73 (s, 2H), 2.08 (p, J=6.1 Hz, 2H), 1.86 (d, J=9.8 Hz, 2H);  $^{13}\text{C}$  NMR (126 MHz, MeOD)  $\delta$  156.74 (J=239.16 Hz), 151.59, 148.92 (J=238.14 Hz), 146.61, 143.45, 143.06, 138.67, 135.89, 130.94, 128.32, 122.39, 118.20, 116.93, 116.06, 113.85, 104.69, 29.48, 27.05, 22.11, 21.80; HRMS (ESI) m/z calcd for C<sub>20</sub>H<sub>21</sub>F<sub>2</sub>N<sub>3</sub>O [M+H]<sup>+</sup> 354.1418, found 354.1421.

Method A: Off-white solid (181 mg, 60%).  $^1\text{H}$  NMR (500 MHz, DMSO-d<sub>6</sub>)  $\delta$  8.15 (d, J=8.9 Hz, 1H), 8.09-8.02 (m, 1H), 7.74 (t, J=2.9 Hz, 1H), 7.23 (t, J=2.4 Hz, 1H), 3.46 (t, J=6.4 Hz, 2H), 2.80 (t, J=6.3 Hz, 2H), 2.30 (s, 3H), 2.03-1.94 (m, 2H), 1.84-1.74 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  144.36, 134.42, 133.65, 130.53, 126.80, 122.88, 120.88, 119.84, 113.93, 110.98, 106.60, 31.17, 27.69, 22.00, 21.57, 19.02; HRMS (ESI) m/z calcd for C<sub>19</sub>H<sub>19</sub>N<sub>4</sub> [M+H]<sup>+</sup> 303.1610, found 303.1611.

**237**

1-Methyl-7-(3-(trifluoromethyl)-1H-pyrazol-4-yl)-8,  
9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthri-  
dine




HSD 02-1236 10

5

**238**

4-(8,9,10,11-Tetrahydro-3H-pyrrolo[3,2-a]phenanthridin-7-yl)-3-(trifluoromethyl)phenol




HSD 02-1238

15

20

Method A: Off-white solid (179 mg, 59%).  $^1\text{H}$  NMR (500 MHz, DMSO-d<sub>6</sub>) δ 8.53 (s, 1H), 7.84-7.74 (m, 3H), 3.33 (s, 3H), 2.85 (t, J=6.1 Hz, 2H), 2.33 (s, 2H), 2.00-1.97 (m, 2H), 1.81-1.77 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO) δ 151.10, 143.71, 141.83, 138.63, 136.21, 130.12, 129.59, 121.02, 118.17, 116.48, 114.04, 29.70, 28.62, 22.63; HRMS (ESI) m/z calcd for C<sub>15</sub>H<sub>18</sub>N<sub>5</sub> [M+H]<sup>+</sup> 304.1562, found 304.1565.

1-Methyl-7-(3-(trifluoromethyl)-1H-pyrazol-4-yl)-8,  
9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthri-  
dine




HSD 02-1237

35

4-(8,9,10,11-Tetrahydro-3H-pyrrolo[4,3-a]phenanthridin-7-yl)-3-(trifluoromethyl)phenol

40



HSD 02-1239

45

50

Method A: Off-white solid (150 mg, 42%).  $^1\text{H}$  NMR (500 MHz, Methanol-d<sub>4</sub>) δ 8.38 (d, J=0.9 Hz, 1H), 8.19 (d, J=9.2 Hz, 1H), 7.88 (d, J=9.2 Hz, 1H), 3.84-3.71 (m, 2H), 3.04 (s, 3H), 2.83-2.80 (m, 2H), 2.00-1.98 (m, 4H);  $^{13}\text{C}$  NMR (126 MHz, MeOD) δ 155.05, 144.54, 141.22, 140.08 (q=38 Hz), 135.79, 133.55, 132.43, 126.71, 124.45 (q, J=270 Hz), 123.66, 120.18, 118.65, 112.60, 109.60, 33.05, 26.90, 21.14, 20.63, 17.53; HRMS (ESI) m/z calcd for C<sub>18</sub>H<sub>15</sub>F<sub>3</sub>N<sub>5</sub> [M+H]<sup>+</sup> 358.1280, found 358.1288.

55

Method A: Off-white solid (142 mg, 36%).  $^1\text{H}$  NMR (500 MHz, DMSO-d<sub>6</sub>) δ 10.24 (s, 1H), 8.55 (s, 1H), 7.84 (d, J=9.0 Hz, 1H), 7.77 (d, J=8.8 Hz, 1H), 7.24 (d, J=8.3 Hz, 1H), 7.19 (d, J=2.5 Hz, 1H), 7.11 (dd, J=8.3, 2.5 Hz, 1H), 3.44-3.24 (m, 2H), 2.57-2.50 (m, 1H), 2.34 (dt, J=17.0, 5.6 Hz, 1H), 2.00-1.83 (m, 2H), 1.82-1.62 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO) δ 157.55, 155.48, 143.04, 141.85, 138.71, 136.25, 132.68, 130.30, 129.99, 129.54, 128.57 (q, J=30.24 Hz), 125.45 (q, J=274.68 Hz), 122.04, 119.30, 116.44, 114.27, 113.02, 112.98, 29.41, 28.15, 22.58, 22.19; HRMS (ESI) m/z calcd for C<sub>21</sub>H<sub>19</sub>F<sub>3</sub>N<sub>5</sub>O [M+H]<sup>+</sup> 386.1480, found 386.1488.



**239**

7-(5-(Trifluoromethyl)-1H-pyrazol-3-yl)-8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridine

**240**

4-(9-(Trifluoromethyl)-8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridin-7-yl)phenol

5



10  
15  
20

Method A: Off-white solid (150 mg, 42%).  $^1\text{H}$  NMR (500 MHz, DMSO-d<sub>6</sub>)  $\delta$  8.56 (s, 1H), 7.91 (d, J=8.7 Hz, 2H), 7.17 (s, 1H), 3.33-3.28 (m, 3H), 3.00 (t, J=6.2 Hz, 2H), 2.02-1.95 (m, 2H), 1.88-1.80 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  144.59, 143.32, 142.97, 142.16, (J=36.83 Hz), 138.87, 136.55, 129.44, 125.49 (J=270.51 Hz), 122.50, 116.27, 115.12, 104.88, 29.83, 27.83, 22.26, 22.22; HRMS (ESI) m/z calcd for C<sub>18</sub>H<sub>15</sub>F<sub>3</sub>N<sub>5</sub>[M+H]<sup>+</sup> 358.1280, found 358.1289.

4-(9-(Trifluoromethyl)-8,9,10,11-tetrahydro-3H-pyrazolo[3,2-a]phenanthridin-7-yl)phenol

Method A: Off-white solid (165 mg, 43%).  $^1\text{H}$  NMR (500 MHz, DMSO-d<sub>6</sub>)  $\delta$  10.27 (s, 1H), 8.60 (s, 1H), 8.11-7.90 (m, 2H), 7.57 (d, J=8.2 Hz, 2H), 7.03 (d, J=8.3 Hz, 2H), 3.54-3.43 (m, 1H), 3.40-3.28 (m, 1H), 3.10-2.97 (m, 1H), 2.90-2.82 (m, 1H), 2.79-2.68 (m, 1H), 2.39-2.30 (m, 1H), 1.94-1.79 (m, 1H);  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  159.74, 152.87, 148.17, 137.78, 131.71, 129.43 (q, J=278.46 Hz), 127.87, 122.81, 121.71, 115.86, 115.01, 37.62 (q, J=26.46 Hz), 29.44, 27.22, 20.90; HRMS (ESI) m/z calcd for C<sub>21</sub>H<sub>19</sub>F<sub>3</sub>N<sub>3</sub>O [M+H]<sup>+</sup> 386.1480, found 386.1484.

4-(9,9-Difluoro-8,9,10,11-tetrahydro-3H-pyrrolo[3,2-a]phenanthridin-7-yl)phenol

40  
45  
50


55

Method A: Off-white solid (157 mg, 41%).  $^1\text{H}$  NMR (500 MHz, DMSO-d<sub>6</sub>)  $\delta$  11.93 (s, 1H), 9.74 (s, 1H), 7.84 (d, J=8.8 Hz, 1H), 7.67 (s, 1H), 7.60-7.50 (m, 1H), 7.39 (d, J=8.0 Hz, 2H), 7.21-7.07 (m, 1H), 6.99-6.83 (m, 2H), 3.65 (dd, J=18.1, 5.8 Hz, 1H), 3.01-2.93 (m, 1H), 2.89-2.81 (m, 1H), 2.78-2.65 (m, 1H), 2.43-2.31 (m, 1H), 1.92-1.77 (m, 1H);  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  157.87, 155.35, 133.27, 131.96, 130.83, 129.75, 127.53, 124.57, 124.44, 121.71, 120.23, 117.24, 115.32, 106.11, 37.63 (q=26.6 Hz), 29.04, 27.78, 21.66; HRMS (ESI) m/z calcd for C<sub>22</sub>H<sub>20</sub>F<sub>3</sub>N<sub>2</sub>O [M+H]<sup>+</sup> 385.1528, found 385.1532.

Method A: Off-white solid (152 mg, 43%).  $^1\text{H}$  NMR (500 MHz, DMSO-d<sub>6</sub>)  $\delta$  9.71 (s, 1H), 8.59 (s, 1H), 7.90 (d, J=9.1 Hz, 1H), 7.87-7.81 (m, 1H), 7.41 (d, J=8.5 Hz, 2H), 6.89 (d, J=8.5 Hz, 2H), 3.63-3.55 (m, 2H), 3.41-3.36 (m, 2H), 2.55-2.50 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  157.94, 156.62, 144.16, 139.61, 138.71, 136.27, 131.03, 130.86, 129.49, 125.65, 124.54, 123.75, 121.86, 120.55, 116.30, 115.37, 115.11, 37.18 (J=26.46 Hz), 29.37 (J=23.94 Hz), 28.01; HRMS (ESI) m/z calcd for C<sub>20</sub>H<sub>18</sub>F<sub>2</sub>N<sub>3</sub>O [M+H]<sup>+</sup> 354.1418, found 354.1421.

**241**

4-(9,9-Difluoro-8,9,10,11-tetrahydro-3H-pyrrolo[3,2-a]phenanthridin-7-yl)phenol




HSD 02-1244

5

**242**

7-(4-Hydroxyphenyl)-8,9,10,11-tetrahydro-3H-pyrrolo[3,2-a]phenanthridine-1-carbonitrile



HSD 02-1247

10

15


20

Method A: Off-white solid (180 mg, 49%).  $^1\text{H}$  NMR (500 MHz, DMSO- $d_6$ )  $\delta$  11.84 (s, 1H), 7.84 (d,  $J=8.8$  Hz, 1H), 7.67 (d,  $J=8.8$  Hz, 1H), 7.53 (d,  $J=3.0$  Hz, 1H), 7.39 (d,  $J=8.1$  Hz, 2H), 7.13 (d,  $J=3.1$  Hz, 1H), 6.88 (d,  $J=8.1$  Hz, 2H), 3.63 (t,  $J=7.1$  Hz, 2H), 3.33 (t,  $J=14.5$  Hz, 2H), 2.48-2.38 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  157.78, 155.53, 143.87, 139.53, 133.29, 131.52, 130.80, 125.76, 124.38, 123.95, 123.87, 122.78, 121.98, 121.20, 120.23, 117.15, 115.32, 106.13, 37.50 ( $J=26.46$  Hz), 29.55 ( $J=23.94$  Hz), 28.22; HRMS (ESI) m/z calcd for  $C_{21}\text{H}_{19}\text{F}_2\text{N}_2\text{O}$  [M+H] $^+$  353.1465, found 353.1470.

Method A: Yellow solid (140 mg, 41%). Method A: Off-white solid (182 mg, 56%).  $^1\text{H}$  NMR (500 MHz, DMSO- $d_6$ )  $\delta$  10.36 (s, 1H), 8.70 (d,  $J=3.1$  Hz, 1H), 8.27 (d,  $J=8.9$  Hz, 1H), 8.19 (d,  $J=9.1$  Hz, 1H), 7.59 (d,  $J=8.0$  Hz, 2H), 7.04 (d,  $J=8.1$  Hz, 2H), 3.77 (t,  $J=6.3$  Hz, 2H), 2.84 (t,  $J=6.3$  Hz, 2H), 1.99-1.91 (m, 2H), 1.87-1.77 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  160.39, 153.97, 152.19, 138.86, 135.26, 135.01, 131.92, 130.79, 123.33, 122.29, 121.56, 119.23, 117.69, 117.36, 115.99, 89.30, 33.48, 27.99, 21.34, 21.30; HRMS (ESI) m/z calcd for  $C_{21}\text{H}_{20}\text{N}_3\text{O}$  [M+H] $^+$  342.1606, found 342.1611.

4-(7,8,9,10-Tetrahydrophenanthridin-6-yl)phenol

Ethyl 8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridine-7-carboxylate



HSD 02-1246


35

40

45

50

HSD 02-1248



55


Method A: Off-white solid (151 mg, 51%).  $^1\text{H}$  NMR (500 MHz, DMSO- $d_6$ )  $\delta$  8.58 (s, 1H), 7.90 (d,  $J=9.1$  Hz, 1H), 7.85 (d,  $J=9.1$  Hz, 1H), 4.38 (q,  $J=7.1$  Hz, 2H), 2.94 (t,  $J=6.3$  Hz, 2H), 1.98 (tt,  $J=7.7, 6.0, 4.6$  Hz, 2H), 1.84 (dd,  $J=7.6, 3.9$  Hz, 2H), 1.34 (t,  $J=7.1$  Hz, 3H).  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  167.34, 148.23, 143.50, 142.89, 139.08, 136.66, 129.37, 128.75, 123.47, 116.23, 115.28, 61.64, 29.54, 26.54, 22.29, 21.87, 14.60; HRMS (ESI) m/z calcd for  $C_{17}\text{H}_{20}\text{N}_3\text{O}_2$  [M+H] $^+$  298.1556, found 298.1562.

Method A: Off-white solid (75 mg, 20%).  $^1\text{H}$  NMR (500 MHz, Methanol- $d_4$ )  $\delta$  8.42 (d,  $J=8.5$  Hz, 1H), 8.16 (d,  $J=8.5$  Hz, 1H), 8.04 (t,  $J=7.7$  Hz, 1H), 7.92 (t,  $J=7.8$  Hz, 1H), 7.60 (d,  $J=8.2$  Hz, 2H), 7.07 (d,  $J=8.3$  Hz, 2H), 3.52 (t,  $J=6.5$  Hz, 2H), 2.90 (t,  $J=6.2$  Hz, 2H), 2.12-2.06 (m, 2H), 1.95-1.84 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, MeOD)  $\delta$  160.77, 156.16, 155.60, 135.74, 132.96, 131.15, 130.92, 129.04, 127.05, 124.04, 122.18, 120.19, 115.59, 27.66, 26.87, 21.56, 20.93; HRMS (ESI) m/z calcd for  $C_{19}\text{H}_{20}\text{NO}$  [M+H] $^+$  378.1545, found 378.1546.

US 12,384,782 B2

**243**


4-(6,7,8,9-Tetrahydro-3H-pyrrolo[3,2-c]phenanthridin-5-yl)phenol



HSD-02-1252

Method A: Pale yellow solid (119 mg, 38%).  $^1\text{H}$  NMR (500 MHz, Methanol-d<sub>4</sub>)  $\delta$  7.73 (d, J=8.8 Hz, 1H), 7.58 (d, J=8.8 Hz, 1H), 7.39-7.32 (m, 3H), 6.96-6.89 (m, 2H), 6.62 (d, J=3.0 Hz, 1H), 3.24 (tt, J=6.6, 1.2 Hz, 2H), 2.72 (t, J=6.3 Hz, 2H), 1.95 (td, J=6.5, 3.0 Hz, 2H), 1.82-1.73 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, MeOD)  $\delta$  157.94, 157.43, 143.79, 134.49, 131.77, 130.32, 129.91, 126.79, 126.36, 123.54, 122.78, 120.97, 114.65, 113.55, 102.78, 28.24, 26.19, 22.54, 22.16; HRMS (ESI) m/z calcd for C<sub>21</sub>H<sub>19</sub>N<sub>2</sub>O [M+H]<sup>+</sup> 315.1497, found 315.1498.

4-(3-(2-Hydroxyethyl)-8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridin-7-yl)phenol




HSD 02-1253

Method A: Off-white solid (177 mg, 49%).  $^1\text{H}$  NMR (500 MHz, DMSO-d)  $\delta$  9.59 (s, 1H), 8.51 (s, 1H), 7.96 (d, J=9.1 Hz, 1H), 7.81 (d, J=9.1 Hz, 1H), 7.39 (d, J=8.5 Hz, 2H), 6.86-6.82 (m, 2H), 4.55 (t, J=5.6 Hz, 2H), 3.88-3.82 (m, 2H), 3.32-3.27 (m, 2H), 2.79 (t, J=6.2 Hz, 2H), 2.01-1.96 (m, 2H), 1.77-1.70 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  157.58, 157.01, 143.57, 142.09, 138.61, 135.29, 131.97, 130.89, 129.53, 129.38, 121.31, 117.15, 115.09, 114.17, 60.84, 51.76, 29.69, 29.23, 22.64; HRMS (ESI) m/z calcd for C<sub>12</sub>H<sub>24</sub>N<sub>3</sub>O<sub>2</sub> [M+H]<sup>+</sup> 362.1869, found 362.1871.

7-(3-(8.26 (s, 1H), 7.95 (d, J=9.1 Hz, 1H), 7.86 (d, J=9.1 Hz, 1H), 3.55 (t, J=6.3 Hz, 2H), 2.72 (t, J=6.3 Hz, 2H), 1.95-1.86 (m, 2H), 1.84-1.77 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  150.24, 144.55, 143.03, 140.24, 139.34, 131.66, 131.35, 130.73, 125.49 (J=2704.68 Hz), 121.28, 121.28, 119.78, 119.14, 117.84, 116.46, 114.90, 31.80, 28.11, 21.99; HRMS (ESI) m/z calcd for C<sub>19</sub>H<sub>14</sub>F<sub>3</sub>N<sub>6</sub> [M+H]<sup>+</sup> 383.1232, found 383.1238.

**244**


6-(8,9,10,11-Tetrahydro-3H-pyrrolo[3,2-a]phenanthridin-7-yl)benzo[d]thiazol-2-amine



HSD-02-1256

Method A: Pale yellow solid (115 mg, 31%).  $^1\text{H}$  NMR (500 MHz, DMSO-d<sub>6</sub>)  $\delta$  7.83 (t, J=1.2 Hz, 1H), 7.77 (dd, J=8.8, 0.8 Hz, 1H), 7.62 (d, J=8.7 Hz, 1H), 7.52 (s, 2H), 7.49 (t, J=2.8 Hz, 1H), 7.42-7.36 (m, 2H), 7.15-7.09 (m, 1H), 3.38 (t, J=6.5 Hz, 2H), 2.80 (t, J=6.1 Hz, 2H), 2.01-1.93 (m, 2H), 1.78-1.68 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  167.48, 155.93, 152.75, 143.42, 142.23, 134.61, 133.18, 131.13, 127.69, 127.23, 124.12, 123.91, 122.33, 122.08, 120.39, 117.29, 116.41, 106.26, 30.02, 29.30, 22.94, 22.64; HRMS (ESI) m/z calcd for C<sub>22</sub>H<sub>19</sub>N<sub>4</sub>S [M+H]<sup>+</sup> 371.1330, found 371.1339.

6-(3,8,9,10-Tetrahydrocyclopenta[c]pyrazolo[4,3-f]quinolin-7-yl)benzo[d]thiazol-2-amine



HSD-02-1257

Method A: Yellow solid (118 mg, 33%).  $^1\text{H}$  NMR (500 MHz, DMSO-d<sub>6</sub>)  $\delta$  8.44 (s, 1H), 8.20 (d, J=1.8 Hz, 1H), 7.90 (d, J=9.2 Hz, 1H), 7.84 (d, J=9.0 Hz, 1H), 7.77 (dd, J=8.3, 1.9 Hz, 1H), 7.60 (s, 2H), 7.43 (d, J=8.3 Hz, 1H), 3.48 (t, J=7.5 Hz, 2H), 3.29 (t, J=7.6 Hz, 2H), 2.25 (p, J=7.5 Hz, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  167.94, 153.47, 152.28, 149.49, 144.86, 138.15, 135.97, 135.08, 133.41, 131.62, 129.24, 126.75, 121.54, 118.85, 117.60, 116.83, 114.58, 33.57, 33.43, 25.01; HRMS (ESI) m/z calcd for C<sub>20</sub>H<sub>16</sub>N<sub>5</sub>S [M+H]<sup>+</sup> 358.1126, found 358.1128.


**245**

N-(4-(2-methyl-8,9,10,11-tetrahydro-3H-pyrrolo[3,2-a]phenanthridin-7-yl)phenyl)methanesulfonamide

**246**

7-(2-Aminobenzo[d]thiazol-6-yl)-8,9,10,11-tetrahydro-3H-pyrrolo[3,2-a]phenanthridine-1-carbonitrile

5




Method A: Pale yellow solid (205 mg, 50%). <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) δ 7.24 (d, J=8.9 Hz, 1H), 6.92 (d, J=8.9 Hz, 1H), 6.86 (d, J=8.3 Hz, 2H), 6.70 (d, J=8.3 Hz, 2H), 6.28 (s, 1H), 2.86-2.78 (m, 2H), 2.29 (s, 3H), 2.11-2.02 (m, 2H), 1.81 (s, 2H), 1.39-1.28 (m, 2H), 1.14-1.04 (m, 2H); <sup>13</sup>C NMR (126 MHz, DMSO) δ 154.13, 148.50, 140.10, 136.74, 132.90, 129.61, 128.08, 126.79, 122.08, 120.26, 119.11, 118.09, 110.65, 104.05, 37.63, 30.40, 26.94, 20.76, 20.43, 11.29; HRMS (ESI) m/z calcd for C<sub>23</sub>H<sub>28</sub>N<sub>3</sub>O<sub>2</sub>S [M+H]<sup>+</sup> 410.1902, found 410.1907.

N-(4-(3,8,9,10-Tetrahydropyran-4-yl)phenyl)methanesulfonamide

Method A: Pale yellow solid (119 mg, 30%). <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) δ 9.19 (s, 2H), 8.69 (d, J=3.1 Hz, 1H), 8.29-8.20 (m, 3H), 7.71 (dd, J=8.3, 1.8 Hz, 1H), 7.66 (d, J=8.3 Hz, 1H), 3.75 (t, J=6.3 Hz, 2H), 2.83 (t, J=6.4 Hz, 2H), 2.02-1.91 (m, 2H), 1.86-1.72 (m, 2H); <sup>13</sup>C NMR (126 MHz, DMSO) δ 169.71, 154.01, 151.40, 138.84, 135.50, 135.06, 130.71, 128.82, 128.33, 126.00, 124.16, 123.58, 121.67, 119.22, 117.85, 117.28, 116.11, 114.43, 89.32, 33.49, 27.97, 21.30; HRMS (ESI) m/z calcd for C<sub>23</sub>H<sub>18</sub>N<sub>5</sub>S [M+H]<sup>+</sup> 396.1283, found 396.1288.

6-(1-Methyl-8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridin-7-yl)benzo[d]thiazol-2-amine



Method A: Off-white solid (179 mg, 47%). <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) δ 11.69 (t, J=2.3 Hz, 1H), 9.91 (s, 1H), 7.89-7.84 (m, 2H), 7.77 (dd, J=8.9, 0.8 Hz, 1H), 7.70 (d, J=8.9 Hz, 1H), 7.48 (t, J=2.7 Hz, 1H), 7.37-7.29 (m, 2H), 7.01-6.96 (m, 11H), 3.50 (t, J=7.5 Hz, 2H), 3.24 t, =7.5 z, 2H), 3.05 (s, 3H), 2.24 (p, J=7.6 Hz, 2H); <sup>13</sup>C NMR (126 MHz, DMSO) δ 150.60, 149.35, 144.61, 138.77, 136.41, 134.23, 132.57, 129.96, 124.46, 123.67, 120.85, 120.10, 119.48, 116.78, 104.29, 33.87, 33.12, 25.08; HRMS (ESI) m/z calcd for C<sub>21</sub>H<sub>22</sub>N<sub>3</sub>O<sub>2</sub>S [M+H]<sup>+</sup> 380.1433, found 380.1440.

Method A: Off-white solid (116 mg, 30%). <sup>1</sup>H NMR (500 MHz, Methanol-d<sub>4</sub>) δ 7.77 (d, J=9.1 Hz, 1H), 7.75-7.68 (m, 2H), 7.53-7.47 (m, 1H), 7.38 (dd, J=8.2, 1.8 Hz, 1H), 3.52-3.42 (m, 2H), 2.90 (s, 3H), 2.81 (q, J=4.3, 3.1 Hz, 2H), 1.89-1.82 (m, 4H); <sup>13</sup>C NMR (126 MHz, MeOD) δ 169.08, 156.70, 151.68, 143.60, 143.42, 143.25, 141.25, 133.99, 130.75, 128.98, 128.59, 126.61, 123.95, 121.19, 116.95, 115.76, 113.89, 31.88, 27.83, 22.07, 21.90, 17.96; HRMS (ESI) m/z calcd for C<sub>22</sub>H<sub>20</sub>N<sub>5</sub>S [M+H]<sup>+</sup> 386.1439, found 386.1447.


**247**

7-(3,5-Dimethyl-1H-pyrazol-4-yl)-8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridine

**248**

7-(1H-Indazol-5-yl)-1,2-dimethyl-8,9,10,11-tetrahydro-2H-pyrazolo[4,3-a]phenanthridine

5




Method A: Off-white solid (193 mg, 60%).  $^1\text{H}$  NMR (500 MHz, DMSO- $\text{d}_6$ )  $\delta$  8.58-8.53 (m, 1H), 7.82 (dd,  $J=9.1, 0.9$  Hz, 1H), 7.76 (d,  $J=9.0$  Hz, 1H), 3.30 (t,  $J=6.5$  Hz, 2H), 2.56 (t,  $J=6.2$  Hz, 2H), 2.00 (s, 9H), 1.76 (qd,  $J=8.6, 7.2, 4.1$  Hz, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  151.69, 144.07, 141.77, 139.31, 135.31, 131.30, 129.63, 121.60, 117.69, 116.32, 114.93, 29.51, 27.72, 22.74, 22.45; HRMS (ESI) m/z calcd for  $\text{C}_{19}\text{H}_{24}\text{N}_5$  [M+H] $^+$  322.2032, found 322.2036.

7-(1H-Indazol-5-yl)-1-methyl-8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridine

Method A: Off-white solid (159 mg, 43%).  $^1\text{H}$  NMR (500 MHz, DMSO- $\text{d}_6$ )  $\delta$  8.12 (s, 1H), 7.93 (dd,  $J=1.6, 0.8$  Hz, 1H), 7.75 (d,  $J=9.0$  Hz, 1H), 7.60 (dt,  $J=8.6, 1.0$  Hz, 1H), 7.55 (dd,  $J=8.6, 1.6$  Hz, 1H), 7.38 (d,  $J=9.0$  Hz, 1H), 4.10 (s, 3H), 3.61 (t,  $J=6.6$  Hz, 3H), 2.79 (t,  $J=6.2$  Hz, 2H), 2.63 (s, 3H), 1.94-1.89 (m, 2H), 1.75-1.65 (m, 3H);  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  158.06, 147.33, 144.38, 143.84, 139.78, 134.44, 133.66, 132.84, 128.49, 128.17, 123.76, 123.05, 121.87, 121.40, 118.85, 118.33, 109.89, 37.78, 30.37, 29.10, 22.71, 22.60, 9.69; HRMS (ESI) m/z calcd for  $\text{C}_{21}\text{H}_{24}\text{N}_5$  [M+H] $^+$  370.2032, found 370.2039.

7-(1H-indazol-5-yl)-2-methyl-8,9,10,11-tetrahydro-3H-pyrrolo[3,2-a]phenanthridine




Method A: Off-white solid (161 mg, 45%).  $^1\text{H}$  NMR (500 MHz, DMSO- $\text{d}_6$ )  $\delta$  8.20 (s, 1H), 8.05 (s, 1H), 7.97 (d,  $J=8.9$  Hz, 1H), 7.91 (d,  $J=9.2$  Hz, 1H), 7.71 (d,  $J=8.6$  Hz, 1H), 7.59 (dd,  $J=8.6, 1.6$  Hz, 1H), 3.51 (q,  $J=7.4, 6.5$  Hz, 2H), 2.93-2.87 (m, 2H), 2.79 (t,  $J=6.2$  Hz, 2H), 1.88-1.73 (m, 4H);  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  153.72, 148.28, 140.25, 139.38, 136.90, 134.68, 130.29, 127.67, 124.60, 123.00, 122.54, 114.31, 110.60, 32.28, 27.98, 22.08, 21.72; HRMS (ESI) m/z calcd for  $\text{C}_{22}\text{H}_{24}\text{N}_5$  [M+H] $^+$  358.2032, found 358.2033.

Method A: Off-white solid (146 mg, 41%).  $^1\text{H}$  NMR (500 MHz, Methanol- $\text{d}_4$ )  $\delta$  8.13 (s, 1H), 7.89 (t,  $J=1.1$  Hz, 1H), 7.69 (d,  $J=8.9$  Hz, 1H), 7.67-7.62 (m, 2H), 7.52 (dd,  $J=8.5, 1.5$  Hz, 1H), 6.89 (s, 1H), 3.46 (t,  $J=6.5$  Hz, 2H), 2.74 (t,  $J=6.2$  Hz, 2H), 2.54 (s, 3H), 2.07-1.98 (m, 3H), 1.85-1.75 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, MeOD)  $\delta$  156.00, 143.82, 142.24, 139.73, 133.98, 133.79, 133.15, 127.95, 127.34, 122.81, 122.28, 121.16, 120.90, 120.51, 115.34, 109.38, 104.02, 29.95, 28.71, 22.50, 22.19, 12.08; HRMS (ESI) m/z calcd for  $\text{C}_{23}\text{H}_{25}\text{N}_4$  [M+H] $^+$  357.2079, found 357.2079.

US 12,384,782 B2

**249**


7-(1H-Indazol-5-yl)-1-methyl-8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridine



5  
HSD-02-1271

**250**

7-(4-Chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)-8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridine




Method A: Off-white solid (180 mg, 48%). <sup>1</sup>H NMR (500 MHz, Methanol-d<sub>4</sub>) δ 8.61 (s, 1H), 8.19 (d, J=5.5 Hz, 1H), 7.87 (q, J=9.3 Hz, 2H), 7.61 (s, 1H), 7.14 (d, J=5.1 Hz, 1H), 3.40 (s, 3H), 2.75-2.66 (m, 2H), 2.06 (p, J=6.3, 5.7 Hz, 2H), 1.89-1.80 (m, 2H); <sup>13</sup>C NMR (126 MHz, MeOD) δ 151.51, 148.69, 143.14, 142.97, 142.52, 136.07, 135.88, 132.62, 128.15, 126.03, 122.42, 117.52, 116.46, 116.07, 113.67, 29.52, 28.07, 22.18, 21.86; HRMS (ESI) m/z calcd for C<sub>21</sub>H<sub>17</sub>ClN<sub>5</sub> [M+H]<sup>+</sup> 374.1172, found 374.1176.


7-(1H-Pyrrolo[2,3-b]pyridin-3-yl)-8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridine

Method A: Off-white solid (163 mg, 46%). <sup>1</sup>H NMR (500 MHz, MeOD-d<sub>4</sub>) δ 9.51 (s, 1H), 8.8 (s, 1H), 8.33-8.31 (m, 2H), 8.24 (d, J=8.5 Hz, 1H), 8.13 (d, J=9.5 Hz, 1H), 8.00 (d, J=7.7 Hz, 1H), 4.25 (s, 3H), 3.69 (t, J=6.2 Hz, 1H), 2.91 (t, J=5.9 Hz, 2H), 2.24-2.19 (m, 2H), 1.97-1.92 (m, 2H); <sup>13</sup>C NMR (126 MHz, MeOD) δ 156.46, 155.04, 149.36, 143.88, 134.90, 134.50, 133.73, 132.46, 132.17, 129.92, 127.08, 124.13, 121.16, 119.24, 116.83, 114.80, 113.44, 32.47, 30.98, 27.74, 21.22, 21.10; HRMS (ESI) m/z calcd for C<sub>22</sub>H<sub>20</sub>N<sub>5</sub> [M+H]<sup>+</sup> 354.1719, found 354.1722.

7-(1H-Pyrrolo[3,2-c]pyridin-3-yl)-8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridine



35  
HSD-02-1273




55  
Method A: Off-white solid (142 mg, 42%). <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) δ 11.92 (s, 1H), 11.72 (s, 1H), 8.57 (dd, J=7.9, 1.7 Hz, 1H), 8.27 (dd, J=4.7, 1.7 Hz, 1H), 7.90 (s, 1H), 7.77 (d, J=8.8 Hz, 1H), 7.68 (d, J=8.9 Hz, 1H), 7.47 (t, J=2.4 Hz, 1H), 7.18-7.12 (m, 1H), 7.11 (d, J=3.0 Hz, 1H), 3.40 (t, J=6.5 Hz, 2H), 3.05 (t, J=6.1 Hz, 2H), 2.05-1.97 (m, 2H), 1.81 (ddt, J=9.3, 6.3, 2.8 Hz, 2H); <sup>13</sup>C NMR (126 MHz, DMSO) δ 150.58, 148.89, 143.52, 143.39, 142.01, 133.07, 130.54, 127.92, 127.10, 124.02, 123.76, 121.43, 120.44, 120.16, 116.48, 116.27, 114.39, 106.19, 30.22, 28.95, 22.89, 22.82; HRMS (ESI) m/z calcd for C<sub>22</sub>H<sub>19</sub>N<sub>4</sub> [M+H]<sup>+</sup> 339.1610, found 339.1615.

Method A: Off-white solid (129 mg, 38%). <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) δ 11.82 (s, 1H), 9.49 (d, J=1.8 Hz, 1H), 8.57 (s, 1H), 8.23 (dd, J=5.7, 2.2 Hz, 1H), 7.93 (d, J=2.1 Hz, 1H), 7.89-7.82 (m, 2H), 7.44 (dd, J=5.9, 1.8 Hz, 1H), 3.33 (s, 17H), 3.07 (t, J=6.2 Hz, 2H), 2.04 (dtt, J=12.3, 6.4, 2.2 Hz, 2H), 1.89-1.78 (m, 2H); <sup>13</sup>C NMR (126 MHz, DMSO) δ 151.34, 145.38, 143.85, 142.15, 140.91, 139.91, 129.62, 129.54, 128.05, 124.66, 120.76, 116.46, 115.21, 107.29, 29.95, 28.95, 22.80, 22.62; HRMS (ESI) m/z calcd for C<sub>21</sub>H<sub>18</sub>N<sub>5</sub> [M+H]<sup>+</sup> 340.1562, found 340.1566.

US 12,384,782 B2

**251**

7-(5H-Pyrrolo[3,2-d]pyrimidin-7-yl)-8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridine




Method A: Off-white solid (171 mg, 50%).  $^1\text{H}$  NMR (500 MHz, DMSO- $d_6$ )  $\delta$  9.72 (s, 1H), 8.83 (s, 1H), 8.55 (s, 1H), 8.07 (s, 1H), 7.93 (d,  $J=9.2$  Hz, 1H), 7.89-7.83 (m, 1H), 3.39-3.33 (m, 2H), 3.11 (t,  $J=6.1$  Hz, 2H), 2.08-2.01 (m, 2H), 1.91-1.81 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  151.93, 151.87, 150.53, 143.67, 142.83, 142.42, 138.64, 136.29, 129.63, 129.46, 128.35, 120.83, 118.56, 116.50, 114.42, 29.99, 28.80, 22.74, 22.53; HRMS (ESI) m/z calcd for  $C_{20}\text{H}_{17}\text{N}_6$  [M+H] $^+$  341.1515, found 341.1517.

7-(6-Chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)-8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridine

Method A: Off-white solid (153 mg, 45%).  $^1\text{H}$  NMR (500 MHz, DMSO- $d_6$ )  $\delta$  11.60 (d,  $J=3.1$  Hz, 1H), 8.56 (s, 1H), 8.32 (dq,  $J=4.3$ , 1.8 Hz, 1H), 7.88-7.77 (m, 4H), 7.17-7.10 (m, 1H), 3.38-3.33 (m, 2H), 2.94 (t,  $J=6.1$  Hz, 2H), 2.03-1.93 (m, 2H), 1.77-1.65 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  152.37, 144.53, 143.65, 142.86, 141.35, 138.56, 136.22, 131.63, 129.70, 129.50, 128.91, 121.53, 119.42, 117.39, 116.76, 116.64, 113.84, 29.65, 27.96, 22.77, 22.43; HRMS (ESI) m/z calcd for  $C_{21}\text{H}_{18}\text{N}_5$  [M+H] $^+$  340.1562, found 340.1567.

4-(8,9,10,11-Tetrahydro-3H-pyrazolo[4,3-a]phenanthridin-7-yl)benzenesulfonamide



Method A: Off-white solid (183 mg, 49%).  $^1\text{H}$  NMR (500 MHz, DMSO- $d_6$ )  $\delta$  11.82 (s, 1H), 9.50 (d,  $J=1.1$  Hz, 1H), 8.55 (s, 1H), 8.23 (d,  $J=5.6$  Hz, 1H), 7.96-7.78 (m, 3H), 7.44 (dd,  $J=5.6$ , 1.1 Hz, 1H), 3.35 (s, 2H), 3.07 (t,  $J=6.1$  Hz, 2H), 2.04 (tdd,  $J=9.2$ , 5.5, 2.2 Hz, 2H), 1.84 (qd,  $J=8.8$ , 7.3, 4.1 Hz, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  151.36, 145.39, 143.74, 142.15, 140.92, 139.90, 138.58, 136.23, 129.62, 128.04, 127.85, 124.65, 120.72, 116.59, 115.20, 114.23, 107.27, 29.96, 28.95, 22.80, 22.62; HRMS (ESI) m/z calcd for  $C_{21}\text{H}_{17}\text{C}_1\text{N}_5$  [M+H] $^+$  374.1172, found 374.1178.

Method A: Off-white solid (197 mg, 52%).  $^1\text{H}$  NMR (500 MHz, DMSO- $d_6$ )  $\delta$  8.59 (s, 1H), 7.93 (d,  $J=8.4$  Hz, 2H), 7.87 (dd,  $J=9.1$ , 0.9 Hz, 1H), 7.80 (d,  $J=9.1$  Hz, 1H), 7.75 (d,  $J=8.5$  Hz, 2H), 3.32 (t,  $J=6.5$  Hz, 2H), 2.76 (t,  $J=6.1$  Hz, 2H), 2.03-1.95 (m, 2H), 1.78-1.69 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  155.52, 144.57, 143.84, 143.78, 142.71, 139.77, 135.26, 130.10, 129.57, 129.20, 125.83, 122.19, 116.19, 115.57, 31.16, 29.66, 28.81, 22.54, 22.43; HRMS (ESI) m/z calcd for  $C_{21}\text{H}_{19}\text{N}_4\text{O}_2\text{S}$  [M+H] $^+$  379.1229, found 379.1234.


**253**

4-(8,9,10,11-Tetrahydro-3H-pyrrolo[3,2-a]phenanthridin-7-yl)benzenesulfonamide


**254**

7-(1-Methyl-1H-indazol-5-yl)-8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridine

5



10



15

20


Method A: Off-white solid (162 mg, 43%).  $^1\text{H}$  NMR (500 MHz, DMSO-d<sub>6</sub>)  $\delta$  11.80 (s, 1H), 7.91 (d, J=8.4 Hz, 2H), 7.80 (d, J=8.9 Hz, 1H), 7.73 (d, J=8.4 Hz, 2H), 7.63 (d, J=8.8 Hz, 1H), 7.51 (d, J=3.1 Hz, 1H), 7.39 (s, 2H), 7.14 (d, J=3.1 Hz, 1H), 3.40 (t, J=6.5 Hz, 2H), 2.75 (t, J=6.2 Hz, 2H), 2.03-1.97 (m, 2H), 1.74 (qd, J=8.8, 7.3, 4.2 Hz, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  154.57, 145.05, 143.70, 143.40, 142.65, 133.35, 130.06, 127.32, 125.76, 124.09, 122.72, 120.30, 116.75, 106.36, 29.96, 28.94, 22.81, 22.46; HRMS (ESI) m/z calcd for C<sub>21</sub>H<sub>20</sub>N<sub>3</sub>O<sub>2</sub>S [M+H]<sup>+</sup> 378.1276, found 378.1279.

7-(1H-Pyrrolo[2,3-b]pyridin-5-yl)-8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridine


Method A: Off-white solid (164 mg, 46%).  $^1\text{H}$  NMR (500 MHz, Methanol-d<sub>4</sub>)  $\delta$  9.13 (s, 1H), 8.84 (s, 1H), 8.26 (d, J=9.2 Hz, 1H), 8.21 (s, 1H), 8.13-8.06 (m, 2H), 7.89 (dd, J=8.5, 1.4 Hz, 1H), 3.63 (t, J=6.4 Hz, 2H), 2.91 (t, J=6.1 Hz, 2H), 2.32-2.11 (m, 2H), 2.05-1.81 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, MeOD)  $\delta$  153.92, 150.61, 144.58, 135.63, 135.49, 134.39, 132.24, 129.30, 126.03, 123.77, 119.99, 117.90, 114.89, 112.48, 31.75, 30.86, 27.89, 21.33, 21.22; HRMS (ESI) m/z calcd for C<sub>22</sub>H<sub>20</sub>N<sub>5</sub> [M+H]<sup>+</sup> 354.1719, found 354.1721.

9-Methyl-7-(3-(trifluoromethyl)-1H-pyrazol-4-yl)-8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridine

40



45



50

55


Method A: Off-white solid (143 mg, 42%).  $^1\text{H}$  NMR (500 MHz, DMSO-d<sub>6</sub>)  $\delta$  11.76 (d, J=2.2 Hz, 1H), 8.56 (s, 1H), 8.41 (d, J=2.1 Hz, 1H), 8.15 (d, J=2.0 Hz, 1H), 7.85 (s, 2H), 7.53 (dd, J=3.4, 2.5 Hz, 1H), 6.51 (dd, J=3.4, 1.8 Hz, 1H), 3.33-3.291 (m, 2H), 2.83 (t, J=6.1 Hz, 2H), 2.04-1.95 (m, 2H), 1.79-1.68 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  155.77, 148.32, 143.79, 142.36, 138.66, 136.36, 129.95, 129.71, 129.03, 128.96, 127.21, 121.73, 119.22, 116.50, 114.34, 100.67, 29.73, 29.23, 22.62; HRMS (ESI) m/z calcd for C<sub>21</sub>H<sub>18</sub>N<sub>5</sub> [M+H]<sup>+</sup> 340.1562, found 340.1565.

Method A: Off-white solid (178 mg, 48%).  $^1\text{H}$  NMR (500 MHz, Methanol-d<sub>4</sub>)  $\delta$  8.60 (s, 1H), 7.97 (d, J=1.1 Hz, 1H), 7.86 (s, 2H), 3.56-3.48 (m, 1H), 3.39-3.32 (m, 2H), 2.77-2.70 (m, 1H), 2.38-2.28 (m, 1H), 2.27-2.18 (m, 1H), 1.97-1.85 (m, 1H), 1.66-1.53 (m, 1H), 1.09 (d, J=6.5 Hz, 3H);  $^{13}\text{C}$  NMR (126 MHz, MeOD)  $\delta$  148.72, 143.06, 142.82, 139.74 (J=28.98 Hz) 134.66, 131.35, 131.12, 131.01, 128.37, 123.01, 122.23, 120.84 (J=269.64 Hz), 115.93, 114.67, 36.13, 30.14, 29.44, 28.15, 20.47; HRMS (ESI) m/z calcd for C<sub>18</sub>H<sub>18</sub>N<sub>5</sub> [M+H]<sup>+</sup> 304.1562, found 304.1565.

US 12,384,782 B2

**255**

7-(3-(Trifluoromethyl)-1H-pyrazol-4-yl)-3,8,9,10-tetrahydrocyclopenta[c]pyrazolo[4,3-f]quinoline




HSD1288

**256**

Method A: Off-white solid (49 mg, 15%). <sup>1</sup>H NMR (500 MHz, MeOD) δ 8.69 (d, J=0.9 Hz, 1H), 8.53 (d, J=0.9 Hz, 1H), 8.32 (dd, J=9.4, 1.0 Hz, 1H), 8.11 (d, J=9.4 Hz, 1H), 4.01-3.93 (m, 2H), 3.72 (t, J=4.0 Hz, 2H); <sup>13</sup>C NMR (126 MHz, MeOD) δ 161.67, 140.75, 139.64, 137.73, 136.67, 133.55, 133.12, 122.29 (q, J=268.38 Hz), 121.46, 119.65, 119.42, 113.74, 108.80, 30.70, 29.72; HRMS (ESI) m/z calcd for C<sub>16</sub>H<sub>11</sub>F<sub>3</sub>N<sub>5</sub> [M+H]<sup>+</sup> 330.0967, found 330.0970.


9-Methyl-7-(3-(trifluoromethyl)-1H-pyrazol-4-yl)-3H-pyrazolo[4,3-f]quinoline



HSD1291

Method A: Off-white solid (185 mg, 54%). <sup>1</sup>H NMR (500 MHz, MeOD) δ 8.76 (s, 1H), 8.44 (s, 1H), 8.33 (d, J=9.3 Hz, 1H), 8.05 (d, J=9.3 Hz, 1H), 3.86 (t, J=7.7 Hz, 2H), 3.21 (t, J=7.7 Hz, 2H), 2.57-2.53 (m, 2H); <sup>13</sup>C NMR (126 MHz, MeOD) δ 160.67, 141.10, 140.00, 138.86, 136.50, 133.37, 132.59, 122.32 (q, J=269.64 Hz), 121.78, 121.15, 118.59, 115.19, 110.20, 35.03, 30.90, 23.82; HRMS (ESI) m/z calcd for C<sub>17</sub>H<sub>13</sub>F<sub>3</sub>N<sub>5</sub> [M+H]<sup>+</sup> 334.1123, found 334.1121.

7-(3-(Trifluoromethyl)-1H-pyrazol-4-yl)-3,8,9,10,11,12-hexahydrocyclohepta[c]pyrazolo[4,3-f]quinoline




HSD1289

Method A: Off-white solid (136 mg, 43%). <sup>1</sup>H NMR (500 MHz, MeOD) δ 8.51 (s, 1H), 8.29-8.21 (m, 1H), 7.91-7.81 (m, 2H), 7.62 (s, 1H), 2.89 (s, 3H); <sup>13</sup>C NMR (126 MHz, MeOD) δ 147.45, 145.74, 144.37, 139.03, 138.40, 135.27, 130.97, 128.87, 125.13 (J=269.64 Hz), 122.50, 121.51, 120.86, 116.35, 114.74, 21.45; HRMS (ESI) m/z calcd for C<sub>15</sub>H<sub>11</sub>F<sub>3</sub>N<sub>5</sub> [M+H]<sup>+</sup> 318.0967, found 318.0971.


Method A: Off-white solid (185 mg, 50%). <sup>1</sup>H NMR (500 MHz, Methanol-d<sub>4</sub>) δ 8.98-8.87 (m, 1H), 8.37-8.27 (m, 2H), 7.99 (d, J=9.2 Hz, 1H), 3.86 (d, J=5.3 Hz, 2H), 3.17-3.04 (m, 2H), 2.05 (p, J=2.7 Hz, 4H), 1.78-1.65 (m, 2H); <sup>13</sup>C NMR (126 MHz, MeOD) δ 160.75, 140.27, 136.43, 133.66, 132.53, 123.83, 122.46, 122.13, 121.07, 120.17 (q, J=269.64 Hz), 118.79, 114.94, 114.65, 110.56, 110.56, 32.30, 30.64, 29.52, 25.85, 23.75; HRMS (ESI) m/z calcd for C<sub>19</sub>H<sub>17</sub>F<sub>3</sub>N<sub>5</sub> [M+H]<sup>+</sup> 372.1436, found 372.1438.

7-(3-(Trifluoromethyl)-1H-pyrazol-4-yl)-8,9-dihydro-3H-cyclobuta[c]pyrazolo[4,3-f]quinolone



HSD1290

7-(1H-1,2,3-Triazol-4-yl)-8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridine




HSD1292

Method A: Off-white solid (159 mg, 55%). <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) δ 8.57 (s, 1H), 8.31 (d, J=1.9 Hz, 1H), 7.87 (d, J=9.2 Hz, 1H), 7.82 (dd, J=9.1, 1.9 Hz, 1H), 3.30 (d, J=6.6 Hz, 2H), 3.12 (d, J=6.4 Hz, 2H), 2.05-1.94 (m, 2H), 1.84 (td, J=10.1, 6.9, 6.3, 3.3 Hz, 2H); <sup>13</sup>C NMR (126 MHz, DMSO) δ 146.46, 143.65, 142.93, 131.52, 129.80, 129.48, 122.18, 116.16, 115.49, 29.87, 28.27, 22.37; HRMS (ESI) m/z calcd for C<sub>16</sub>H<sub>15</sub>N<sub>6</sub> [M+H]<sup>+</sup> 291.1358, found 291.1360.


**257**

Methyl 3-(8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridin-7-yl)-1H-pyrrole-2-carboxylate



Method A: Off-white solid (142 mg, 41%).  $^1\text{H}$  NMR (500 MHz, DMSO-d<sub>6</sub>)  $\delta$  12.20 (s, 1H), 8.50 (s, 1H), 7.52 (s, 1H), 7.34 (s, 1H), 3.80 (s, 3H), 3.32-3.24 (m, 2H), 3.01 (t, J=6.1 Hz, 2H), 2.03-1.91 (m, 2H), 1.88-1.74 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  161.40, 150.78, 143.78, 142.06, 138.38, 136.17, 136.16, 129.69, 129.00, 125.75, 125.46, 122.08, 121.04, 116.53, 114.14, 51.67, 29.86, 28.94, 22.68, 22.50; HRMS (ESI) m/z calcd for C<sub>20</sub>H<sub>19</sub>N<sub>4</sub>O<sub>2</sub> [M+H]<sup>+</sup> 347.1508, found 347.1513.

2-(4-(8,9,10,11-Tetrahydro-3H-pyrazolo[4,3-a]phenanthridin-7-yl)-1H-pyrazol-1-yl)ethan-1-ol




Method A: Off-white solid (126 mg, 38%).  $^1\text{H}$  NMR (500 MHz, Methanol-d<sub>4</sub>)  $\delta$  8.51 (s, 1H), 8.12 (s, 1H), 7.99 (s, 1H), 7.87 (d, J=9.2 Hz, 1H), 7.79 (d, J=9.0 Hz, 1H), 4.34 (t, J=5.4 Hz, 2H), 3.97 (t, J=5.4 Hz, 2H), 3.35-3.32 (m, 2H), 3.00 (t, J=6.2 Hz, 2H), 2.10-2.03 (m, 2H), 1.95-1.86 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, MeOD)  $\delta$  149.36, 143.28, 143.07, 139.58, 138.49, 135.72, 131.37, 129.45, 128.70, 121.71, 121.43, 116.16, 113.49, 60.48, 54.17, 29.73, 28.38, 22.12, 22.03; HRMS (ESI) m/z calcd for C<sub>19</sub>H<sub>20</sub>N<sub>5</sub>O [M+H]<sup>+</sup> 334.1668, found 334.1675.

**258**

7-(1,3-Dimethyl-1H-pyrazol-4-yl)-8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridine


5 HSD1295



Method A: Off-white solid (180 mg, 57%).  $^1\text{H}$  NMR (500 MHz, DMSO-d<sub>6</sub>)  $\delta$  8.53 (s, 1H), 7.92 (s, 1H), 7.81 (d, J=9.0 Hz, 1H), 7.76 (d, J=9.1 Hz, 1H), 3.82 (s, 3H), 3.27 (t, J=6.5 Hz, 3H), 2.81 (t, J=6.2 Hz, 2H), 2.26 (s, 3H), 2.01-1.88 (m, 2H), 1.82-1.67 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  150.70, 147.24, 143.71, 141.82, 139.32, 135.07, 131.72, 129.87, 129.57, 121.05, 118.85, 116.35, 114.88, 38.70, 29.70, 28.60, 22.60, 13.53; HRMS (ESI) m/z calcd for C<sub>19</sub>H<sub>20</sub>N<sub>5</sub> [M+H]<sup>+</sup> 318.1719, found 318.1725.

7-(1H-Imidazol-4-yl)-8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridine


35 HSD1296



Method A: Off-white solid (168 mg, 58%).  $^1\text{H}$  NMR (500 MHz, DMSO-d<sub>6</sub>)  $\delta$  8.62-8.53 (m, 2H), 7.93-7.82 (m, 3H), 3.36-3.23 (m, 2H), 3.09-2.97 (m, 2H), 2.02-1.94 (m, 2H), 1.90-1.78 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  144.79, 143.75, 142.88, 138.70, 136.05, 132.80, 131.40, 129.06, 128.65, 122.65, 121.92, 116.12, 115.25, 29.94, 27.98, 22.22; HRMS (ESI) m/z calcd for C<sub>17</sub>H<sub>16</sub>N<sub>5</sub> [M+H]<sup>+</sup> 290.1406, found 290.1415.

1-Iodo-7-(3-(trifluoromethyl)-1H-pyrazol-4-yl)-8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridine


55 HSD1297



**259**


Method A: Off-white solid (145 mg, 30%). <sup>1</sup>H NMR (500 MHz, Methanol-d<sub>4</sub>) δ 8.90 (s, 1H), 8.35 (s, 1H), 8.33 (d, J=9.1 Hz, 1H), 8.00 (d, J=9.2 Hz, 1H), 3.67 (t, J=6.4 Hz, 2H), 2.81 (t, J=6.2 Hz, 2H), 2.18 (qd, J=7.8, 6.3, 4.5 Hz, 2H), 2.04-1.90 (m, 2H); <sup>13</sup>C NMR (126 MHz, MeOD) δ 154.90, 142.03, 140.54, 139.83, 134.96, 134.44, 134.02, 132.40, 124.40, 122.30 (J=269.64 Hz), 121.60, 118.81, 114.76, 109.91, 30.80, 27.22, 21.20, 20.87; HRMS (ESI) m/z calcd for C<sub>17</sub>H<sub>16</sub>N<sub>5</sub> [M+H]<sup>+</sup> 484.0246, found 484.0252.

7-(3-Phenyl-1H-pyrazol-4-yl)-8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridine



Method A: Off-white solid (168 mg, 45%). <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) δ 8.81 (s, 1H), 8.27 (d, J=9.1 Hz, 2H), 8.17 (d, J=9.2 Hz, 1H), 7.35-7.22 (m, 5H), 3.51-3.43 (m, 2H), 2.55-2.49 (m, 0H), 1.95-1.82 (m, 2H), 1.72-1.61 (m, 2H); <sup>13</sup>C NMR (126 MHz, DMSO) δ 145.52, 135.52, 132.94, 129.41, 128.96, 128.85, 128.19, 126.99, 123.39, 120.03, 114.91, 109.66, 30.80, 27.32, 21.75, 21.27; HRMS (ESI) m/z calcd for C<sub>23</sub>H<sub>20</sub>N<sub>5</sub> [M+H]<sup>+</sup> 366.1719, found 366.1726.

7-(3-(Trifluoromethyl)-1H-pyrazol-4-yl)-8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridin-9-amine




Method A: Off-white solid (137 mg, 37%). <sup>1</sup>H NMR (500 MHz, Methanol-d<sub>4</sub>) δ 8.57 (d, J=7.7 Hz, 1H), 8.03-8.00 (m, 1H), 7.87-7.83 (m, 2H), 3.92-3.82 (m, 1H), 3.65-3.53 (m, 1H), 3.49-3.38 (m, 1H), 2.81-2.65 (m, 2H), 2.25-2.17 (m, 1H), 2.08-1.96 (m, 1H); <sup>13</sup>C NMR (126 MHz, MeOD) δ 148.28, 143.27, 142.44, 142.22, 139.73, 134.64, 130.59, 129.31, 128.37, 122.83 (q, J=269.64 Hz), 122.00, 118.74, 115.86, 115.82, 114.97, 46.06, 36.25, 30.30, 28.58; HRMS (ESI) m/z calcd for C<sub>16</sub>H<sub>16</sub>F<sub>3</sub>N<sub>6</sub> [M+H]<sup>+</sup> 373.1389, found 373.1393.

**260**


3-Methyl-3-(4-(8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridin-7-yl)-1H-pyrazol-1-yl)tetrahydro-thiophene 1,1-dioxide

HSD1308



Method A: Off-white solid (126 mg, 30%). <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) δ 8.54-8.48 (m, 1H), 8.47 (s, 1H), 8.08 (s, 1H), 7.81 (s, 2H), 4.22 (dd, J=14.1, 1.7 Hz, 1H), 3.59 (d, J=14.1 Hz, 1H), 3.42 (ddd, J=12.7, 7.7, 4.6 Hz, 1H), 3.29 (d, J=6.5 Hz, 2H), 3.19 (ddd, J=13.1, 9.6, 7.5 Hz, 1H), 3.15-3.07 (m, 1H), 2.55 (ddd, J=13.9, 9.6, 7.7 Hz, 1H), 1.98 (ddt, J=12.1, 6.1, 3.3 Hz, 2H), 1.84 (qd, J=9.1, 7.4, 4.0 Hz, 2H), 1.75 (s, 3H); <sup>13</sup>C NMR (126 MHz, DMSO) δ 149.12, 143.66, 142.26, 140.19, 138.52, 136.20, 129.53, 129.02, 128.80, 123.04, 121.18, 116.52, 114.29, 65.32, 61.46, 51.53, 35.09, 29.87, 28.53, 27.91, 22.63, 22.50.


7-(3-(Pyridin-3-yl)-1H-pyrazol-4-yl)-8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridine



Method A: Off-white solid (172 mg, 47%). <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) δ 8.56 (d, J=1.0 Hz, 1H), 8.49 (dd, J=2.2, 0.9 Hz, 1H), 8.36 (dd, J=4.7, 1.7 Hz, 1H), 7.98 (s, 1H), 7.83 (dd, J=9.0, 0.9 Hz, 1H), 7.72 (d, J=8.0, 2.3, 1.7 Hz, 1H), 7.68 (d, J=9.0 Hz, 1H), 7.25 (ddd, J=8.0, 4.8, 0.9 Hz, 1H), 3.29 (t, J=6.5 Hz, 2H), 2.58 (t, J=6.2 Hz, 2H), 1.89 (ddt, J=9.2, 6.4, 4.2 Hz, 2H), 1.73-1.64 (m, 2H); <sup>13</sup>C NMR (126 MHz, DMSO) δ 150.81, 148.62, 147.71, 143.91, 143.51, 142.22, 140.11, 135.03, 134.04, 133.41, 130.51, 129.58, 129.11, 123.91, 121.95, 119.13, 116.29, 115.55, 29.57, 28.27, 22.59, 22.35; HRMS (ESI) m/z calcd for C<sub>22</sub>H<sub>19</sub>N<sub>6</sub> [M+H]<sup>+</sup> 367.1671, found 367.1675.


**261**

7-(1-Phenyl-1H-pyrazol-4-yl)-8,9,10,11-tetrahydro-  
3H-pyrazolo[4,3-a]phenanthridine



Method A: Off-white solid (186 mg, 51%).  $^1\text{H}$  NMR (500 MHz, DMSO-d<sub>6</sub>)  $\delta$  8.55 (s, 1H), 7.95 (s, 1H), 7.88-7.73 (m, 2H), 7.37-7.23 (m, 1H), 6.79 (s, 1H), 6.63 (s, 1H), 3.31 (t, J=6.4 Hz, 2H), 2.58 (t, J=6.1 Hz, 2H), 1.94-1.85 (m, 2H), 1.74-1.65 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  150.93, 143.68, 142.18, 138.73, 136.97, 136.67, 136.31, 131.22, 130.28, 129.55, 127.67, 125.20, 123.94, 122.00, 118.02, 116.54, 114.31, 29.56, 28.10, 22.55, 22.32; HRMS (ESI) m/z calcd for C<sub>23</sub>H<sub>20</sub>N<sub>5</sub> [M+H]<sup>+</sup> 366.1719, found 366.1720.


7-(3-(Thiophen-3-yl)-1H-pyrazol-4-yl)-8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridine



Method A: Off-white solid (177 mg, 46%).  $^1\text{H}$  NMR (500 MHz, DMSO-d<sub>6</sub>)  $\delta$  8.89 (d, J=1.8 Hz, 1H), 8.55 (s, 1H), 8.29 (d, J=1.7 Hz, 1H), 7.95 (d, J=8.2 Hz, 2H), 7.83 (s, 2H), 7.57-7.46 (m, 2H), 7.39-7.28 (m, 1H), 3.29 (d, J=6.5 Hz, 2H), 3.07 (t, J=6.2 Hz, 2H), 2.03-1.94 (m, 2H), 1.86 (tt, J=9.6, 5.4 Hz, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  148.63, 143.82, 142.45, 142.18, 141.18, 140.01, 139.07, 130.03, 129.57, 129.19, 127.95, 126.90, 124.53, 121.44, 119.01, 118.46, 116.29, 29.86, 28.53, 22.57, 22.45; HRMS (ESI) m/z calcd for C<sub>21</sub>H<sub>18</sub>N<sub>5</sub>S [M+H]<sup>+</sup> 372.1283. found 372.1286.


**262**

7-(3-(tert-Butyl)-1H-pyrazol-4-yl)-8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridine




Method A: Off-white solid (176 mg, 51%).  $^1\text{H}$  NMR (500 MHz, MeOD)  $\delta$  8.55 (s, 1H), 7.88-7.79 (m, 2H), 7.53 (s, 1H), 3.37-3.31 (m, 2H), 2.67 (t, J=6.2 Hz, 2H), 2.08-1.97 (m, 2H), 1.90-1.81 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, MeOD)  $\delta$  152.31, 143.08, 142.67, 138.68, 135.79, 131.90, 128.29, 122.19, 116.70, 116.13, 113.68, 32.29, 32.24, 29.44, 29.30, 28.47, 22.15, 21.89; HRMS (ESI) m/z calcd for C<sub>21</sub>H<sub>24</sub>N<sub>5</sub> [M+H]<sup>+</sup> 346.2032, found 346.2021.

4-(8,9,10,11-Tetrahydro-3H-pyrazolo[4,3-a]phenanthridin-7-yl)-1H-pyrazole-3-carboxylic acid



Method A: Off-white solid (167 mg, 50%).  $^1\text{H}$  NMR (500 MHz, DMSO-d<sub>6</sub>)  $\delta$  NH 8.62 (s, 1H), 8.25 (s, 1H), 7.99 (d, J=9.1 Hz, 1H), 7.76 (d, J=9.4 Hz, 1H), 3.30 (t, J=6.5 Hz, 2H), 2.93-2.78 (m, 2H), 2.03-1.91 (m, 2H), 1.83-1.74 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  162.03, 148.76, 145.57, 139.73, 137.07, 136.25, 131.58, 128.69, 123.61, 122.18, 121.89, 116.71, 115.13, 30.40, 28.34, 21.77. HRMS (ESI) m/z calcd for C<sub>18</sub>H<sub>16</sub>N<sub>5</sub>O<sub>2</sub> [M+H]<sup>+</sup> 334.1304, found 334.1308.


7-(1-(2-Chloroethyl)-1H-pyrazol-4-yl)-8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridine



**263**


Method A: Off-white solid Yield: (26 mg, 28%) <sup>1</sup>H NMR (500 MHz, Methanol-d<sub>4</sub>) δ 8.83 (s, 1H), 8.55 (d, J=0.8 Hz, 1H), 8.29-8.20 (m, 2H), 8.12 (d, J=9.2 Hz, 1H), 4.68 (t, J=5.6 Hz, 2H), 4.11-4.04 (m, 2H), 3.62 (t, J=6.4 Hz, 2H), 3.13 (t, J=6.2 Hz, 2H), 2.25-2.15 (m, 2H), 2.07-1.97 (m, 2H); <sup>13</sup>C NMR (126 MHz, Methanol-d<sub>4</sub>) δ 154.27, 143.82, 140.54, 134.63, 133.72, 131.88, 122.97, 118.99, 114.92, 112.57, 53.74, 42.44, 31.04, 27.80, 21.23.

2,3-Dimethyl-7-(3-(trifluoromethyl)-1H-pyrazol-4-yl)-3,6,8,9,10,11-hexahydro-2H-pyrazolo[3,4-a]phenanthridine



Method A Off-white solid, Yield: (40 mg, 20%) <sup>1</sup>H NMR (500 MHz, Methanol-d<sub>4</sub>) δ 8.33 (s, 1H), 8.27 (d, J=9.0 Hz, 1H), 7.53 (d, J=9.0 Hz, 1H), 4.27 (s, 3H), 3.95 (t, J=6.4 Hz, 2H), 2.79-2.76 (m, 5H), 2.13-2.05 (m, 2H), 1.98-1.86 (m, 2H); <sup>13</sup>C NMR (126 MHz, Methanol-d<sub>4</sub>) δ 156.81, 142.12, 141.73, 138.79, 135.59, 132.97, 132.27, 129.07, 122.32 (q, J=268), 121.35, 119.06, 111.69, 110.05, 36.88, 31.69, 27.09, 21.21, 20.94, 8.19.

5-Fluoro-7-(3-(trifluoromethyl)-1H-pyrazol-4-yl)-8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridine




Method A White solid. Yield: (94 mg, 25%) <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) δ 8.60 (s, 1H), 8.25 (s, 1H), 7.69 (d, J=9.9 Hz, 1H), 3.29 (t, J=6.4 Hz, 2H), 2.71 (t, J=6.2 Hz, 2H), 1.95 (dt, J=12.3, 4.6 Hz, 2H), 1.87-1.71 (m, 2H); <sup>13</sup>C NMR (126 MHz, DMSO-d<sub>6</sub>) δ 158.10, 156.09, 148.56, 142.63, 134.68, 134.59, 131.84, 131.42, 123.43 (q, J=268), 122.90, 119.33, 112.71, 29.54, 28.19, 22.40, 22.13. HRMS (ESI) m/z calcd for C<sub>18</sub>H<sub>14</sub>F<sub>4</sub>N<sub>5</sub> [M+H]<sup>+</sup> 376.1185, found 376.1185.

**264**

7-(3-(Trifluoromethyl)-1H-pyrazol-4-yl)-8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridin-5-ol

HSH158




10  
HSH127

Method A Off-white solid, Yield: (21 mg, 11%) <sup>1</sup>H NMR (500 MHz, Methanol-d<sub>4</sub>) δ 9.05 (s, 1H), 8.35 (t, J=1.0 Hz, 1H), 8.19 (s, 1H), 3.63 (t, J=6.4 Hz, 2H), 2.79 (t, J=6.2 Hz, 2H), 2.24-2.14 (m, 2H), 2.06-1.90 (m, 2H); <sup>13</sup>C NMR (126 MHz, Methanol-d<sub>4</sub>) δ 154.95, 142.50, 139.83, 135.25, 134.31, 133.85, 132.44, 123.87, 122.28 (q, J=269.64), 120.97, 115.06, 109.89, 30.71, 27.27, 21.14, 20.80.

25  
5-Bromo-7-(3-(trifluoromethyl)-1H-pyrazol-4-yl)-8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridine

HSH162




35  
40

Method A Off-white solid, Yield: (10 mg, 2%) <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) δ 8.61 (s, 1H), 8.29 (s, 2H), 3.32-3.28 (m, 2H), 2.75 (t, J=6.2 Hz, 2H), 1.96 (m, 2H), 1.78 (m, 2H); <sup>13</sup>C NMR (126 MHz, DMSO-d<sub>6</sub>) δ 148.91, 143.00, 139.74, 139.73, 139.70, 131.56, 131.54, 131.51, 124.67, 123.42, 122.68, 121.27 (q, J=270.9 Hz), 119.30, 55.37, 29.71, 28.24, 22.49, 22.17.

50  
5-Chloro-7-(3-(trifluoromethyl)-1H-pyrazol-4-yl)-8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridine

HSH163

55




US 12,384,782 B2

**265**


Method A Off-white solid. Yield: (12 mg, 5%).  $^1\text{H}$  NMR (500 MHz, DMSO-d<sub>6</sub>)  $\delta$  8.62 (s, 1H), 8.29 (s, 1H), 8.09 (s, 1H), 3.31-3.26 (m, 2H), 2.75 (t, J=6.2 Hz, 2H), 2.06-1.87 (m, 2H), 1.82-1.67 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO-d<sub>6</sub>)  $\delta$  148.69, 143.00, 139.26, 132.77, 131.55, 131.55, 129.57, 123.42 (q, J=269), 122.85, 119.37, 119.36, 115.32, 29.72, 28.23, 22.48, 22.16.

4-Methyl-7-(3-(trifluoromethyl)-1H-pyrazol-4-yl)-8, 10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridine



Method A Off-white solid, Yield: (20 mg, 5%).  $^1\text{H}$  NMR (500 MHz, DMSO-d<sub>6</sub>)  $\delta$  8.55 (s, 1H), 8.20 (s, 1H), 7.56 (s, 1H), 3.32-3.30 (m, 2H), 2.68 (t, J=6.2 Hz, 2H), 2.63 (s, 3H), 1.96 (m, 2H), 1.77 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO-d<sub>6</sub>)  $\delta$  148.32, 144.01, 141.68, 139.48, 136.72, 131.12, 129.51, 128.11, 124.44, 123.55 (q, J=269), 121.41, 119.83, 116.19, 29.44, 28.13, 22.61, 22.41, 17.46.

7-(3-(Trifluoromethyl)-1H-pyrazol-4-yl)-8,9,10,11-tetrahydro-3[1,2,3]triazolo[4,5-a]phenanthridine




Method A Off-white solid, Yield: (72 mg, 20%).  $^1\text{H}$  NMR (500 MHz, Methanol-d<sub>4</sub>)  $\delta$  8.40 (d, J=9.2 Hz, 1H), 8.33 (s, 1H), 8.05 (d, J=9.2 Hz, 1H), 4.01 (t, J=6.4 Hz, 2H), 2.82 (t, J=6.3 Hz, H), 2.13 (dp, J=9.3, 3.1 Hz, 2H), 2.02-1.93 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, MeOD)  $\delta$  154.39, 145.35, 140.07, 139.75, 138.56, 137.77, 134.33, 132.14, 122.37 (q, J=269.6 Hz), 121.20, 120.95, 116.39, 111.31, 30.87, 27.26, 21.12, 21.07; HRMS (ESI) m/z calcd for C<sub>17</sub>H<sub>14</sub>F<sub>3</sub>N<sub>6</sub> [M+H]<sup>+</sup> 359.1232, found 359.1239.

**266**

7-(3-(Trifluoromethyl)-1H-pyrazol-4-yl)-8,9,10,11-tetrahydroisoxazolo[4,5-a]phenanthridine


HSD1316



Method A: Off-white solid (126 mg, 35%).  $^1\text{H}$  NMR (500 MHz, Methanol-d<sub>4</sub>)  $\delta$  9.70-9.59 (m, 1H), 8.34-8.22 (m, 3H), 3.62 (t, J=6.4 Hz, 2H), 2.79 (t, J=6.3 Hz, 2H), 2.19-2.08 (m, 2H), 2.00-1.86 (m, 2H). HRMS (ESI) m/z calcd for C<sub>18</sub>H<sub>14</sub>F<sub>3</sub>N<sub>4</sub>O [M+H]<sup>+</sup> 359.1120, found 359.1122.

7-(3-(Trifluoromethyl)-1H-pyrazol-4-yl)-8,9,10,11-tetrahydroisothiazolo[4,5-a]phenanthridine

HSD1317



Method A: Off-white solid (120 mg, 32%).  $^1\text{H}$  NMR (500 MHz, Methanol-d<sub>4</sub>)  $\delta$  9.94 (s, 1H), 8.78 (d, J=8.9 Hz, 1H), 8.41 (s, 1H), 8.21 (d, J=8.9 Hz, 1H), 3.85 (t, J=6.1 Hz, 2H), 2.87 (t, J=6.1 Hz, 2H), 2.24-2.13 (m, 2H), 2.00 (td, J=11.2, 9.5, 5.6 Hz, 2H);  $^{13}\text{C}$  NMR (126 MHz, MeOD)  $\delta$  156.17, 155.87, 155.79, 145.11, 140.04, 139.75, 136.42, 135.01, 132.65, 129.80, 125.95, 125.43, 121.58, 120.19, 118.46, 109.79, 32.51, 27.76, 21.37, 20.63; HRMS (ESI) m/z calcd for C<sub>18</sub>H<sub>14</sub>F<sub>3</sub>N<sub>4</sub>S [M+H]<sup>+</sup> 375.0891, found 375.0899.


3-Methyl-7-(3-(trifluoromethyl)-1H-pyrazol-4-yl)-8, 9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridine

HSD1315

50

55


HSD1318



**267**


Method A: Off-white solid (148 mg, 40%).  $^1\text{H}$  NMR (500 MHz, Methanol-d<sub>4</sub>)  $\delta$  8.77 (d, J=0.9 Hz, 1H), 8.42 (dd, J=9.3, 0.9 Hz, 1H), 8.38 (d, J=0.9 Hz, 1H), 8.07 (d, J=9.3 Hz, 1H), 4.32 (s, 3H), 3.68 (t, J=6.3 Hz, 2H), 2.82 (t, J=6.2 Hz, 2H), 2.22-2.12 (m, 2H), 2.05-1.92 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, MeOD)  $\delta$  155.03, 142.35, 140.13 (q, J=37.8 Hz), 138.47, 135.21, 134.39, 134.19, 132.52, 124.04, 122.33 (q, J=269.6 Hz), 119.30, 118.65, 115.97, 109.85, 35.32, 30.84, 27.26, 21.19, 20.86; HRMS (ESI) m/z calcd for C<sub>19</sub>H<sub>17</sub>F<sub>3</sub>N<sub>5</sub> [M+H]<sup>+</sup> 372.1436, found 372.1438.

6-(5-Fluoro-8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridin-7-yl)benzo[d]thiazol-2-amine



Method A: Off-white solid (148 mg, 38%).  $^1\text{H}$  NMR (500 MHz, DMSO-d<sub>6</sub>)  $\delta$  8.56 (s, 1H), 7.91-7.84 (m, 1H), 7.70 (d, J=9.8 Hz, 1H), 7.57 (d, J=2.4 Hz, 2H), 7.45-7.38 (m, 2H), 3.36-3.32 (m, 2H), 2.84 (t, J=6.1 Hz, 2H), 2.04-1.97 (m, 2H), 1.79-1.71 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  167.68, 158.36 (d, J=253.26 Hz), 157.08, 153.14, 142.83, 136.79, 136.49, 134.35, 133.64, 131.24, 131.14, 127.29, 122.53, 122.22, 117.37, 113.06, 98.20, 29.80, 29.24, 22.52, 22.44; HRMS (ESI) m/z calcd for C<sub>21</sub>H<sub>17</sub>FN<sub>5</sub>S [M+H]<sup>+</sup> 390.1189, found 390.1195.

6-(8,9,10,11-Tetrahydro-3H-[1,2,3]triazolo[4,5-a]phenanthridin-7-yl)benzo[d]thiazol-2-amine




Method A: Off-white solid (112 mg, 30%).  $^1\text{H}$  NMR (500 MHz, DMSO-d<sub>6</sub>)  $\delta$  8.03 (d, J=9.1 Hz, 1H), 7.92-7.88 (m, 2H), 7.57 (s, 2H), 7.44 (dd, J=8.2, 1.7 Hz, 1H), 7.40 (d, J=8.2 Hz, 1H), 3.69 (t, J=6.5 Hz, 2H), 2.85 (t, J=6.2 Hz, 2H), 2.02-1.98 (m, 2H), 1.79-1.73 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  167.75, 158.87, 153.15, 145.33, 143.19, 139.18,

**268**

133.64, 131.24, 130.36, 130.18, 127.24, 122.15, 118.50, 117.37, 116.27, 29.93, 29.07, 22.66, 22.39. HRMS (ESI) m/z calcd for C<sub>20</sub>H<sub>17</sub>N<sub>6</sub>S [M+H]<sup>+</sup> 373.1235, found 373.1237.

7-(3-Isopropyl-1H-pyrazol-4-yl)-8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridine



HSD1321


HSD1319

30  
35

Method A: Off-white solid (136 mg, 41%).  $^1\text{H}$  NMR (500 MHz, DMSO-d<sub>6</sub>)  $\delta$  8.82 (s, 1H), 8.23 (d, J=14.6 Hz, 2H), 7.97 (s, 1H), 3.49 (t, J=6.2 Hz, 2H), 3.02 (dd, J=14.1, 7.3 Hz, 1H), 2.84-2.66 (m, 2H), 2.20-1.96 (m, 2H), 1.91-1.76 (m, 2H), 1.26-1.08 (m, 6H). HRMS (ESI) m/z calcd for C<sub>20</sub>H<sub>22</sub>N<sub>5</sub> [M+H]<sup>+</sup> 332.1875, found 332.1875.

4-(7-(3-(Trifluoromethyl)-1H-pyrazol-4-yl)-8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridin-9-yl)morpholine

HSD1320

50  
55

HSD1322


60  
65

Method A: Off-white solid (110 mg, 25%).  $^1\text{H}$  NMR (500 MHz, Methanol-d<sub>4</sub>)  $\delta$  8.64 (s, 1H), 8.13 (s, 1H), 7.95 (d, J=9.2 Hz, 1H), 7.90 (d, J=9.2 Hz, 1H), 4.17-3.37 (m, 11H), 3.29-3.19 (m, 1H), 3.19-3.08 (m, 1H), 2.85-2.70 (m, 1H), 2.14 (qd, J=12.1, 5.8 Hz, 1H). HRMS (ESI) m/z calcd for C<sub>22</sub>H<sub>22</sub>F<sub>3</sub>N<sub>6</sub>O [M+H]<sup>+</sup> 443.1807, found 443.1809.

**269**

6-(3-Methyl-8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridin-7-yl)benzo[d]thiazol-2-amine

HSD1323



Method A: Off-white solid (138 mg, 36%).  $^1\text{H}$  NMR (500 MHz, DMSO-d<sub>6</sub>)  $\delta$  8.50 (d, J=0.9 Hz, 1H), 8.02-7.95 (n, 1H), 7.91-7.85 (m, 2H), 7.63 (s, 2H), 7.46-7.36 (m, 2H), 4.17 (s, 3H), 3.31 (t, J=6.5 Hz, 2H), 2.82 (t, J=6.1 Hz, 2H), 2.01-1.95 (m, 2H), 1.83-1.66 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  167.75, 156.84, 152.94, 143.09, 142.79, 138.18, 135.06, 133.62, 131.17, 129.90, 129.18, 127.28, 122.20, 121.53, 117.29, 117.17, 114.03, 36.31, 29.76, 29.17, 22.58, 22.54. HRMS (ESI) m/z calcd for C<sub>22</sub>H<sub>20</sub>N<sub>5</sub>S [M+H]<sup>+</sup> 386.1439, found 386.1442.


Methyl 7-(2-aminobenzo[d]thiazol-6-yl)-8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridine-1-carboxylate

followed by addition of acetyl chloride (30 mg, 1.5 mmol). After that reaction was continued for overnight at room temperature. After completion of reaction, reaction mixture was extracted with ethyl acetate (2×20 mL) and washed with brine solution and the crude was purified with dichloromethane:methanol (90:10) by flash column chromatography to get the desired product as yellow solid (73 mg, 70%).

**270**

5


HSD1325



$^1\text{H}$  NMR (500 MHz, Methanol-d<sub>4</sub>)  $\delta$  8.76 (s, 1H), 8.38 (d, J=9.3 Hz, 1H), 8.31-8.24 (m, 1H), 8.20 (d, J=9.3 Hz, 1H), 7.88-7.84 (m, 1H), 7.76 (d, J=8.4 Hz, 1H), 4.32 (s, 3H), 3.67 (t, J=6.3 Hz, 2H), 2.95 (t, J=6.1 Hz, 2H), 2.26-2.18 (m, 2H), 1.99-1.87 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, MeOD)  $\delta$  170.98, 155.22, 149.49, 141.56, 138.36, 135.15, 134.18, 132.65, 129.29, 127.49, 125.42, 124.19, 123.58, 118.90, 118.87, 115.92, 114.54, 35.36, 31.10, 27.83, 21.22, 21.15; HRMS (ESI) m/z calcd for C<sub>23</sub>H<sub>20</sub>N<sub>5</sub>O<sub>2</sub>S [M+H]<sup>+</sup> 414.1389, found 414.1388.

HSD1324

40 7-(3-(Trifluoromethyl)-1H-pyrazol-4-yl)-8,9,10,11-tetrahydro-3H-imidazo[4,5-a]phenanthridine




Method A: Off-white solid (120 mg, 28%);  $^1\text{H}$  NMR (500 MHz, DMSO-d<sub>6</sub>)  $\delta$  8.55 (s, 1H), 8.15 (s, 1H), 8.08 (d, J=1.9 Hz, 1H), 7.59 (dt, J=8.3, 1.9 Hz, 1H), 7.56 (dd, J=8.2, 1.8 Hz, 1H), 3.99 (s, 3H), 3.21-3.11 (m, 2H), 2.91-2.77 (m, 2H), 1.87-1.68 (m, 4H);  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  169.32, 166.59, 153.43, 150.43, 140.96, 140.33, 138.84, 131.42, 129.03, 128.38, 125.04, 123.58, 122.59, 118.02, 116.40, 111.98, 53.45, 30.28, 27.43, 21.69, 21.65. HRMS (ESI) m/z calcd for C<sub>23</sub>H<sub>20</sub>N<sub>5</sub>O<sub>2</sub>S [M+H]<sup>+</sup> 430.1338, found 430.1348.

N-(6-(8,9,10,11-Tetrahydro-3H-pyrazolo[4,3-a]phenanthridin-7-yl)benzo[d]thiazol-2-yl)acetamide

Compound HSD992 (93 mg, 0.25 mmol) was dissolved in a mixture of DMF (2 mL) and triethylamine (2 equiv),

55  
60  
65

Method A: Off-white solid (75 mg, 21%).  $^1\text{H}$  NMR (500 MHz, Methanol-d<sub>4</sub>)  $\delta$  8.30 (s, 1H), 7.99 (d, J=1.2 Hz, 1H), 7.93 (d, J=9.0 Hz, 1H), 7.83 (d, J=8.9 Hz, 1H), 3.68 (d, J=6.7 Hz, 2H), 2.68 (t, J=6.3 Hz, 2H), 2.08-1.98 (m, 2H), 1.91-1.83 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, MeOD)  $\delta$  149.00, 145.68, 143.27, 142.66, 140.11, 130.25, 130.05, 124.01, 122.80 (q, J=270.51 Hz), 118.99, 118.30, 115.91, 112.78, 94.71, 29.26, 27.75, 22.04, 21.86. HRMS (ESI) m/z calcd for C<sub>18</sub>H<sub>15</sub>F<sub>3</sub>N<sub>5</sub> [M+H]<sup>+</sup> 358.1280, found 358.1286.





**271**

2-(trifluoromethyl)-7-(3-(trifluoromethyl)-1H-pyrazol-4-yl)-8,9,10,11-tetrahydro-3H-imidazo[4,5-a]phenanthridine

**272**


7-(3-(Trifluoromethyl)-1H-pyrazol-4-yl)-8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthidine-9-carbonitrile

5



Method A: Off-white solid (106 mg, 25%). <sup>1</sup>H NMR (500 MHz, Methanol-d<sub>4</sub>) δ 7.99 (s, 1H), 7.90 (d, J=9.1 Hz, 1H), 7.85 (d, J=9.1 Hz, 1H), 3.91-3.75 (m, 2H), 2.68 (t, J=6.3 Hz, 2H), 2.07-1.92 (m, 2H), 1.94-1.77 (m, 2H); <sup>13</sup>C NMR (126 MHz, MeOD) δ 149.46, 144.26, 143.57, 140.04, 139.76, 137.30, 131.82, 130.86, 130.17, 126.46, 124.94 (q, J=269.64 Hz), 120.67, 120.32 (q, J=268.64 Hz), 118.93, 114.85, 29.42, 27.82, 21.99, 21.94. HRMS (ESI) m/z calcd for C<sub>19</sub>H<sub>14</sub>F<sub>6</sub>N<sub>5</sub> [M+H]<sup>+</sup> 426.1153, found 426.1155.


Methyl 7-(3-(trifluoromethyl)-1H-pyrazol-4-yl)-8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridine-1-carboxylate



Method A: Off-white solid (100 mg, 26%). <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) δ 8.78 (s, 1H), 8.39 (s, 1H), 8.13 (d, J=9.5, 4.5 Hz, 1H), 7.97 (d, J=9.2, 4.4 Hz, 1H), 3.61-3.50 (m, 2H), 3.48-3.36 (m, 1H), 3.12-2.95 (m, 2H), 2.37-2.22 (m, 2H). HRMS (ESI) m/z calcd for C<sub>19</sub>H<sub>14</sub>F<sub>3</sub>N<sub>6</sub> [M+H]<sup>+</sup> 383.1232, found 383.1237.

1-Methyl-7-(3-(trifluoromethyl)-1H-pyrazol-4-yl)-8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridine-9-carbonitrile

35




Method A: Off-white solid (83 mg, 20%). <sup>1</sup>H NMR (500 MHz, Methanol-d<sub>4</sub>) δ 8.36-8.34 (m, 1H), 8.33 (d, J=9.2 Hz, 1H), 8.07 (d, J=9.2 Hz, 1H), 4.09 (s, 3H), 3.41 (t, J=6.0 Hz, 2H), 2.83 (t, J=6.5 Hz, 2H), 2.04-1.96 (m, 2H), 1.94-1.87 (m, 2H); <sup>13</sup>C NMR (126 MHz, MeOD) δ 165.69, 155.80, 143.04, 140.76, 140.09, 139.80, 136.05, 134.16, 132.40, 124.22, 122.30 (268.38), 120.37, 111.65, 115.75, 109.90, 52.41, 31.10, 26.62, 21.03, 20.75; HRMS (ESI) m/z calcd for C<sub>20</sub>H<sub>17</sub>F<sub>3</sub>N<sub>5</sub>O<sub>2</sub> [M+H]<sup>+</sup> 416.1334, found 416.1343.

Method A: Off-white solid (59 mg, 15%). <sup>1</sup>H NMR (500 MHz, Methanol-d<sub>4</sub>) δ 8.37 (d, J=1.0 Hz, 1H), 8.21 (d, J=9.2 Hz, 1H), 7.89 (d, J=9.2 Hz, 1H), 3.94 (t, J=6.6 Hz, 2H), 3.49-3.42 (m, 1H), 3.20 (dd, J=17.3, 5.9 Hz, 1H), 3.09 (d, J=7.5 Hz, 1H), 3.06 (s, 3H), 2.39 (m, J=12.6, 6.0, 3.4 Hz, 1H), 2.21 (m, J=13.3, 8.5, 6.5 Hz, 1H); <sup>13</sup>C NMR (126 MHz, Methanol-d<sub>4</sub>) δ 151.72, 141.79, 137.08, 132.47, 129.46, 126.34, 123.81, 123.71, 123.64, 122.20 (q, J=270), 112.62, 109.78, 109.78, 30.62, 30.56, 29.87, 24.22, 23.60, 23.54, 17.53.

**273**

8,9,10,11-Tetrahydro-3H-pyrazolo[4,3-a]phenanthridine-7-carboxylic acid (HSD1251)




Off-white solid (40%).  $^1\text{H}$  NMR (500 MHz, DMSO-d<sub>6</sub>)  $\delta$  8.60 (s, 1H), 7.90 (d, J=9.0 Hz, 1H), 7.83 (d, J=9.5 Hz, 1H), 3.32-3.26 (m, 1H), 3.06-2.96 (m, 2H), 2.03-1.92 (m, 2H), 1.87-1.75 (m, 2H).

N-Cyclopropyl-8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridine-7-carboxamide

**274**


9-Methyl-7-(3-(trifluoromethyl)-1H-pyrazol-4-yl)-8,9,10,11-tetrahydro-3H-indazolo[5,4-c][2,7]naphthyridine



Method A: Off-white solid (96 mg, 26%).  $^1\text{H}$  NMR (500 MHz, Methanol-d<sub>4</sub>)  $\delta$  8.19 (s, 1H), 8.05-7.98 (m, 1H), 7.26 (d, J=8.9 Hz, 1H), 6.81 (d, J=8.9 Hz, 1H), 6.49-6.40 (m, 1H), 4.26 (d, J=11.1 Hz, 1H), 3.66-3.51 (m, 1H), 3.06-2.89 (m, 2H), 2.65-2.53 (m, 1H), 2.32 (s, 3H), 1.96 (t, J=10.9 Hz, 1H);  $^{13}\text{C}$  NMR (126 MHz, MeOD)  $\delta$  139.53, 136.09, 131.98, 131.66, 129.91, 123.14 (q, J=269.6 Hz), 119.98, 118.88, 117.25, 110.66, 107.76, 55.06, 54.96, 51.22, 44.41, 40.51.


6-(9-Methyl-8,9,10,11-tetrahydro-3H-indazolo[5,4-c][2,7]naphthyridin-7-yl)benzo[d]thiazol-2-amine

HSD1333 40



To a solution of HSD1251 (50 mg, 0.18 mmol) in DMF (2.5 mL) was added cyclopropylamine (0.19 mmol), HOBT (0.18 mmol), EDCI·HCl (0.18 mmol) and DIPEA (0.39 mmol). Reaction was continued for 12 h at room temperature and monitored by TLC. After completion, reaction mixture was extracted with ethyl acetate and washed with brine solution and dried over Na<sub>2</sub>SO<sub>4</sub>. Crude was purified with flash chromatography to get the desired product as white solid (70% yield, 39 mg). NMR (500 MHz, DMSO-d<sub>6</sub>)  $\delta$  8.59-8.53 (m, 2H), 7.91-7.82 (m, 2H), 3.05-2.97 (m, 2H), 2.92-2.82 (m, 1H), 2.02-1.92 (m, 2H), 1.85-1.74 (m, 2H), 0.77-0.66 (m, 2H), 0.62-0.54 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  169.02, 150.75, 143.04, 142.46, 138.96, 136.49, 129.42, 129.13, 123.13, 116.31, 114.78, 29.62, 26.70, 23.08, 22.44, 22.07, 6.21. HRMS (ESI) m/z calcd for C<sub>18</sub>H<sub>19</sub>N<sub>4</sub>O [M+H]<sup>+</sup> 307.1559, found 307.1565.


Method A: Off-white solid (81 mg, 21%).  $^1\text{H}$  NMR (500 MHz, DMSO-d<sub>6</sub>)  $\delta$  7.74 (d, J=1.7 Hz, 1H), 7.45 (s, 2H), 7.32 (d, J=8.1 Hz, 1H), 7.26 (dd, J=8.2, 1.8 Hz, 1H), 7.19 (d, J=8.8 Hz, 1H), 6.79 (d, J=8.9 Hz, 1H), 6.33 (d, J=4.8 Hz, 1H), 5.95 (s, 1H), 3.94 (d, J=11.0 Hz, 1H), 3.46-3.40 (m, 2H), 2.80-2.71 (m, 2H), 2.25-2.17 (m, 1H), 2.12 (s, 3H), 1.77 (t, J=10.6 Hz, 1H);  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  167.11, 153.11, 140.29, 135.76, 134.70, 132.26, 132.06, 131.56, 125.86, 120.50, 119.90, 118.66, 118.03, 117.84, 111.01, 107.40, 61.27, 55.89, 46.15.



## US 12,384,782 B2

**275**


N-(7-(3-(Trifluoromethyl)-1H-pyrazol-4-yl)-8,9,10,  
11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridin-9-yl)  
acetamide



HSD1337 10

15  
20

HSD1341


**276**

7-(3-(Trifluoromethyl)-1H-pyrazol-4-yl)-8,9,10,11-tetrahydro-3H-indazolo[5,4-c][2,7]naphthyridine

In this case tert-butyl 4-oxopiperidine-1-carboxylate was used as cyclic ketone using method A. Boc-group was deprotected in-situ due to presence of HCl in the reaction and desired compound was precipitated out in the reaction mixture which was filtered and washed with ethanol.

Method A: Off-white solid (137 mg, 33%). <sup>1</sup>H NMR (500 MHz, Methanol-d<sub>4</sub>) δ 8.56 (s, 1H), 8.02 (s, 1H), 7.86 (s, 2H), 4.25-4.09 (m, 1H), 3.63-3.55 (m, 1H), 3.50-3.42 (m, 2H), 3.02-2.92 (m, 1H), 2.71-2.59 (m, 1H), 2.40-2.30 (m, 1H), 1.98-1.90 (m, 4H); <sup>13</sup>C NMR (126 MHz, DMSO) δ 169.42, 153.60, 148.04, 140.41, 138.26, 134.78, 129.37, 127.68, 122.95, 122.23, 115.48, 110.76, 44.12, 34.25, 29.21, 27.37, 23.11. HRMS (ESI) m/z calcd for C<sub>20</sub>H<sub>18</sub>F<sub>3</sub>N<sub>6</sub>O [M+H]<sup>+</sup> 415.1494, found 415.1498.


7-(3-(Difluoromethyl)-1-methyl-1H-pyrazol-4-yl)-5-fluoro-8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridine



HSD1340 45

50  
55

HSD1342



Method A: Off-white solid (37 mg, 10%). <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) δ 8.50 (s, 1H), 8.27 (s, 1H), 7.69-7.62 (m, 1H), 7.49 (t, J=54.7 Hz, 1H), 3.97 (s, 3H), 3.32-3.24 (m, 2H), 2.94-2.83 (m, 2H), 2.02-1.92 (m, 2H), 1.85-1.73 (m, 2H); <sup>13</sup>C NMR (126 MHz, DMSO) δ 158.06, 156.05, 148.40, 144.52, 144.34, 144.16, 143.02, 136.82, 136.43, 134.20, 132.97, 131.01, 122.11, 119.91, 113.31, 112.93, 111.45, 109.58, 98.48, 98.29, 31.15, 29.80, 28.54, 22.27.

Method A: Same cyclic ketone as in HSD1341: Off-white solid (60 mg, 16%). <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) δ 8.60 (s, 1H), 8.28 (s, 1H), 7.71 (d, J=10.0 Hz, 1H), 3.85 (s, 2H), 3.24 (q, J=5.1, 4.2 Hz, 2H), 3.16 (t, J=4.4 Hz, 2H); <sup>13</sup>C NMR (126 MHz, DMSO) δ 158.12 (d, J=253.26 Hz), 146.55, 141.41, 139.52, 139.23, 138.48, 134.96, 131.48, 123.42 (q, J=269.64 Hz), 122.86, 118.58, 112.68, 99.76, 97.55, 55.01, 47.19, 42.89; HRMS (ESI) m/z calcd for C<sub>17</sub>H<sub>13</sub>F<sub>4</sub>N<sub>6</sub>[M+H]<sup>+</sup> 377.1138, found 377.1138.

**277**


N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridine-7-carboxamide

**278**


7-(Isoquinolin-6-yl)-8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridine

5

H8D1343



10



HSD1347

20


To a solution of HSD1251 (50 mg, 0.18 mmol) in DMF (2.5 mL) was added 4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)aniline (0.19 mmol), HATU (0.18 mmol), and DIPEA (0.39 mmol). Reaction was continued for 12 h at room temperature and monitored by TLC. After completion, reaction mixture was extracted with ethyl acetate and washed with brine solution and dried over  $\text{Na}_2\text{SO}_4$ . Crude was purified with flash chromatography to get the desired product as Off-white solid (50% yield, 47 mg).  $^1\text{H}$  NMR (500 MHz, DMSO- $d_6$ )  $\delta$  10.93 (s, 1H), 8.63 (s, 1H), 8.29 (d,  $J=2.2$  Hz, 1H), 8.05 (dd,  $J=8.5$ , 2.3 Hz, 1H), 7.98-7.89 (m, 2H), 7.71 (d,  $J=8.5$  Hz, 1H), 3.56 (s, 2H), 3.34-3.30 (m, 2H), 3.13 (t,  $J=6.2$  Hz, 2H), 2.37 (s, 8H), 2.14 (s, 3H), 1.99 (ddt,  $J=8.9$ , 6.3, 2.9 Hz, 2H), 1.87-1.79 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  166.54, 149.19, 143.71, 142.60, 138.52, 132.53, 131.81, 129.74, 129.42, 128.11 (q,  $J=28.9$  Hz), 125.91 (q,  $J=274.6$  Hz), 123.78, 123.53, 117.19, 117.14, 116.03, 57.94, 55.22, 53.19, 46.22, 29.73, 26.89, 22.37, 22.07; HRMS (ESI) m/z calcd for  $\text{C}_{28}\text{H}_{30}\text{F}_3\text{N}_6\text{O} [\text{M}+\text{H}]^+$  523.2433, found 523.2433.

Method A: Off-white solid (178 mg, 51%).  $^1\text{H}$  NMR (500 MHz, DMSO- $d_6$ )  $\delta$  9.34 (s, 1H), 8.65-8.45 (m, 2H), 8.23-8.08 (m, 2H), 7.94-7.75 (m, 4H), 3.36-3.01 (m, 2H), 2.84-2.64 (m, 2H), 2.03-1.80 (m, 2H), 1.74-1.50 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  155.87, 152.56, 143.58, 143.17, 142.64, 138.79, 136.42, 135.77, 135.39, 129.57, 129.30, 127.89, 127.63, 127.02, 124.06, 122.13, 121.09, 116.40, 114.60, 29.61, 28.83, 22.51, 22.40.

7-(Isoquinolin-8-yl)-8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridine

7-(2-aminobenzo[d]thiazol-6-yl)-3H-pyrazolo[4,3-f]quinoline-9-carboxylic acid


45



50

HSD1345

55



HSD1349

Method A: Brown solid (140 mg, 40%).  $^1\text{H}$  NMR (500 MHz, Methanol- $d_4$ )  $\delta$  8.67 (d,  $J=1.0$  Hz, 1H), 8.61 (s, 1H), 8.46 (d,  $J=5.8$  Hz, 1H), 8.07 (dt,  $J=8.4$ , 1.1 Hz, 1H), 7.95-7.90 (m, 2H), 7.86 (s, 2H), 7.70 (dd,  $J=7.0$ , 1.1 Hz, 1H), 3.45-3.36 (m, 2H), 2.71-2.57 (m, 1H), 2.42-2.30 (m, 1H), 2.08-2.02 (m, 2H), 1.84-1.71 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, MeOD)  $\delta$  154.18, 149.50, 144.02, 143.31, 141.71, 138.68, 136.43, 130.58, 130.53, 128.48, 128.34, 126.97, 126.93, 122.66, 121.40, 115.96, 29.52, 27.69, 22.02, 21.75.

Method A: Brown solid (126 mg, 35%).  $^1\text{H}$  NMR (500 MHz, DMSO- $d_6$ )  $\delta$  8.70 (d,  $J=1.8$  Hz, 1H), 8.48-8.35 (m, 3H), 8.32 (s, 1H), 8.25 (dd,  $J=8.5$ , 1.9 Hz, 1H), 8.00 (d,  $J=9.2$  Hz, 1H), 7.96 (d,  $J=9.1$  Hz, 1H), 7.51 (d,  $J=8.5$  Hz, 1H);  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  170.36, 169.08, 153.15, 146.62, 138.70, 132.42, 129.93, 129.24, 125.78, 120.77, 117.16, 117.04, 115.21.

US 12,384,782 B2


**279**

7-(Isoquinolin-7-yl)-8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridine


**280**

7-(Isoquinolin-4-yl)-8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridine

5



HSD1350



HSD1352


Method A: Off-white solid (105 mg, 30%). <sup>1</sup>H NMR (500 MHz, Methanol-d<sub>4</sub>) δ 9.33 (d, J=1.4 Hz, 1H), 8.61 (s, 1H), 8.50 (dd, J=5.9, 1.4 Hz, 1H), 8.29 (s, 1H), 8.09 (d, J=8.4 Hz, 1H), 7.98 (dt, J=8.4, 1.6 Hz, 1H), 7.93-7.85 (m, 2H), 3.47-3.37 (m, 2H), 2.84 (t, J=6.2 Hz, 2H), 2.17-2.08 (m, 2H), 1.89-1.82 (m, 2H); <sup>13</sup>C NMR (126 MHz, MeOD) δ 156.08, 152.22, 143.84, 143.20, 141.99, 140.04, 138.79, 136.00, 135.65, 132.00, 129.69, 128.57, 128.47, 127.97, 126.35, 122.41, 120.88, 113.80, 29.64, 28.49, 22.13, 22.04.

Method A: Off-white solid (262 mg, 75%). <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) δ 9.41 (d, J=0.9 Hz, 1H), 8.61 (s, 1H), 8.50 (s, 1H), 8.28-8.14 (m, 1H), 7.94-7.80 (m, 2H), 7.73-7.62 (m, 2H), 7.38-7.31 (m, 1H), 3.44-3.35 (m, 2H), 2.64-2.54 (m, 1H), 2.40-2.27 (m, 1H), 2.00-1.95 (m, 3H), 1.77-1.65 (m, 2H); <sup>13</sup>C NMR (126 MHz, DMSO) δ 153.43, 152.80, 143.82, 142.90, 142.62, 138.81, 136.47, 134.12, 132.07, 131.60, 130.70, 129.60, 128.54, 128.33, 128.02, 124.62, 122.35, 116.52, 114.67, 29.59, 27.87, 22.50, 22.16. HRMS (ESI) m/z calcd for C<sub>23</sub>H<sub>19</sub>N<sub>4</sub> [M+H]<sup>+</sup> 351.1610. found 351.1611.


7-(Quinolin-2-yl)-8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridine

9-(Pyridin-2-yl)-7-(3-(trifluoromethyl)-1H-pyrazol-4-yl)-3H-pyrazolo[4,3-f]quinoline

35



HSD1351



HSD1356

Method A: Off-white solid (150 mg, 43%). <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) δ 8.61 (s, 1H), 8.50 (d, J=8.5 Hz, 1H), 8.09-8.03 (m, 2H), 8.00 (d, J=8.4 Hz, 1H), 7.89 (s, 2H), 7.80 (dd, J=8.3, 6.8, 1.5 Hz, 1H), 7.69-7.62 (m, 1H), 3.38 (d, J=6.6 Hz, 2H), 3.09 (t, J=6.2 Hz, 2H), 2.02 (dp, J=9.3, 3.2 Hz, 2H), 1.82-1.71 (m, 2H); <sup>13</sup>C NMR (126 MHz, DMSO) δ 159.31, 154.53, 146.93, 143.32, 143.03, 138.94, 136.97, 136.58, 130.38, 130.26, 129.68, 129.51, 128.37, 127.38, 122.95, 122.49, 116.48, 114.65, 29.86, 28.31, 22.54, 22.43; HRMS (ESI) m/z calcd for C<sub>23</sub>H<sub>19</sub>N<sub>4</sub> [M+H]<sup>+</sup> 351.1610, found 351.1608.

Method C: Off-white solid (160 mg, 42%). <sup>1</sup>H NMR (500 MHz, Methanol-d<sub>4</sub>) δ 8.80 (ddt, J=5.0, 1.7, 0.7 Hz, 1H), 8.37 (s, 1H), 8.14 (td, J=7.7, 1.7 Hz, 1H), 8.01 (d, J=9.2 Hz, 1H), 7.92 (dd, J=9.3, 0.9 Hz, 1H), 7.82-7.65 (m, 3H), 6.69 (s, 1H); <sup>13</sup>C NMR (126 MHz, MeOD) δ 157.76, 157.73, 149.27, 147.72, 146.52, 145.30, 139.22 (q, J=36.54 Hz), 138.53, 131.12, 129.05, 129.02, 124.48, 124.45, 124.33, 123.02 (q, J=268.38 Hz), 121.14, 120.71, 119.57, 115.74.

40

45


50

55

## US 12,384,782 B2

**281**


7-(Quinolin-6-yl)-8,9,10,11-tetrahydro-3H-pyrazolo  
[4,3-a]phenanthridine



HSD1357

**282**

3-Chloro-4-(8,9,10,11-tetrahydro-3H-pyrazolo[4,3-  
a]phenanthridin-7-yl)phenol




HSD1359

Method A: Off-white solid (192 mg, 55%).  $^1\text{H}$  NMR (500 MHz, DMSO- $d_6$ )  $\delta$  9.01 (dd,  $J=4.6, 1.7$  Hz, 1H), 8.62 (s, 1H), 8.13 (d,  $J=8.5$  Hz, 1H), 7.90 (d,  $J=9.1$  Hz, 1H), 7.82 (d,  $J=8.8$  Hz, 1H), 7.77 (t,  $J=7.6$  Hz, 1H), 7.59-7.52 (m, 1H), 7.49 (t,  $J=7.6$  Hz, 1H), 7.34 (d,  $J=8.3$  Hz, 1H), 3.49-3.36 (m, 2H), 2.61-2.54 (m, 2H), 2.39-2.23 (m, 1H), 2.02-1.87 (m, 2H), 1.77-1.60 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  153.87, 150.73, 148.39, 146.91, 143.65, 142.78, 138.83, 136.48, 130.02, 129.95, 129.78, 129.52, 127.55, 126.67, 125.91, 122.43, 121.73, 116.49, 114.82, 29.57, 27.63, 22.47, 22.06 HRMS (ESI) m/z calcd for  $\text{C}_{23}\text{H}_{19}\text{N}_4$  [M+H] $^+$  351.1610. found 351.1611.


7-(Quinolin-3-yl)-8,9,10,11-tetrahydro-3H-pyrazolo  
[4,3-a]phenanthridine

Method A: Off-white solid (178 mg, 51%).  $^1\text{H}$  NMR (500 MHz, Methanol- $d_4$ )  $\delta$  8.55 (s, 1H), 7.88-7.76 (m, 2H), 7.18 (d,  $J=8.3$  Hz, 1H), 6.97 (d,  $J=2.4$  Hz, 1H), 6.88 (dd,  $J=8.3, 2.4$  Hz, 1H), 3.39-3.31 (m, 2H), 2.67 (dt,  $J=17.3, 6.3$  Hz, 1H), 2.54 (dt,  $J=17.2, 6.2$  Hz, 1H), 2.07-1.98 (m, 2H), 1.91-1.74 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, MeOD)  $\delta$  158.50, 155.40, 143.33, 142.83, 138.70, 135.81, 132.99, 130.85, 130.10, 128.23, 122.36, 116.12, 115.69, 114.11, 113.67, 29.44, 27.16, 22.10, 21.82. HRMS (ESI) m/z calcd for  $\text{C}_{20}\text{H}_{17}\text{ClN}_3\text{O}$  [M+H] $^+$  350.1060, found 350.1063.

3-Fluoro-5-(8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]  
phenanthridin-7-yl)phenol



HSD1358




HSD1360

Method A: Off-white solid (162 mg, 46%).  $^1\text{H}$  NMR (500 MHz, DMSO- $d_6$ )  $\delta$  9.14 (s, 1H), 8.61-8.60 (m, 2H), 8.10 (t,  $J=7.25$  Hz, 2H), 7.89 (s, 2H), 7.83 (t,  $J=6.95$  Hz, 1H), 7.68 (d,  $J=7.8$  Hz, 1H), 3.39 (t,  $J=5.65$  Hz, 2H), 2.92 (t,  $J=5.75$  Hz, 2H), 2.06-2.02 (m, 2H), 2.07-1.98 (m, 2H), 1.78-1.77 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, MeOD)  $\delta$  153.88, 151.60, 147.28, 143.90, 142.87, 138.80, 136.53, 136.17, 134.00, 130.35, 129.97, 129.70, 129.19, 128.96, 127.45, 122.16, 116.44, 114.74, 29.75, 28.86, 22.58; HRMS (ESI) m/z calcd for  $\text{C}_{23}\text{H}_{19}\text{N}_4$  [M+H] $^+$  351.1610, found 351.1613.

Method A: Off-white solid (117 mg, 35%).  $^1\text{H}$  NMR (500 MHz, Methanol- $d_4$ )  $\delta$  8.59 (s, 1H), 7.91-7.82 (m, 2H), 7.20 (d,  $J=8.3$  Hz, 1H), 6.98 (d,  $J=2.4$  Hz, 1H), 6.89 (dd,  $J=8.3, 2.4$  Hz, 1H), 3.48-3.35 (m, 2H), 2.70 (dt,  $J=17.3, 6.3$  Hz, 1H), 2.57 (dt,  $J=17.2, 6.2$  Hz, 1H), 2.10-2.03 (m, 2H), 1.92-1.82 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, MeOD)  $\delta$  158.52, 155.48, 143.37, 142.83, 135.85, 132.99, 130.91, 130.84, 130.11, 128.26, 122.39, 116.16, 115.69, 114.11, 113.71, 29.48, 27.18, 22.13, 21.84.

**283**


7-(Isoquinolin-1-yl)-8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridine

**284**

1-Methyl-7-(1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridine-9-carbonitrile

5

HSD1361

10  
15  
20

HSD1363


35

Method A: Off-white solid (54 mg, 13%). <sup>1</sup>H NMR (500 MHz, Methanol-d<sub>4</sub>) δ 7.96 (s, 1H), 7.85-7.75 (m, 2H), 4.07 (s, 3H), 3.74-3.64 (m, 2H), 3.14-3.07 (m, 1H), 3.03-2.96 (m, 1H), 2.33-2.25 (m, 1H), 2.13-2.04 (m, 1H); <sup>13</sup>C NMR (126 MHz, MeOD) δ 147.28, 143.95, 143.52, 141.31, 141.20, 139.12, 132.56, 128.83, 126.48, 123.95, 122.46 (q, J=269.64 Hz), 121.58, 118.93, 114.92, 114.10, 38.46, 30.48, 29.49, 25.02, 24.24. HRMS (ESI) m/z calcd for C<sub>21</sub>H<sub>18</sub>F<sub>3</sub>N<sub>6</sub> [M+H]<sup>+</sup> 411.1545 found 411.1548.


7-(1-Methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridine

40

HSD1362

45  
50  
55

HSD1365




Method A: Off-white solid (163 mg, 42%). <sup>1</sup>H NMR (500 MHz, Methanol-d<sub>4</sub>) δ 8.22 (s, 1H), 7.92 (d, J=9.2 Hz, 1H), 7.86 (d, J=9.2 Hz, 1H), 4.15 (d, J=1.1 Hz, 3H), 3.79 (t, J=6.1 Hz, 2H), 2.73 (t, J=6.2 Hz, 2H), 2.01-1.83 (m, 4H); <sup>13</sup>C NMR (126 MHz, MeOD) δ 158.09, 154.86, 141.34, 135.93, 132.97, 131.61, 125.26, 123.06, 118.25, 118.16, 101.38, 56.07, 31.36, 27.62, 21.62, 21.18. HRMS (ESI) m/z calcd for C<sub>19</sub>H<sub>17</sub>F<sub>3</sub>N<sub>5</sub>O [M+H]<sup>+</sup> 388.1385, found 388.1390.

Method A: Off-white solid (112 mg, 30%). <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) δ 8.58-8.53 (m, 1H), 8.20-8.13 (m, 1H), 7.88-7.80 (m, 1H), 7.80-7.73 (m, 1H), 4.03-3.96 (m, 3H), 3.28-3.14 (m, 2H), 2.69 (t, J=6.6 Hz, 2H), 2.01-1.93 (m, 2H), 1.81-1.75 (m, 2H); <sup>13</sup>C NMR (126 MHz, DMSO) δ 148.11, 143.48, 142.15, 138.76, 138.47, 136.40, 133.48, 130.33, 129.58, 123.20 (q, J=270.9 Hz), 121.98, 120.45, 116.40, 114.51, 29.54, 28.23, 22.57, 22.30. HRMS (ESI) m/z calcd for C<sub>19</sub>H<sub>17</sub>F<sub>3</sub>N<sub>5</sub>[M+H]<sup>+</sup> 372.1436, found 372.1444.

**285**

7-(3-(Trifluoromethyl)-1H-pyrazol-4-yl)-3,8,10,11-tetrahydropyrazolo[4,3-f]thiopyrano[3,4-c]quinolone




HSD1366

5

**286**

9-Cyclopropyl-7-(3-(trifluoromethyl)-1H-pyrazol-4-yl)-3H-pyrazolo[4,3-f]quinolone



HSD1371

10

15

20


Method A: Gray solid (124 mg, 33%).  $^1\text{H}$  NMR (500 MHz, DMSO- $d_6$ )  $\delta$  8.78 (s, 1H), 8.44 (s, 1H), 8.15 (d,  $J=9.1$  Hz, 1H), 8.02 (d,  $J=9.2$  Hz, 1H), 3.80 (s, 2H), 3.69 (t,  $J=6.1$  Hz, 2H), 3.17 (t,  $J=6.0$  Hz, 2H). HRMS (ESI)  $m/z$  calcd for  $C_{17}\text{H}_{13}\text{F}_3\text{N}_5\text{S} [\text{M}+\text{H}]^+$  376.0844, found 376.0840.

1-(7-(3-(Trifluoromethyl)-1H-pyrazol-4-yl)-3,8,10,11-tetrahydro-9H-indazolo[5,4-c][2,7]naphthyridin-9-yl)ethan-1-one

Method A: Off-white solid (124 mg, 36%).  $^1\text{H}$  NMR (500 MHz, DMSO- $d_6$ )  $\delta$  8.80 (s, 1H), 8.66 (s, 1H), 7.91 (dd,  $J=9.1$ , 2.8 Hz, 1H), 7.80 (d,  $J=9.1$  Hz, 1H), 7.62 (d,  $J=2.8$  Hz, 1H), 2.69-2.53 (m, 1H), 1.28 (dq,  $J=9.3$ , 4.0, 3.2 Hz, 2H), 0.94 (di,  $J=5.2$ , 2.4 Hz, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  148.26, 147.74, 145.97, 145.51, 138.44, 131.97, 129.51, 123.71, 122.38, 121.62, 121.41, 118.34, 116.44, 115.57, 16.42, 7.59.

4-(3,8,9,10,11,12-Hexahydrocyclohepta[c]pyrazolo[4,3-f]quinolin-7-yl)-2,6-diiodophenol

35




HSD1370

40

45

50

55



HSD1376

Method C: Off-white solid (60 mg, 15%).  $^1\text{H}$  NMR (500 MHz, DMSO- $d_6$ )  $\delta$  8.76 (d,  $J=27.3$  Hz, 1H), 8.45 (d,  $J=10.1$  Hz, 1H), 8.13 (d,  $J=9.1$  Hz, 1H), 7.90 (d,  $J=9.1$  Hz, 1H), 4.61 (s, 2H), 3.93 (t,  $J=5.8$  Hz, 2H), 3.64 (d,  $J=6.0$  Hz, 2H), 3.49 (d,  $J=6.1$  Hz, 1H), 2.16 (s, 2H), 1.99 (s, 1H);  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  169.21, 140.24, 139.55, 139.27, 134.78, 132.70, 131.88, 128.81, 123.06, 122.63, 120.92, 115.44, 67.49, 42.57, 42.23, 30.01, 25.60. HRMS (ESI)  $m/z$  calcd for  $C_{19}\text{H}_{16}\text{F}_3\text{N}_6\text{O} [\text{M}+\text{H}]^+$  401.1338, found 401.1328.

Method A: Yellow solid (203 mg, 35%).  $^1\text{H}$  NMR (500 MHz, DMSO- $d_6$ )  $\delta$  9.92 (s, 1H), 8.72 (d,  $J=17.9$  Hz, 1H), 8.00 (d,  $J=9.1$  Hz, 1H), 7.93-7.84 (m, 3H), 3.61-3.52 (m, 2H), 3.04-2.96 (m, 2H), 1.97-1.81 (m, 4H), 1.70-1.59 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  156.48, 150.93, 145.52, 141.82, 140.39, 137.85, 136.37, 133.12, 128.72, 121.97, 115.53, 87.03, 31.53, 31.18, 30.00, 26.90, 24.65. HRMS (ESI)  $m/z$  calcd for  $C_{21}\text{H}_{18}\text{I}_2\text{N}_3\text{O} [\text{M}+\text{H}]^+$  581.9539, found 581.9544.


**287**

7-(4-Hydroxy-3,5-diiodophenyl)-8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridin-9-ol


**288**

7-(4-Hydroxy-3,5-diiodophenyl)-8,9,10,10-tetrahydro-3H-pyrazolo[4,3-a]phenanthridine-1-carbonitrile

5



HSD1377

10  
15  
20


HSD1380

Method A: Yellow solid (175 mg, 30%). <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) δ 10.20 (s, 1H), 8.80 (s, 1H), 8.22 (d, J=9.3 Hz, 1H), 8.16 (d, J=9.1 Hz, 1H), 8.12 (s, 2H), 4.07 (dq, J=10.8, 6.9, 4.9 Hz, 1H), 3.56 (dt, J=19.1, 6.2 Hz, 1H), 3.50-3.46 (m, 1H), 2.99 (dd, J=16.5, 4.1 Hz, 1H), 2.75 (dd, J=16.5, 6.7 Hz, 1H), 2.20-2.09 (m, 1H), 2.07-1.96 (m, 1H); <sup>13</sup>C NMR (126 MHz, DMSO) δ 157.81, 154.46, 148.61, 140.62, 136.28, 135.37, 130.03, 122.73, 114.93, 87.09, 63.37, 36.50, 29.26, 28.51. HRMS (ESI) m/z calcd for C<sub>20</sub>H<sub>16</sub>I<sub>2</sub>N<sub>3</sub>O<sub>2</sub> [M+H]<sup>+</sup> 583.9332, found 583.9336.


2,6-Dibromo-4-(8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridin-7-yl)phenol

Method A: Yellow solid (224 mg, 38%). <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) δ 9.77 (s, 1H), 7.93 (s, 2H), 7.86-7.77 (m, 2H), 3.40 (t, J=6.5 Hz, 2H), 2.77 (t, J=6.2 Hz, 2H), 1.90 (ddt, J=9.2, 6.5, 3.0 Hz, 2H), 1.75 (ddt, J=9.2, 6.4, 3.0 Hz, 2H); <sup>13</sup>C NMR (126 MHz, DMSO) δ 155.88, 155.23, 144.40, 143.50, 140.00, 139.78, 136.45, 131.67, 129.81, 121.16, 120.30, 117.66, 116.23, 114.52, 86.91, 31.76, 28.66, 22.03, 21.81. HRMS (ESI) m/z calcd for C<sub>22</sub>H<sub>15</sub>I<sub>2</sub>N<sub>3</sub>O [M+H]<sup>+</sup> 590.9304, found 590.9325.

2,6-Diido-4-(1-methyl-8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridin-7-yl)phenol

35  
40  
45  
50  
55

HSD1379



HSD1381

Method A: Off-white solid (113 mg, 24%). <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>4</sub>) δ 10.25 (s, 1H), 8.58 (s, 1H), 7.92 (d, J=9.1 Hz, 1H), 7.85 (d, J=9.1 Hz, 1H), 7.79 (s, 2H), 3.29 (d, J=6.6 Hz, 2H), 2.80 (t, J=6.1 Hz, 2H), 2.03-1.93 (m, 2H), 1.79-1.67 (m, 2H); <sup>13</sup>C NMR (126 MHz, DMSO) δ 152.73, 151.40, 144.73, 142.09, 136.53, 133.76, 133.49, 129.93, 127.88, 122.31, 115.95, 111.95, 29.92, 28.66, 22.34. HRMS (ESI) m/z calcd for C<sub>20</sub>H<sub>16</sub>Br<sub>2</sub>N<sub>3</sub>O [M+H]<sup>+</sup> 471.9660, found 471.9645.

Method A: Yellow solid (244 mg, 42%). <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) δ 10.08 (s, 1H), 8.04 (d, J=9.6 Hz, 3H), 7.95 (d, J=8.9 Hz, 1H), 3.61-3.50 (m, 2H), 2.92 (s, 3H), 2.82-2.71 (m, 2H), 1.87-1.74 (m, 4H); <sup>13</sup>C NMR (126 MHz, DMSO) δ 157.30, 140.34, 130.74, 125.25, 87.10, 32.52, 27.67, 21.87, 21.55. HRMS (ESI) m/z calcd for C<sub>21</sub>H<sub>18</sub>I<sub>2</sub>N<sub>3</sub>O [M+H]<sup>+</sup> 581.9539 found 581.9534.


**289**

(5-(8,9,10,11-Tetrahydro-3H-pyrazolo[4,3-a]phenanthridin-7-yl)thiophen-3-yl)boronic acid

**290**

1-Methyl-7-(3-(trifluoromethyl)-1H-pyrazol-4-yl)-8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridin-9-amine

5



Method A: Off-white solid (157, 45%).  $^1\text{H}$  NMR (500 MHz, DMSO-d<sub>6</sub>)  $\delta$  8.54 (s, 1H), 8.08 (s, 2H), 8.05 (s, 1H), 7.91 (d, J=6.8 Hz, 1H), 7.84 (d, J=9.1 Hz, 1H), 7.78 (d, J=9.0 Hz, 1H), 3.11 (t, J=6.1 Hz, 2H), 2.46 (s, 2H), 2.06-1.98 (m, 2H), 1.88 (qd, J=8.6, 7.1, 3.9 Hz, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO-d<sub>6</sub>)  $\delta$  149.49, 145.18, 143.33, 143.01, 138.66, 137.70, 136.36, 133.33, 129.32, 128.70, 121.48, 116.41, 114.79, 30.05, 29.29, 22.62, 22.38.

N-(2-(4-Methylpiperazin-1-yl)ethyl)-7-(3-(trifluoromethyl)-1H-pyrazol-4-yl)-8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridine-1-carboxamide


Method A: Off-white solid (89 mg, 23%).  $^1\text{H}$  NMR (500 MHz, DMSO-d<sub>6</sub>)  $\delta$  8.55 (s, 2H), 8.44 (s, 1H), 8.10 (d, J=9.1 Hz, 1H), 8.02 (d, J=9.3 Hz, 1H), 3.82-3.71 (m, 2H), 3.68-3.59 (m, 1H), 3.14-3.04 (m, 1H), 2.94 (s, 3H), 2.90-2.79 (m, 1H), 2.42-2.28 (m, 1H), 1.91-1.78 (m, 1H);  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  144.18, 140.74, 139.47, 139.18, 138.89, 132.95, 129.06, 125.24, 122.97 (q, J=269.64 Hz), 113.03, 45.50, 31.39, 30.49, 26.00, 18.97. HRMS (ESI) m/z calcd for C<sub>19</sub>H<sub>18</sub>F<sub>3</sub>N<sub>6</sub> [M+H]<sup>+</sup> 387.1545, found 387.1540.

(2-Methoxy-5-(8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridin-7-yl)phenyl)boronic acid

35

30

40




Pale yellow solid.  $^1\text{H}$  NMR (500 MHz, Methanol-d<sub>4</sub>)  $\delta$  8.29 (s, 1H), 8.25 (d, J=9.2 Hz, 1H), 8.03 (d, J=9.2 Hz, 1H), 3.75 (t, J=6.4 Hz, 2H), 3.58 (t, J=6.0 Hz, 2H), 3.41 (s, 4H), 3.19-3.05 (m, 4H), 3.01-2.96 (m, 2H), 2.91 (s, 3H), 2.81 (t, J=6.5 Hz, 2H), 2.01-1.92 (m, 2H), 1.92-1.87 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, MeOD)  $\delta$  167.01, 154.73, 144.30, 143.47, 140.67, 136.64, 133.59, 132.09, 124.38, 122.36 (q, J=268.38 Hz), 121.24, 119.27, 111.50, 110.90, 55.67, 52.74, 49.61, 42.13, 36.36, 30.49, 26.83, 21.20, 20.97. HRMS (ESI) m/z calcd for C<sub>26</sub>H<sub>30</sub>F<sub>3</sub>N<sub>8</sub>O [M+H]<sup>+</sup> 527.2495, found 527.2495.

Method A: White solid (166 mg, 48%).  $^1\text{H}$  NMR (500 MHz, DMSO-d<sub>6</sub>)  $\delta$  8.57-8.51 (m, 1H), 7.83 (s, 2H), 7.76 (d, J=6.0 Hz, 3H), 7.60 (dd, J=8.5, 2.4 Hz, 1H), 7.06 (d, J=8.5 Hz, 1H), 3.87 (s, 3H), 3.36-3.32 (m, 2H), 2.78 (t, J=6.1 Hz, 2H), 2.05-1.95 (m, 2H), 1.78-1.69 (m, 2H);  $^{13}\text{C}$  NMR (126 MHz, DMSO)  $\delta$  163.59, 156.90, 143.67, 142.28, 138.64, 136.72, 136.33, 133.31, 132.83, 129.70, 129.44, 121.61, 116.55, 114.27, 110.23, 55.95, 29.73, 29.20, 22.67, 22.62. HRMS (ESI) m/z calcd for C<sub>21</sub>H<sub>21</sub>BN<sub>3</sub>O<sub>3</sub>[M+H]<sup>+</sup> 374.1676, found 374.1671.


**291**

(5-(8,9,10,11-Tetrahydro-3H-pyrazolo[4,3-a]phenanthridin-7-yl)furan-2-yl)boronic acid



Method A: Yellow solid (133 mg, 40%). <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) δ 8.64-8.60 (m, 1H), 8.02-7.94 (m, 2H), 7.31-7.21 (m, 1H), 6.79 (m, 1H), 3.35-3.34 (m, 2H), 3.07-3.03 (m, 2H), 2.00 (s, 2H), 1.86 (s, 2H); <sup>13</sup>C NMR (126 MHz, DMSO) δ 154.27, 145.25, 129.18, 122.17, 116.19, 112.66, 30.33, 28.05, 22.07. HRMS (ESI) m/z calcd for C<sub>18</sub>H<sub>17</sub>BN<sub>3</sub>O<sub>3</sub> [M+H]<sup>+</sup> 334.1363, found 334.1363.

5-Fluoro-7-(1H-pyrazol-4-yl)-8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridine




Method A: Off-white solid (64 mg, 21%). <sup>1</sup>H NMR (500 MHz, Methanol-d<sub>4</sub>) δ 8.81 (s, 1H), 8.29 (s, 2H), 8.00 (d, J=10.3 Hz, 1H), 3.57 (t, J=6.4 Hz, 2H), 3.09 (t, J=6.2 Hz, 2H), 2.20-2.10 (m, 2H), 2.03-1.82 (m, 2H); <sup>13</sup>C NMR (126 MHz, MeOD) δ 153.31, 146.28, 135.79, 133.97, 133.51, 126.93, 123.44, 112.98, 111.93, 103.01, 30.97, 27.96, 21.18. HRMS (ESI) m/z calcd for C<sub>17</sub>H<sub>15</sub>FN<sub>5</sub> [M+H]<sup>+</sup> 308.1311, found 308.1312.

(7-(3-(Trifluoromethyl)-1H-pyrazol-4-yl)-8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridin-1-yl) methanol

Compound HSD1329 (100 mg) was dissolved in anhydrous THF and cooled on using dry ice acetone under argon. After that LAH (1 molar solution in THF, 1 equiv.) was added dropwise and reaction was continued to stir for overnight at room temperature. Reaction was quenched by slow addition of water and THF mixture slowly under cooling condition. Reaction mixture filtered and purified by flash column chromatography.

**292**


HSD1392



white solid (75 mg, 80%). <sup>1</sup>H NMR (500 MHz, Methanol-d<sub>4</sub>) δ 7.98 (s, 1H), 7.79 (d, J=8.4 Hz, 2H), 5.24 (s, 2H), 3.70 (s, 2H), 2.71 (t, J=5.8 Hz, 2H), 2.00-1.84 (m, 4H); <sup>13</sup>C NMR (126 MHz, MeOD) δ 148.12, 144.28, 143.66, 139.73, 133.60, 130.48, 130.17, 128.88, 124.42, 118.85, 114.15, 60.41, 29.11, 27.68, 22.06, 21.83. HRMS (ESI) m/z calcd for C<sub>19</sub>H<sub>17</sub>F<sub>3</sub>N<sub>5</sub>O [M+H]<sup>+</sup> 388.1385, found 388.1380.

1-Methyl-7-(3-(trifluoromethyl)-1H-pyrazol-4-yl)-8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridine-8,9,9,10,10,-d<sub>6</sub>


Deuterated (D<sub>8</sub>) cyclohexanone was used as a ketone using same method A



Method A: Off-white solid (68 mg, 18%). <sup>1</sup>H NMR (500 MHz, Methanol-d<sub>4</sub>) δ 8.20 (s, 1H), 7.72 (d, J=8.9 Hz, 1H), 7.68 (d, J=8.7 Hz, 1H), 3.40-3.37 (m, 2H), 2.89 (s, 3H); HRMS (ESI) m/z calcd for C<sub>19</sub>H<sub>11</sub>D<sub>6</sub>F<sub>3</sub>N<sub>5</sub> [M+H]<sup>+</sup> 378.1813, 378.1804.

5-Fluoro-7-(3-(trifluoromethyl)-1H-pyrazol-4-yl)-8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridine-8,9,9,10,10,-d<sub>6</sub>

Deuterated (D<sub>8</sub>) cyclohexanone was used as a ketone using same method A




**293**

Method A: Off-white solid (76 mg, 20%).  $^1\text{H}$  NMR (500 MHz, Methanol-d<sub>4</sub>)  $\delta$  8.80 (s, 1H), 8.24 (s, 1H), 7.96 (d, J=9.9 Hz, 1H), 3.53 (s, 2H);  $^{13}\text{C}$  NMR (126 MHz, MeOD)  $\delta$  154.06 (q, J=255.78 Hz), 144.99, 140.18, 139.89, 139.23, 134.60, 134.02, 131.99, 128.78, 124.39, 122.45 (q, J=269.64 Hz), 118.14, 112.31, 111.91, 102.86, 30.30, 26.74, 20.13, 16.82. HRMS (ESI) m/z calcd for C<sub>18</sub>H<sub>8</sub>D<sub>6</sub>F<sub>4</sub>N<sub>5</sub>[M+H]<sup>+</sup> 382.1562 found 382.1556.


7-(3-(Trifluoromethyl)-1H-pyrazol-4-yl)-3H-pyrazolo[4,3-f]quinoline-9-carboxylic acid

Pyruvic acid as ketone substrate.



Method A: Pale yellow solid (100 mg, 29%).  $^1\text{H}$  NMR (500 MHz, Methanol-d<sub>4</sub>)  $\delta$  8.69 (s, 1H), 8.32 (s, 1H), 7.96-7.87 (m, 2H), 7.82 (s, 1H);  $^{13}\text{C}$  NMR (126 MHz, MeOD)  $\delta$  173.72, 147.71, 146.35, 143.54, 139.55, 138.93, 134.30, 131.27, 128.76, 122.98 (q, J=269.64 Hz), 120.75, 118.19, 117.21, 116.10, 115.45.

3,3-Dimethyl-5-(8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridin-7-yl)benzo[c][1,2]oxaborol-1(3H)-ol




Method A: Off-white solid (54 mg, 14%).  $^1\text{H}$  NMR (500 MHz, Methanol-d<sub>4</sub>)  $\delta$  7.83 (d, J=9.1 Hz, 1H), 7.77 (d, J=9.1 Hz, 1H), 7.73-7.68 (m, 1H), 7.47 (t, J=1.1 Hz, 1H), 7.41 (dd, J=7.4, 1.4 Hz, 1H), 3.24 (t, J=6.5 Hz, 2H), 2.69 (t, J=6.2 Hz, 2H), 2.05-1.94 (m, 2H), 1.79-1.71 (m, 2H), 1.56 (s, 6H);  $^{13}\text{C}$  NMR (126 MHz, MeOD)  $\delta$  162.29, 157.20, 143.50, 143.12, 129.88, 129.44, 128.35, 127.81, 122.15, 120.98, 119.24, 119.15, 115.90, 110.35, 98.72, 84.23, 29.51, 29.30, 28.40, 28.29, 22.07, 21.97; HRMS (ESI) m/z calcd for C<sub>23</sub>H<sub>23</sub>BN<sub>3</sub>O<sub>2</sub> [M+H]<sup>+</sup> 384.1883 found 384.1882.

**294**


3,3-Dimethyl-6-(8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridin-7-yl)benzo[c][1,2]oxaborol-1(3H)-ol

HSD1399



Method A: Off-white solid (62 mg, 16%).  $^1\text{H}$  NMR (500 MHz, Methanol-d<sub>4</sub>)  $\delta$  8.62 (s, 1H), 7.88 (dd, J=17.5, 9.0 Hz, 2H), 7.79-7.68 (m, 1H), 7.65-7.59 (m, 1H), 7.55-7.46 (m, 1H), 3.53-3.40 (m, 2H), 2.93-2.72 (m, 2H), 2.11 (dt, J=11.5, 6.6 Hz, 2H), 1.94-1.76 (m, 2H), 1.60 (s, 6H);  $^{13}\text{C}$  NMR (126 MHz, MeOD)  $\delta$  162.13, 157.52, 154.20, 143.64, 139.57, 138.67, 131.57, 130.39, 129.75, 128.47, 122.21, 120.28, 113.77, 84.16, 29.64, 28.56, 28.27, 22.16, 22.05. HRMS (ESI) m/z calcd for C<sub>23</sub>H<sub>23</sub>BN<sub>3</sub>O<sub>2</sub> [M+H]<sup>+</sup> 384.1883 found 384.1880.

(2-Methoxy-3-(8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridin-7-yl)phenyl)boronic acid




Method A: Off-white solid (41 ng, 11%).  $^1\text{H}$  NMR (500 MHz, Methanol-d<sub>4</sub>)  $\delta$  8.58 (s, 1H), 7.89 (d, J=9.2 Hz, 1H), 7.83 (d, J=9.1 Hz, 1H), 7.42 (d, J=7.3 Hz, 1H), 7.32 (d, J=7.4 Hz, 1H), 7.24 (t, J=7.4 Hz, 1H), 3.48 (s, 3H), 3.44-3.35 (m, 2H), 2.82 (dd, J=15.9, 7.2 Hz, 1H), 2.51 (dt, J=17.3, 5.9 Hz, 1H), 2.09-2.00 (m, 2H), 1.89-1.82 (m, 1H), 1.81-1.76 (m, 1H);  $^{13}\text{C}$  NMR (126 MHz, MeOD)  $\delta$  159.79, 155.68, 142.96, 133.21, 132.37, 131.13, 130.91, 128.28, 124.23, 123.00, 122.24, 60.00, 29.48, 27.03, 22.16, 21.79. HRMS (ESI) m/z calcd for C<sub>21</sub>H<sub>21</sub>BN<sub>3</sub>O<sub>3</sub> [M+H]<sup>+</sup> 374.1676, found 374.1670.

(7-(3-(Trifluoromethyl)-1H-pyrazol-4-yl)-8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridin-5-yl)ethane-1,2-diamine

N<sup>1</sup>, N<sup>1</sup>, N<sup>2</sup>, Trimethylethane-1,2-diamine (0.5 mL) was added to mixture of compound HSH-1-156 (50 mg, 0.13


**295**

mmol) and powdered K<sub>2</sub>CO<sub>3</sub> (2 equiv), dissolved in DMSO (1 mL). The reaction mixture was heated at 200° C. in a pressure tube for 24 h. After completion of reaction, reaction was purified by silica-gel flash chromatography using dichloromethane:methanol (80:20) as solvent system.



Yellow solid (8 mg, 13%). <sup>1</sup>H NMR (500 MHz, Methanol-d<sub>4</sub>) δ 8.51 (s, 1H), 8.07 (s, 1H), 7.45 (s, 1H), 3.52 (t, J=6.4 Hz, 2H), 3.37 (t, J=6.4 Hz, 2H), 3.21-3.16 (m, 2H), 2.98 (s, 3H), 2.66 (t, J=6.6 Hz, 2H), 2.43 (s, 6H), 2.10-2.04 (m, 2H), 1.92-1.84 (m, 2H); <sup>13</sup>C NMR (126 MHz, MeOD) δ 148.52, 146.67, 143.98, 139.58, 138.84, 131.49, 131.11, 123.95, 122.86, 120.72, 119.24, 112.05, 56.25, 52.86, 44.02, 43.71, 39.62, 29.85, 27.71, 22.14, 21.75; HRMS (ESI) m/z calcd for C<sub>23</sub>H<sub>24</sub>F<sub>3</sub>N<sub>7</sub> [M+H]<sup>+</sup> 458.2280, found 458.2276.

5-(Piperidin-1-yl)-7-(3-(trifluoromethyl)-1H-pyrazol-4-yl)-8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridine



Method A: Off-white solid (66 mg, 15%). <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) δ 8.39 (s, 1H), 8.15 (s, 1H), 7.12 (s, 1H), 3.24 (d, J=6.4 Hz, 2H), 3.17 (t, J=5.2 Hz, 4H), 2.62 (t, J=6.2 Hz, 2H), 1.93 (tt, J=7.6, 5.2, 4.3 Hz, 2H), 1.80-1.72 (m, 2H), 1.64 (t, J=5.8 Hz, 4H), 1.53 (q, J=6.1 Hz, 2H); <sup>13</sup>C NMR (126 MHz, DMSO) δ 150.46, 146.47, 142.38, 139.11, 136.28, 131.34, 130.26, 123.57 (q, J=263.34 Hz), 123.19, 120.16, 120.08, 111.84, 53.57, 31.18, 29.81, 28.19, 26.16, 24.64, 22.68, 22.29; HRMS (ESI) m/z calcd for C<sub>23</sub>H<sub>24</sub>F<sub>3</sub>N<sub>6</sub> [M+H]<sup>+</sup> 441.2015, found 441.2012.


**296**

7-(4-Fluoro-3-nitrophenyl)-8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridine

5

HSD1403

10



15

20

Method A: Yellow solid (145 mg, 40%). <sup>1</sup>H NMR (500 MHz, Methanol-d<sub>4</sub>) δ 8.63 (s, 1H), 8.31 (dd, J=7.2, 2.2 Hz, 1H), 7.96 (ddd, J=8.6, 4.3, 2.3 Hz, 1H), 7.93-7.87 (m, 2H), 7.58 (dd, J=11.0, 8.6 Hz, 1H), 3.44 (d, J=7.2 Hz, 3H), 2.84 (t, J=6.2 Hz, 2H), 2.18-2.08 (m, 2H), 1.94-1.83 (m, 2H); <sup>13</sup>C NMR (126 MHz, MeOD) δ 153.80, 144.17, 137.50, 137.15, 136.31, 129.49, 128.62, 128.52, 126.50, 125.92, 122.66, 118.07, 117.90, 29.65, 28.38, 22.02.

30

2-Fluoro-5-(8,9,10,11-tetrahydro-3H-naphtho[1,2-e]indazol-7-yl)aniline

35


Compound HSD1404 (100 mg) was dissolved in 5 mL THF and purged with argon for 15 minute. After that palladium (10% on carbon, 20 mol %) was added and hydrogen balloon was used for hydrogenation for 6 h. After completion, reaction mixture was filtered through sintered funnel, concentrated and purified by flash column chromatography.

40

HSD1353B

45

HSD1405




55

Pale yellow solid (83 mg, 90%). <sup>1</sup>H NMR (500 MHz, Methanol-d<sub>4</sub>) δ 8.55 (s, 1H), 7.90-7.78 (m, 2H), 7.07 (dd, J=11.3, 8.2 Hz, 1H), 6.96 (dd, J=8.6, 2.1 Hz, 1H), 6.74 (ddd, J=8.2, 4.3, 2.1 Hz, 1H), 3.34 (d, J=7.9 Hz, 3H), 2.77 (t, J=6.2 Hz, 2H), 2.06 (td, J=8.6, 7.2, 4.6 Hz, 2H), 1.88-1.78 (m, 2H); <sup>13</sup>C NMR (126 MHz, MeOD) δ 157.17, 153.73, 152.53 (d, J=239.4 Hz) 143.38, 136.87, 135.81, 135.63, 135.52, 129.70, 128.38, 122.05, 117.94, 117.38, 116.11, 114.39, 114.24, 113.58, 29.59, 28.41, 22.17, 22.06. HRMS (ESI) m/z calcd for C<sub>21</sub>H<sub>19</sub>FN<sub>3</sub> [M+H]<sup>+</sup> 332.1563, found 332.1560.

**297**

7-(3-Fluoro-4-nitrophenyl)-8,9,10,11-tetrahydro-3H-pyrazolo[4,3-a]phenanthridine



HSD1409

Method A: Yellow solid (145 mg, 40%) <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) δ 8.57 (s, 1H), 8.26 (t, J=8.2 Hz), 7.89-20 7.81 (m, 3H), 7.66 (dd, J=8.4, 1.4 Hz, 1H), 3.32 (s, 2H), 2.81 (t, J=5.8 Hz, 2H), 2.01-2.79 (m, 2H), 1.76-1.74 (m, 2H); <sup>13</sup>C NMR (126 MHz, DMSO) δ 155.83, 153.75, 153.45, 149.27, 149.20, 143.60, 143.07, 139.01, 136.56, 129.52, 126.51, 122.60, 119.60, 119.43, 116.28, 114.94, 29.66, 228.50, 25 22.45, 22.33.

Those skilled in the art will recognize that numerous modifications can be made to the specific implementations described above. The implementations should not be limited to the particular limitations described. Other implementations may be possible.

While the inventions have been illustrated and described in detail in the drawings and foregoing description, the same is to be considered as illustrative and not restrictive in character, it being understood that only certain embodiments have been shown and described and that all changes and modifications that come within the spirit of the invention are desired to be protected.

It is intended that the scope of the present methods and compositions be defined by the following claims. However, it must be understood that this disclosure may be practiced otherwise than is specifically explained and illustrated without departing from its spirit or scope. It should be understood by those skilled in the art that various alternatives to the embodiments described herein may be employed in practicing the claims without departing from the spirit and scope as defined in the following claims.

## REFERENCES

50


- 1) Ten things you should know about protein kinases: IUPHAR Review 14. Fabbro et al. *Br J Pharmacol* 2015, 172, 2675.
- 2) 25 years of small molecular weight kinase inhibitors: potentials and limitations. Fabbro *Mol Pharmacol* 2015, 87, 766.
- 3) Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia O'Hare et al. *Blood* 2007 110, 2242-2249.
- 4) Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML. Lindblad et al. *Oncogene* 2016, 35 (39), 5119-31
- 5) Rho kinase regulates the survival and transformation of cells bearing oncogenic forms of KIT, FLT3, and BCR-ABL. Mali et al. *Cancer Cell* 2011, 20 (3), 357-69.

**298**


- 6) Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease. Kontzias et al. *Curr. Opin. Pharmacol.* 2012, 12 (4), 460-70.
- 7) Rho Kinase (ROCK) Inhibitors. James et al. *J Cardiovasc Pharmacol.* 2007, 50 (1), 17-24
- 8) An emerging treatment option for glaucoma: Rho kinase inhibitors. Wang and Chang *Clin Ophthalmol.* 2014, 8, 883-90.
- 9) LRRK2 in Parkinson's disease: protein domains and functional insights. Mata et al. *Trends Neurosci.* 2006, 29 (5), 286-93
- 10) Recent synthetic developments in a powerful imino Diels-Alder reaction (Povarov reaction): application to the synthesis of N-polyheterocycles and related alkaloids. Kouznetsov *Tetrahedron*, 2009, 65, 2721; b) Povarov and Mikhailov *Izv Akad Nauk SSR, Ser Khim* 1963, 953.

The invention claimed is:


1. A compound, wherein the compound is




HSD1342



HSD1335






HSD1336




US 12,384,782 B2

**299**


-continued




2. A compound, wherein the compound is



HSD-02-939



HSD 02-1211




HSD-02-983


**300**

-continued


HSD-02-993




HSD1334




HSD1335




HSD1336



HSD1338




HSD1341



US 12,384,782 B2

**301**


-continued




HSD1366

**302**


-continued




HSD1383




HSD1368




HSD1369




HSD1370




HSD1384



HSD1388



HSD1382




HSD1503

US 12,384,782 B2


**303**

-continued



HSD1504

5



HSD1505

10


15

20

25


**304**

-continued



HSD1506

HSD1508



\* \* \* \* \*